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ABSTRACT
It is clear that there are substantial changes in lipids and lipoproteins in normal 
pregnancy with up to four-fold rise in triglycerides and up to a 50% increase in 
cholesterol. It is generally held that such changes exist to meet the demands of the 
feto-placental unit in terms of cellular proliferation and development and also to 
support lactation. In some situations the mechanisms regulating this physiologic 
hyperlipidaemia may malfunction. In women with pre-eclampsia, plasma free fatty 
acids and triglyceride concentrations climb substantially above those observed in 
normal pregnancy and do so well in advance of the appearance of clinical 
manifestations of the disorder. Lipoprotein classes are not homogeneous entities but 
include subclasses of differing function and metabolic potential. For example, particles 
such as low density lipoprotein itself can be broken down into distinct subpopulations 
with small, dense LDL (LDL-III) exhibiting strong atherogenic potential, in particular, 
promoting the development of foam cells and stimulating endothelial dysfunction. In 
the non-pregnant situation, plasma triglyceride is the major factor promoting the 
synthesis of LDL-III. However, this relationship is not linear, rather recent cross- 
sectional studies imply a threshold effect: synthesis of LDL-III proceeding only once 
triglyceride concentrations go beyond a ‘threshold’ value. To the best of our 
knowledge no longitudinal studies have been designed to examine this phenomenon in 
individual subjects. The physiological changes in plasma triglyceride which 
accompany pregnancy provide such an opportunity. In addition, at the time this thesis 
was initiated there was no information on the concentrations of very low density 
(VLDL) and LDL subfractions in pre-eclampsia. The primary objectives of the thesis 
were: to establish the lipoprotein subfraction changes occurring during the 
physiological hyperlipidaemia of normal pregnancies and the pathological 
hyperlipidaemia of pre-eclampsia. In addition, the consequences of the altered 
lipoprotein metabolism in pre-eclampsia for the promotion of the characteristic 
endothelial dysfunction present in this disorder was examined, as well as the 
relationship between lipid changes and haemostatic factors during normal gestation. 
Finally, lipid and lipoprotein concentrations in pregnancies complicated by IUGR, a 
condition in which the placental appearance is similar to that seen in pre-eclampsia but 
where the maternal systemic problems of hypertension and proteinuria are absent, 
were documented.
Plasma lipids and lipoprotein subfractions were quantified in 10 normal pregnant 
women at 5 weekly intervals from 10 to 35 weeks of gestation, together with 
circulating hepatic lipase and serum oestradiol concentrations. Concentrations of 
VLDLi, VLDL2 and IDL increased in parallel as plasma triglyceride increased with 
advancing gestation, and LDL mass increased by 70%. In addition, in six of the 10 
women studied, the LDL subfraction pattern was modified towards a smaller denser
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pattern in a manner indicative of a “threshold” transition. The concept of a threshold 
was of critical importance to our understanding of this important aspect of lipoprotein 
physiology. This “threshold” transition, if it occurred, did so at varying gestational 
ages and triglyceride concentrations for different women.
Circulating concentrations of coagulation and fibrinolytic markers were measured and 
related to changes in plasma lipids and oestradiol. Strong and similar individual 
correlations were observed between increases in FVII, PAI, t-PA and D-dimer (but 
not vWF) and increases in both oestradiol and triglyceride. Associations between 
increments in plasma cholesterol and haemostatic factors (except for FVII), were 
somewhat weaker. These data suggest that oestradiol-induced hypertriglyceridaemia 
may be a cause of elevations in plasma Factor VII activity, PAI and t-PA, and fibrin 
turnover (D-dimer) during normal pregnancy, but is poorly related to the increase in 
vWF antigen.
Next, plasma concentrations of VLDL, and LDL subfractions and pre-heparin hepatic 
lipase activity were compared in women with pre-eclampsia and healthy, age, 
gestational age and weight-matched controls. Women with pre-eclampsia exhibited 
higher median plasma triglyceride,VLDLi and VLDL2 concentrations, whereas total
plasma cholesterol, IDL and total LDL concentrations were the same in cases and 
controls. Furthermore, women with pre-eclampsia demonstrated markedly elevated 
median plasma concentrations of small, dense LDL, LDL-III. Consistent with studies 
in non-pregnant populations, the concentration of small, dense LDL correlated 
positively with plasma triglyceride concentration. Since, both VLDLi and small,
dense LDL-III are damaging to the endothelium, elevated concentrations of these 
lipoprotein species may contribute to the expression of pre-eclampsia.
Fourth, we have related lipid concentrations to endothelial behaviour in myometrial 
vessels bathed in plasma from normal and pre-eclamptic pregnancies. A significant 
correlation was observed between endothelial behaviour and apo AI concentrations, 
whereas no associations were seen with other lipid parameters measured. These 
results were consistent with data from studies in non-pregnant individuals where HDL 
cholesterol has been positively and strongly related to endothelial function. We 
postulated that this relationship may reflect a direct effect of HDL particles since they 
are antioxidative and cardioprotective. Alternatively, rather than a direct influence of 
Apo AI on endothelial behaviour, some other factor(s) dictating Apo AI metabolism 
and thus Apo AI concentrations may relate to endothelial behaviour. In particular, the 
efficiency of triglyceride catabolism which in the non-pregnant situation, is a major 
determinant of Apo AI and HDL-cholesterol concentrations, may be involved.
Next, a mechanistic scheme for the generation of the hyperlipidaemia in pre-eclampsia 
was devised. It was suggested that increased plasma cytokine (IL-1, TNF-a) 
concentrations resulting from activation of macrophages/neutrophils either directly or 
indirectly through endothelial activation, or the placenta itself, may enhance the 
peripheral lipolysis already activated in normal pregnancy by HPL. This, in 
association with cytokine mediated de novo hepatic fatty acid synthesis, would then 
result in an increased flux of free fatty acids to the liver. These are channelled 
predominantly into hepatic triglyceride synthesis and lead to an increased secretion 
(over and above that of normal pregnancy) of large, triglyceride-rich VLDL particles, 
which are also removed less efficiently than normal. Accumulation of free triglyceride 
occurs in the hepatocyte when there is saturation of this pathway. This triglyceride 
accumulation is sufficient to explain the fatty changes in the liver seen in pre-eclampsia 
and AFLP, which as previously discussed may be a variant of the pre-eclampsia 
process. Furthermore, it was suggested that increased concentrations of triglyceride- 
rich lipoproteins in the circulation may contribute both directly and, through the 
generation of small, dense LDL, indirectly to endothelial dysfunction and therefore 
expression of pre-eclampsia in the mother, despite potentially benefiting fetal nutrition.
Finally, we examined lipid changes in pregnancies complicated by IUGR. The results 
of this study demonstrated that LDL levels which normally increase by around 70% in 
uncomplicated pregnancies, fail to rise appropriately in pregnancies complicated by 
IUGR. The mechanisms for this observation are unclear but clearly, given the 
importance of LDL particles in delivering cholesterol to the placenta for hormonal 
synthesis and for transport to the fetus, such low levels may contribute to the 
pathogenesis of growth restriction. In addition, these data suggest that LDL- 
cholesterol measurements may be useful in identifying mothers with IUGR 
pregnancies.
In conclusion, the results of our novel studies have given deeper insight into the 
unique features associated with the hyperlipidaemia of normal pregnancy, particularly 
with reference to lipoprotein subfraction concentrations. Some of this information is 
clearly relevant to our understanding of the factors which govern generation of small, 
dense LDL in the non-pregnant population, and atherosclerosis. Furthermore, data 
presented in this thesis suggest that in some situations (pre-eclampsia and IUGR) 
mechanisms regulating this physiologic hyperlipidaemia may malfunction, with 
potential ramifications for the clinical expression or diagnosis of these conditions.
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CHAPTER I
INTRODUCTION
1. PLASM A LIPIDS AND LIPOPROTEINS
1.1 Lipids
Lipids and fat soluble compounds are critical for normal metabolism in biological 
systems. Three specific lipid compounds, cholesterol, triglyceride, and phospholipids 
are found widespread throughout the body. Cholesterol occurs in both polar (free 
cholesterol), and non-polar (cholesteryl ester) forms. Cholesterol serves as a structural 
component of cell membranes and for the synthesis of steroid hormones and bile 
acids. Phospholipids, amphoteric molecules having a polar head and a non polar tail, 
are structural components of cell membranes. Phospholipids also function in 
intracellular signalling, solubilisation of non polar substances in the intestine, and 
stabilisation of alveoli in the lung. Triglycerides, which are non polar substances, are 
used primarily as a source of energy and fatty acids. Certain fatty acids derived from 
triglycerides are also involved in cell signalling. These three lipid components can be 
synthesised de novo or provided in the diet.
The difficulty of transporting lipids in blood, an aqueous medium, has been overcome 
by the formation of lipid/lipoprotein particles referred to as lipoproteins. Lipoproteins 
are spherical particles which contain the non polar lipids, cholesteryl ester and 
triglyceride, in their core and proteins and the more polar lipids, phospholipid and free 
cholesterol, on their surfaces. The polar portions of the latter are orientated towards 
the aqueous medium. The protein components, referred to as apolipoproteins (apo) or 
apoproteins, are found on the surface and extend into the core of the lipoprotein 
particle depending on the type of apolipoprotein. Currently six major subclasses of 
lipoproteins have been identified. These are: chylomicrons, very low density 
lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density lipoprotein 
(LDL), high density lipoprotein (HDL) and lipoprotein little “a” [Lp(a)]. Each of these 
has a unique composition and content of protein and lipid which define their function.
The function and metabolic paths of the major lipoprotein subclasses are summarised 
as follows:
1.2 Chylom icrons
Chylomicrons are the largest of the lipoprotein particles. These particles have 
apolipoprotein apo B-48 as their structural protein and also contain apo-AI, A-IV, C’s, 
and E. Chylomicrons are synthesised by the intestine following the ingestion of fat
1
and serve to transport dietary lipid from the intestine to various tissues in the body. 
Upon entering the circulation via the thoracic lymph duct the following scenario is 
envisioned to occur: The chylomicron particle binds to heparan sulfate proteoglycans 
lining the vascular epithelium where, in the presence of apo C-II, the triglyceride is 
lipolysed by lipoprotein lipase (LPL). This is likely a dynamic process, lipolysis of 
triglyceride within a single particle occurring at multiple sites. Another process which 
occurs involving chylomicron particles is the exchange of triglyceride for cholesteryl 
ester with HDL particles. The exchange is mediated by cholesteryl ester transfer 
protein (CETP). As the chylomicron loses lipid mass during lipolysis and becomes 
enriched in cholesteryl ester its affinity for the C apolipoproteins, which inhibit the 
binding of chylomicrons to hepatic chylomicron receptors is decreased. At the same 
time, apo E content of the chylomicron particle is increased which increases the 
affinity of the particle for the chylomicron remnant receptors. At some point, the ratio 
of apo C: apo E is low enough to promote avid binding of this particle to hepatic 
receptors, at which point the particle is removed from the circulation.
1.3 Very Low Density Lipoproteins
VLDL is the next largest lipoprotein particle. It is synthesised in the liver and has 
apoB-100 as its major structural protein. VLDL function primarily to carry lipid from 
the liver to different tissues throughout the body. The metabolism of VLDL is thought 
to be similar to that of chylomicrons, the particle undergoes LPL-mediated lipolysis 
and CETP-mediated exchange of triglyceride for cholesteryl ester with HDL. As with 
chylomicrons, VLDL lose apo C apoproteins and gain apo E during lipolysis. Unlike 
chylomicrons, lipolysed VLDL are thought to have a number of metabolic fates: 1. 
receptor mediated removal by the liver, 2 . receptor - mediated removal by a proposed 
VLDL receptor found in skeletal muscle, 3. conversion to LDL via IDL.
VLDL can be separated into two major subfractions distinct in their metabolic 
properties and defined by their hydrated density - VLDLi (Sf 60-400), larger,
triglyceride-rich particles, and VLDL2 (Sf 20-60), smaller, relatively cholesterol -
enriched species. Both can be synthesised directly by the liver, and in addition 
VLDL2 are formed by the delipidation of VLDLj. VLDLj are the preferred substrate
of CETP and readily undergo neutral lipid exchange whilst VLDL2 are overproduced
in common hypercholesterolaemias.
1.4 Interm ediate Density Lipoproteins
IDL are best characterised as being VLDL remnants, in transit between VLDL and 
LDL. These particles are rich in cholesteryl ester. In addition to the main structural 
protein, apo B-100, IDL has a relatively high concentration of apo E. Normally, the 
concentration of IDL in the plasma is low. IDL are thought to bind to heparan sulfate 
proteoglycans at which point their triglyceride and phospholipid are lipolysed by 
hepatic lipase (HL). This, in turn, results either in their uptake by hepatic receptors or
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conversion to LDL. As with VLDL, IDL can be divided into subfractions.
1.5 Low Density Lipoprotein
LDL are the major cholesterol-carrying particles in the blood and function to deliver 
cholesterol throughout the body as well as to the liver for its metabolism, excretion or 
resecretion on VLDL. LDL has apo B-100 as its major protein component and, 
although it is derived from IDL, has a relatively low apo E concentration. Removal of 
LDL from the plasma occurs via an LDL receptor-mediated process, which is 
regulated, or via a scavenger receptors found on macrophages and fibroblasts. It is 
thought that when excessive amounts of LDL are cleared via this latter pathway, 
macrophages become cholesterol-laden foam cells which accumulate in the vascular 
endothelium, initiating the development of atherosclerosis.
LDL comprises several subpopulations of heterogeneous particles (the exact number 
depending on the method of separation used). In the early 1980s, Krauss and Burke 
separated LDL into four major subclasses using density gradient ultracentrifugation 
(DGUC) and gradient gel electrophoresis. The DGUC was later refined by Griffin et 
al (1990) to separate LDL into three sub fractions - LDL-I (d= 1.025-1.034), LDL-II 
(d= 1.034-1.044), and LDL-III (d= 1.044-1.060) and permit quantitation of these 
species. LDL-I is relatively large and lipid-rich whereas LDL-III is small, dense and 
rich in protein and phospholipid. These subfractions are believed to have differing 
atherogenic potential. Sufferers of CHD often have a predominance of LDL-III which 
is particularly atherogenic. The potential mechanisms explaining the atherogenicity of 
small, dense LDL-III are detailed in section 4.3.
1.6 High Density Lipoproteins
HDL are the most abundant lipoproteins in plasma but also have a significant 
extravascular presence. They are synthesised by both liver and small intestine, as 
discoid apo A containing particles and are present in the plasma in two major forms, 
HDL2 and HDL3. These can be further subclassified for example by immunoaffinity
methods depending on their apo A content. Some HDL particles contain both apo AI 
and apo A ll and thought to be of hepatic origin. Other particles contain only apo AI 
and appear to originate in the intestine.
HDL function as mediators of reverse cholesterol transport, the process responsible 
for the return of cholesterol from peripheral tissues to the liver. Free cholesterol from 
cells and the surface layer of triglyceride-rich lipoproteins transfer to the nascent HDL. 
This is esterified by lecithin:cholesterol acyl transferase (LCAT) and these cholesteryl 
esters move from the surface to the core of the HDL particle, which, as a result, 
transforms from a flattened disc into a more spherical particle. In so doing, a gradient 
is established allowing more free cholesterol to transfer to HDL. This cholesteryl ester 
is then transferred by CETP to triglyceride-rich lipoproteins, preferentially VLDLi, in
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exchange for triglyceride. The apo B-100 containing lipoproteins are cleared by the 
liver, thus completing reverse cholesterol transport. The triglyceride enriched HDL 
are then hydrolysed by HL forming smaller HDL3 which are than available for free
cholesterol acquisition.
An additional role for HDL is that of a repository for the small, exchangeable 
apolipoproteins (apoC and apo E) donating them to chylomicrons and VLDL prior to 
lipolysis. These apoproteins are later shed back into the HDL density range. HDL 
catabolism is performed by the liver via apo E-facilitated receptor uptake.
1.7 Lipoprotein (a)
Lipoprotein (a) is a more recently discovered lipoprotein whose physiological function 
is as yet unclear. It is positively associated with CHD and is postulated to be both 
thrombogenic and atherogenic. Plasma levels vary from nil to 200 mg/dl and have 
strong heritability. It can simplistically be described as LDL with an additional protein, 
apo (a), attached by a disulphide bond to the apoB. Apo(a) is synthesised by the liver 
and has a high degree of sequence homology with plasminogen. It is a highly 
glyosylated, hydrophilic protein with low affinity for lipid. Despite the similarity with 
LDL, Lp(a) binds less avidly to the LDL receptor.
2. THE APOLIPOPROTEINS
Apolipoproteins are responsible for the regulation of lipoprotein inter-relationships and 
the maintenance of lipoprotein homeostasis. They act as ligands for receptor binding 
and as cofactors for lipolytic enzymes.
2.1 Apolipoprotein A
The A apoproteins consist of three main apoA’s - apo AI, apo All and apo AIV. Apo 
AI is the main protein component of HDL accounting for 70% of its protein. It is also 
present to lesser extent on chylomicrons but is transferred to HDL on hydrolysis of the 
former. It is synthesised by both the liver and small intestine and has been shown to 
have several isoforms. Its main role is as the structural apoprotein for HDL and as a 
cofactor for LCAT. Apo All, synthesised by the liver, is the second most abundant 
protein in HDL. It activates LCAT and appears to enhance the lipid binding properties 
of apoAI. Apo AIV is present on newly secreted chylomicrons but it is readily 
displaced and the majority of it is found free in the plasma. Its role is as yet uncertain 
but it possibly acts as an LCAT activator.
2.2 Apolipoprotein B
Apoprotein B in the delipidated state is insoluble in aqueous solutions and must 
therefore be denatured with, for example, sodium dodecyl sulphate or urea in order to 
be characterised. Two types of apo B are found in plasma - apoB-100 and apoB-48.
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ApoB-100 is the main protein moiety of VLDL, IDL and LDL. It is synthesised 
primarily by the liver and is an obligatory component of these lipoproteins, being 
present as one mole per particle. It does not exchange between lipoproteins but 
remains with the particle from secretion to catabolism. It acts as a ligand for receptor 
recognition and uptake of the particle. However, conformational changes of the apoB 
during lipolysis of VLDL regulate the lipoprotein uptake so that it is only IDL and 
LDL that are cleared by this mechanism. VLDL appear to be cleared by an apoE- 
mediated mechanism.
ApoB-48 is as described above the major protein in chylomicrons. It is formed 
following editing of the apoB message so that a stop translation codon (UAA) is found 
at position 2153 rather than the codon (CAA) that codes for glutamine in apoB-100.
2.3 Apolipoprotein C
There are three apoC proteins - apoCI, apoCII and apoCIII. They are present on 
HDL, chylomicrons and VLDL, the first supplying the latter two with this protein on 
their entry into the circulation. ApoCI is the smallest of the three apoproteins and acts 
as an activator of LCAT. ApoCII is an essential cofactor of lipoprotein lipase. 
ApoCIII appears to have an inhibitory effect on the lipolysis and clearance of 
chylomicrons and VLDL. It exists in three forms depending on sialylation - CIIIo, 
CIIIj and CIII2, the subscript reflecting the number of sialic acid residues present.
2.4 Apolipoprotein E
ApoE, present on chylomicron remnants, VLDL and large HDL particles, is 
synthesised by the liver and functions as a ligand for the hepatic uptake of 
lipoproteins. Isoelectric focusing reveals three common apoE isoforms - E3, E2 and 
E4. Apo E2 and E4 arise from point mutations of the wild type, E3. The differing 
isoforms do have physiological effects, in particular on the metabolism of LDL 
precursors.
3. THE ENZYMES OF LIPOPROTEIN METABOLISM
3.1 Lipoprotein lipase (LPL)
LPL hydrolyses triglyceride in chylomicrons and VLDL and requires apoCII as a 
cofactor. It is found mainly in adipose tissue and skeletal muscle where it is bound to 
the capillary endothelium. In women LPL activity is greater in the gluteal adipose 
tissue than in the abdominal tissue, whereas in men the converse is true. Overall, the 
amounts of LPL in adipose tissue are higher in women than in men. Regular alcohol 
intake increases the amount of LPL in the adipose tissue, whereas exercise increases 
that in skeletal muscle.
5
3.2 Hepatic lipase (HL)
HL hydrolyses triglyceride in HDL2 and by so doing mediates the conversion of
HDL2 to HDL3. Additionally, it delipidates IDL to form LDL and is thought to be
responsible for the interconversion between LDL subclasses. It is found on hepatic 
endothelial cells and concentrations in women are lower than those in men.
The triglyceride lipases are structurally related to pancreatic lipase. In addition to their 
role as enzymes, both have been shown to act as ligands for the binding of 
triglyceride-rich lipoproteins to cell membranes. Although each lipase is capable of 
hydrolysing each lipoprotein in vitro, in vivo they are selective - LPL preferentially 
acts on triglyceride-rich lipoproteins, and HL on HDL and LDL particles.
3.3 Cholesteryl ester transfer protein (CETP) and Lecithin cholesterol 
acyl transferase (LCAT)
LCAT and CETP are involved in reverse cholesterol transport. LCAT esterifies 
cholesterol with fatty acids, preferably linoleic acid, taken from lecithin. CETP 
catalyses the neutral lipid exchange of cholesterol esters from HDL and LDL to the 
triglyceride-rich lipoproteins in exchange for triglyceride.
4. HYPERTRIGLYCERIDAEM IA, LIPOPROTEIN SUBFRACTIONS 
AND CORONARY HEART DISEASE
4.1 Background
With respect to lipid metabolism, normal human pregnancy is characterised by an 
increase predominately in plasma triglyceride levels. Therefore, it is relevant to 
describe the effect of an increase in triglyceride concentrations on lipoprotein 
subfraction concentrations in non-pregnant individuals. Furthermore, it is important 
to recognise that documentation and understanding of such changes has assumed 
considerable clinical importance as there is an emerging consensus that a moderate 
elevation in plasma triglyceride may be an independent risk factor for coronary heart 
disease.
4.2 Triglycerides and Cardiovascular disease
Plasma low density lipoprotein-cholesterol (LDL-cholesterol) has long been regarded 
as the key lipid fraction in the pathogenesis of atherosclerosis. This view has recently 
been reinforced by the results of studies showing that lowering plasma LDL 
cholesterol concentrations using statins is an effective primary and secondary 
prevention measure for coronary artery disease (CAD) (Shepherd et al, 1995, 
Scandinavian Simvastatin Survival Study Group, 1994). However, there is 
accumulating evidence that elevated plasma triglycerides and related abnormalities
constitute an independent cardiovascular risk factor.
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Data from the PROCAM study, an eight year observational follow-up of 4559 middle- 
aged men, has revealed a significant and independent association between serum 
triglycerides and the incidence of major coronary events. In fact, the highest 
cardiovascular risk was seen in patients with an LDL/HDL ratio of greater than five in 
combination with a serum triglyceride concentration of greater than 2.3 mmol/1 
(Assmann et al, 1996). In a carefully-performed prospective case-control study based 
on a cohort from the Physicians' Health Study, serum triglyceride concentrations were 
a strong and independent predictor of outcome over seven years of follow-up, 
independent of HDL-cholesterol (Stampfer et al, 1996). Further evidence comes 
from a meta-analysis incorporating data from eight population-based prospective 
studies in more than 28,000 patients (-80%  male), and controlling for HDL- 
cholesterol. This analysis demonstrated that for every 1 mmol increase in serum 
triglyceride the relative risk of coronary heart disease increased by 14% in men and 
37% in women (Hokanson & Austin, 1996).
M echanisms by which elevations in triglyceride concentrations contribute to 
atherogenesis include not only effects of LDL and HDL subfractions (succeeding 
section), but also by impacting upon thrombogenic parameters and endothelial 
function. A discussion of these latter two areas are detailed in sections 5.1 and 5.2, 
respectively. Furthermore, since normal pregnancy is associated also with alterations 
in thrombogenic factors and pre-eclampsia is characterised by endothelial dysfunction, 
the role of lipids in such changes is investigated in this thesis (Chapters III and VI).
4.3  The effect of raised triglyceride on VLDL and LDL subfraction  
concentrations in non-pregnant individuals
Part of the cardiovascular risk associated with elevated triglyceride levels is mediated 
through its influence of LDL and HDL subfractions. In order to understand these 
effects, it is necessary first to introduce the concept of metabolic channelling. This 
refers to the conversion of VLDL to LDL not via a single delipidation pathway but 
rather by parallel processing pathways. For example, large VLDL (VLDLi) when 
delipidated gives rise to remnants in the smaller VLDL2 and IDL density intervals and
these are inefficiently converted to a class of LDL (smaller, denser) which is cleared 
slowly from the plasma. Newly synthesised small VLDL (VLDL2), on the other 
hand, is rapidly and almost quantitatively delipidated to large buoyant LDL which is 
catabolised relatively rapidly.
Studies of normolipaemic subjects from our laboratory have demonstrated that as 
plasma triglyceride increases across the normal range, the hepatic synthesis and 
elaboration of the large VLDLi sub fraction is predominately favoured such that the
association of plasma triglycerides with VLDLi shows a significantly steeper slope
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than that of VLDL2 (Tan et al, 1996). Increased VLDLi levels, in turn, favour 
synthesis of small dense LDL-III by the following mechanistic scheme: an increase in 
the concentration of VLDLi expands the plasma triglyceride pool, and this via the
action of CETP (which facilitates neutral lipid exchange between lipoprotein particles) 
promotes the net transfer of triglyceride into LDL-II, the major LDL species. HL then 
lipolyses triglyceride enriched LDL-II to generate small, dense LDL-III. It is currently 
postulated that an elevated HL activity (in the male range; males have twice the HL 
activity of females) is necessary to generate LDL-III in high amounts (Figure 1).
Small dense LDL-III particles are more atherogenic than lighter fractions. They are 
poorly recognised by the LDL-receptor mediated clearance mechanism and therefore 
stay in the plasma compartment for longer. They have a longer half life than any of 
the other fractions and penetrate the arterial intima more readily. They are also more 
readily oxidised and may contain less antioxidant, and they are more easily taken up 
by macrophages to create foam cells (Tribble, 1995). The overall effect is highly 
atherogenic. Indeed, in a recent study from our laboratory, the risk of coronary artery 
disease or myocardial infarction was observed to be considerably greater in those 
individuals with higher concentrations of LDL-III (>100mg/dl) (Griffin et al, 1994). 
The relative risk for coronary artery disease associated with LDL-III>100 mg/dl was
4.5 (p<0.01), and that for myocardial infarction 6.9 (p<0.001).
4.4 ‘Threshold’ relationship between triglyceride and LDL-III
With respect to the generation of LDL-III in hypertriglyceridaemia, there is an 
additional complexity. Recent cross-sectional studies have prompted the suggestion 
that as plasma triglyceride increases, generation of LDL-III occurs only when a 
threshold concentration of serum triglyceride concentrations is exceeded (Griffin et al 
1994, Tan et al 1996). Thus, at low-normal plasma triglyceride concentrations, there 
is a positive association between LDL-II concentration and plasma triglyceride. Above 
a certain ‘threshold’ plasma triglyceride value, however, (reportedly about 1.3 - 1.5 
mmol/L in men), LDL-II concentration correlates negatively with plasma triglyceride, 
and LDL-III concentration, which had been relatively constant below this triglyceride 
concentration, correlates positively with plasma triglyceride. However, to the best of 
our knowledge no longitudinal studies have been designed to examine this 
phenomenon in individual subjects. The physiological changes in plasma triglyceride 
which accompany pregnancy provides such an opportunity.
4.5 Triglycerides and HDL concentrations
Increasing triglyceride levels also have a deleterious effect on HDL concentrations. In 
fact HDL-cholesterol concentrations are strongly inversely correlated with plasma 
triglyceride. In the presence of large triglyceride-rich VLDLi particles, increased
CETP mediated exchange will generate HDL that is triglyceride enriched and these are
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Figure 1. This hypothetical scheme links a number of observations and suggests 
mechanisms whereby moderate elevations of plasma triglyceride levels can 
adversely affect the structure and'metabolism of low density lipoprotein and 
therefore its atherogenic potential. Two processes are thought to favour the 
formation of small, dense, slowly metabolised LDL. First, when the liver has an 
abundant supply of triglyceride it releases very low density lipoprotein particles of 
increased size, i.e. large VLDLi. These, after delipidation, form slowly 
catabolised LDL. Second, a raised level o f triglyceride-rich VLDL arising in part 
from low lipoprotein lipase activity leads to increased neutral-lipid exchange and 
the generation of triglyceride-rich LDL. The action of hepatic lipase removes this 
lipid from the core o f LDL and shrinks the particle. Recent evidence has shown 
that smaller LDL species are more readily oxidised than larger ones and are thus 
more likely to penetrate the artery wall and be digested by resident macrophages.
9
favourable substrates for HL. This enzyme acts to remove lipid from the core of 
HDL, reducing its size and results in the conversion of HDL2 to HDL3. HDL2 is 
thought to have a greater cardioprotective effect compared to HDL3.
4.6 Hypertriglyceridaemia and the Atherogenic Lipoprotein Profile
As noted above, high plasma triglyceride levels are associated with high 
concentrations of small, dense LDL (LDL-III) and reduced HDL-cholesterol 
concentrations. This triad of raised triglycerides, small dense LDL and reduced HDL- 
cholesterol comprises the ‘atherogenic lipoprotein phenotype’ (ALP), and is the 
commonest lipoprotein pattern in patients with myocardial infarction (Superko 1996). 
The ALP is intimately linked with insulin resistance. It is often not expressed in 
young males and premenopausal women and hence hormonal factors have been 
suggested to affect the full penetrance of the phenotypic picture. Furthermore, 
environmental factors such as diet, exercise and the use of lipid altering medications 
may also affect the expression of the trait. Interest in ALP is not simply because of 
clustering of coronary risk factors in families but there is evidence that predominance 
of small, dense LDL particles appears to be common in the general population, with a 
prevalence of at least 30%. Thus a combination of both genetic and environmental 
factors identifies the individuals susceptible to premature coronary artery disease.
4.7 Insulin resistance and the Atherogenic Lipoprotein Profile
W hat then is the link between insulin resistance and lipid metabolism? Available 
evidence suggest that both insulin resistance and ALP are associated with increased 
risk of coronary artery disease. Insulin resistance is associated with a number of 
metabolic disturbances and so is the ALP. Insulin resistant individuals have higher 
plasma triglyceride, lower HDL cholesterol and small, dense LDL particles, almost 
identical to the ALP. The only difference is the disturbance in glucose metabolism in 
insulin resistant individuals. One might ask whether they are just part of the same 
spectrum of metabolic abnormality or whether one is subset of the other? Furthermore 
the prevalence of small, dense LDL estimated at approximately 30% in the general 
population is similar to the prevalence of 25% estimated for insulin resistance 
syndrome. Insulin suppresses the release of free fatty acids (FFAs) from adipose 
tissue and in insulin resistant states, the suppressive effect of insulin on fatty acid 
release from adipose tissue after a meal is impaired. Insulin resistance is also 
associated with a decreased responsiveness of LPL to the action of insulin. This is 
particularly important for postprandial activation of LPL with resultant elevation of 
plasma triglyceride. Prolonged residence of triglyceride-rich particles in the circulation 
leads to increased exchange of their triglyceride with cholesteryl ester in HDL through 
the action of CETP. The failure of suppression of FFA during the postprandial period 
in insulin resistant individuals aggravates the increase in VLDL-triglyceride already 
present. The elevation in plasma triglyceride concentrations reflects an increased 
number of the larger triglyceride-rich VLDLi particles both in normals and in insulin
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resistant individuals. The insulin resistant individuals with higher plasma triglyceride 
levels would thus have a predominance of large triglyceride-rich VLDLi particles and
it is these particles that determine the rate of triglyceride transfer into LDL and HDL 
since triglyceride-rich VLDL has been shown to be the preferred substrate for CETP 
action. The triglyceride in such triglyceride-enriched LDL particles may then be 
removed by HL, leading to small, dense LDL particles. Thus we can see that the link 
between insulin resistance, hypertriglyceridaemia and decreased HDL cholesterol 
concentrations could be mediated through disruption of the normal multifactorial role 
of insulin in co-ordinating postprandial lipid metabolism.
5. HYPERLIPIDAEM IA, THROM BOGENESIS AND ENDOTHELIAL  
D Y SFU N C TIO N
5.1 H yperlipidaem ia and throm bogenesis
The old view of atherogenesis and thrombogenesis as two separate entities has been 
replaced by a ‘unified field theory’ that links them closer together. There is now a 
great deal of evidence that plasminogen activator inhibitor-1 (PAI-1) activity is 
enhanced (and fibrinolysis impaired) in patients with hypertriglyceridaemia. In 
addition, triglyceride-rich lipoproteins have been shown to promote PAI-1 release 
from cultured human umbilical vein endothelial cells (Stiko-Rahm et al 1990), and are 
the major independent predictors of PAI-1 levels in NIDDM patients (Panahloo et al
1995). Elevated PAI-1 levels may be a marker of endothelial dysfunction, and cause a 
profound depression of fibrinolytic activity, contributing to the pathogenesis of 
vascular disease (Hamsten 1995). Lipolysed remnants of triglyceride-rich lipoproteins 
also promote an enhanced thrombogenic tendency by increasing circulating Factor VII 
levels (Mitropoulos et al 1993). In epidemiological studies plasma triglyceride levels 
have, in addition, been demonstrated to have significant associations with coagulation 
factors IX and fibrinogen (Woodward et al 1997). Thus there is plentiful evidence to 
suggest strong links between hypertriglyceridaemia and impaired fibrinolysis.
5.2. H yperlipidaem ia and endothelial dysfunction
A considerable body of evidence relates impaired endothelial vasomotor function to 
CAD. Several studies implicate coronary vessel endothelial vasomotor dysfunction in 
the pathogenesis of myocardial ischaemia in patients with stable CAD, and particularly 
in the pathogenesis of unstable angina, in which platelet aggregation and thrombin 
formation have a more prominent role (Zeiher 1996, Levine et al 1995). Endothelial 
dysfunction results in abnormal vascular reactivity which in turn increases the 
haemodynamic stress on plaques (Vita et al 1989) and thus increases the likelihood of 
plaque rupture (Loree et al 1992) and thrombosis (Levine et al 1995). In patients with 
early coronary atherosclerosis, progressive impairment in endothelial vasomotor 
function is observed (Zeiher et al 1993). Endothelial dysfunction is not limited to the 
coronary circulation, and can also be detected in peripheral arteries (Anderson et al
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1995). Furthermore, the assessment of endothelial vasomotion in these peripheral 
arteries has been shown to correlate with endothelial dysfunction in the coronary 
arteries (Anderson et al 1995) and to relate directly to coronary dysfunction (Zeiher
1996).
Endothelial vasomotor dysfunction is also evident in patients with risk factors for 
CAD long before structural vascular changes or clinical symptoms occur: Abnormal 
endothelial function has been described in hypertension (Panza et al 1993), NIDDM 
(McVeigh et al 1992), and obesity/insulin resistance (Steinberg et al 1996). With 
respect to lipids, hypercholesterolaemia has repeatedly been shown to be associated 
with endothelial dysfunction, whereas cholesterol-lowering therapy has been 
demonstrated to result in improved endothelial-dependent vasomotion (Anderson et al 
1995, Treasure et al 1995).
However, there are several possible mechanisms (Sattar et al, In press) by which 
elevations in triglyceride-rich lipoproteins (and related metabolic perturbances) may 
mediate endothelial dysfunction. There is evidence to suggest that triglyceride-rich 
particles may be directly damaging to the endothelium; this may be principally via 
oxidative mechanisms. Triglyceride-rich particles can cross the endothelial barrier and 
enter the arterial wall, thus placing them in a position to promote direct endothelial 
damage. These particles stimulate endothelial expression of adhesion molecules and 
the prothrombotic factor PAI-1. By reducing LDL size and HDL cholesterol 
concentrations, triglyceride-rich particles may indirectly  promote endothelial 
dysfunction. Small, dense LDL as mentioned above are more susceptible to oxidative 
damage whereas HDL particles protect the endothelium via its antioxidant properties as 
HDL has been found to protect against LDL oxidation (Hessler et al 1979). HDL may 
also play a role in reverse transport of potentially reactive hydroperoxide species for 
hepatic detoxification . In addition, free fatty acids, which are the major substrates for 
endogenous synthesis of triglyceride-rich particles, are also potentially damaging to 
the endothelium. This occurs via oxidative stress, by facilitating transfer of LDL 
across the endothelium, and by enhancing toxicity of triglyceride-rich particles. 
Finally, there is recent strong evidence to suggest that increased postprandial 
circulating concentrations of triglyceride-rich particles and remnant particles may be 
deleterious to the endothelium (Vogel et al 1997, Plotnick et al 1997).
6. LIPOPROTEIN M ETABOLISM IN PREGNANCY
6.1 B ack grou n d
As described above, a complex system to transport lipids via blood has evolved in all 
higher species. Its function is to aid the absorption of dietary lipids, to distribute them 
to peripheral tissues for the synthesis of cell membranes, to store the excess in adipose 
tissues for later use, and to release them at a controlled rate when required to meet
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energy demands. A physiological hyperlipidaemia of pregnancy has co-evolved in 
mammals to accelerate these processes at a time of rapid development of fetal and 
placental tissues and to ensure an adequate accretion of body fat to support lactation 
(Dugdale 1986). This condition is characterised by a marked elevation in plasma 
lipids, a progressive decline in serum glucose and amino acids, and a shift in maternal 
energy metabolism from glucose to more dependence on fatty acids and ketone bodies. 
This phenomenon has been recognised for nearly 150 years, although its precise 
metabolic foundations remain elusive (Virchow 1847).
6.2 Very Low Density Lipoprotein
VLDL level rises throughout pregnancy, particularly markedly in the third trimester, 
and is responsible for the rise in triglyceride levels (Figure 2), (Warth et al 1975, 
Fahraeus et al 1985, Montelongo et al 1992). Triglyceride concentrations increase 
anywhere between 200-400% so that by the end of pregnancy a proportion of women 
will be frankly hypertriglyceridaemic (trig>2.3 mmol/1). Current evidence favours 
enhanced synthesis of apoB-containing triglyceride-rich VLDL, rather than reduction 
in catabolism, although it is likely that both mechanisms contribute. Kinetic studies 
are required to confirm the dominant mechanism responsible for elevated VLDL 
levels.
6.3 Low Density Lipoprotein
LDL cholesterol concentrations fall significantly in the first trimester probably as a 
result of enhanced catabolism secondary to an oestrogen mediated upregulation of 
hepatic LDL receptors. After eight weeks, however, LDL cholesterol levels begin to 
rise and do so steeply. This rise is probably due to enhanced conversion of VLDL to 
LDL. By term LDL cholesterol concentrations have increased by around 70% (Warth 
et al 1975, Fahraeus et al 1985, Montelongo et al 1992) (Figure 2). The rise in LDL 
triglyceride levels is more marked than LDL cholesterol and this believed to be the 
result of a combination of two effects. Firstly, the reduction in hepatic lipase activity, 
as a consequence of pregnancy hyperoestrogenaemia, could mediate LDL triglyceride 
enrichment. A second potential mechanism, driven by high VLDL concentrations, is 
an increased flux of VLDL-triglyceride to LDL in exchange for cholesteryl ester (as in 
Figure 1) (Montelongo et al 1992).
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FIGURE 2 Typical lipid changes in normal pregnancy
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6.4 H igh D ensity L ipopro teins
T h e  h y p e r t r i g l y c e r i d a e m i a  o f  p r e g n a n c y  is d i s t i n g u i s h e d  f ro m  o t h e r  
h y p e r tr ig ly c e r id ae m ia s  by an increase  o f  H D L  cho les te ro l ra ther than a fall. H D L  
ch o le s te ro l  rises to m a x im u m  at around  25 -30  w eeks ,  the H D L 2 subfrac tion  be ing
m a in ly  re sp o n s ib le  (F ah raeu s  et al 1985) (F ig u re  2). T he  m ech a n ism s  likely  
re sp o n sib le  for this are co m p lex  but probably  involve enhanced  synthesis o f  apo  A-I, 
the m ain  protein consti tuen t o f  H D L, and reduced  ca tabolism  o f  H D L 2 secondary  to a
fall in hepatic  lipase activity . A fter 25-30  w eeks  H D L  cholesterol and H D L 2 levels
begin  to fall despite little change in hepatic lipase activity and a continual rise in p lasm a 
ap o  A-I. T hus ,  o th e r  fac to rs  are invo lved  and  p robab ly  push  the ba lance  to w ard s  
e n h a n ced  ca tabo lism  (A lvarez  et al 1996). T he higher triglyceride levels at this stage 
are likely to be involved  by facilitating increased neutral lipid exchange betw een  H D L  
and  V L D L  particles.
6.5 P o ten tia l M echanism s for P regnancy H yperlipidaem ia
T h e  m e c h a n is m (s )  for  the g en e ra t io n  o f  the h y p e r tr ig ly ce r id aem ia  o f  p re g n an cy
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appears to differ from the mechanism in the non-pregnant population. Although, 
pregnancy is an insulin resistant state, the rise in oestrogens is likely to contribute to 
the pattern of change in the lipoproteins. At the end of the first trimester, the 
lipoprotein pattern is similar to that observed in women on oral oestrogen containing 
preparations: elevated plasma triglyceride concentration with a parallel increment in 
HDL cholesterol, whereas LDL cholesterol are lowered (Walsh et al 1991). Increased 
HDL-cholesterol concentrations are likely mediated via oestrogen induced increased 
hepatic apo A-I synthesis and reduced hepatic lipase activity. LDL cholesterol 
concentrations are also likely oestrogen induced, mediated via hepatic LDL receptor 
up-regulation.
In the late second trimester of human pregnancy there is an increased flux of free fatty 
acids (FFAs) promoted by a combination of stimulation of hormone sensitive lipase 
(HSL) (Martin-Hidalgo et al 1994) by human placental lactogen (HPL), and relative 
resistance to the effects of insulin (which normally acts to suppress FFA release from 
adipose tissue). Normally, FFAs released from adipocytes by the action of HSL are 
taken up by liver and subject to two alternative routes of metabolism; one is their 
reassimilation into triglyceride molecules, while the other is oxidation by 
mitochondrial B-oxidative pathways which results in the generation of energy and the 
synthesis of ketones. The delivery of substrate for triglyceride synthesis in the form 
of free fatty acids is known from cell culture work to be the major determinant of 
VLDL secretion (Dixon & Ginsberg 1993). Studies in the mouse suggest that late 
pregnancy is also associated with a mild impairment in p-oxidative function (Grimbert 
et al 1993). However, as total hepatic lipids remained unchanged, it appears that in 
normal murine pregnancy this decreased oxidation of fat in the liver is compensated 
for by the increased secretion of VLDL, in agreement with studies in other animal 
models (Weinstein et al 1979, Wasfi et al 1980). Furthermore, in a recent single 
human case study oestrogen has been demonstrated to inhibit hepatic lipid oxidation 
with resultant increase in serum triglyceride concentration (O'Sullivan et al, 1995). 
Thus the rise in plasma triglyceride-rich lipoproteins, which is maximal in the third 
trimester, is likely to be due to a combination of increased FFA flux and oestrogen 
mediated reduced hepatic p-oxidation. Overall, the perturbations in lipoprotein 
concentrations during pregnancy are in keeping with the concept of fatty acid supply to 
the placenta for trans-placental transport.
Beyond simple gross changes in the concentrations of lipoproteins, there appear to be 
qualitative changes in lipoprotein composition also. Studies in animal models have 
demonstrated that there is a specific increase in phosphatidylcholine (PC) 16:0 / 22:6 
n-3 (DHA) content of maternal liver and plasma phospholipids during late pregnancy 
(Burdge et al, 1994). This has been shown to be due to modifications to the rate of 
PC synthesis and to the com position o f the pools used in PC and 
phosphatidylethanolamine synthesis. These changes have also been observed in
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h u m a n  pregnancy .  T h e  s im p les t  ex p lan a tio n  for increased  synthesis o f  l iver PC in 
p reg n an cy  is to support  increased  hepatic  lipopro te in  synthesis  and secretion  for the 
supply  o f  lipid nutrients to the fetus to support neurological developm ent, and adipose 
and  m am m ary  s torage sites. This  w o rk  also  suggests  that the supply o f  P U F A  to the 
d ev e lo p in g  fetus is the result o f  specific adapta tions to maternal hepatic phospholip id  
b iosynthesis  ra ther than passive transfer from  the maternal diet.
7.0 PLA CEN TA L L IPID  U PTAK E M ECHANISM S
R ecen t  research  has d em ons tra ted  that the p lacen ta  has several potential lipid uptake 
m ech an ism s  (Figure 3).
Maternal  blood
. s V L D L - R
P lacen ta
Figure 3. Placental lipid up take m echanism s. LPL; Lipoprotein lipase;
FA B P: Fatty Acid B inding  Protein; V L D L -R : V L D L  receptor; Oxd LD L-R; oxidised  
L D L  receptor; LDL-R: L D L  receptor
7.1 L ipopro te in  Lipase
Placental lipoprotein lipase activity has been isolated from animal and hum an placentas 
(B one t  et al, 1992) F urtherm ore ,  it has been  previously  suggested  that p lacental L P L  
h y d ro ly s i s  t r ig ly c e r id e s  f ro m  m a te rn a l  V L D L  and  no t the t r ig ly ce r id e s  f ro m  
ch y lo m ic ro n s  (D utta -R oy , 1995). This  w ould  seem  to add support to the concep ts  o f  
m a te rn a l  rem o d e l l in g  o f  l ipop ro te ins  before  delivery  and  m ay serve  as p ro tec tive  
m e c h a n i s m  to the fe tus  f ro m  the im m e d ia te  im p ac t  o f  an u n u su a l  fa tty  ac id  
co m p o s i t io n  in the m aternal meal. It is no tew orthy ,  how ever,  that the ev idence  for a 
spec if ic  h ydro lyses  e ffec t  on V L D L  o f  p lacen ta l  L P L  is based  en tire ly  on an im al 
s tud ies .  F u rtherm ore ,  a spec if ic ity  o f  p lacenta l  L P L  for V L D L  w ould  im ply  that it 
d iffe rs  from  L P L  isolated in every  o ther  hum an  tissue. C learly ,  this requires  further 
investigation.
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Nevertheless, changes in placental LPL activity as pregnancy proceeds are consistent 
with a concept of placental fatty acid transport. In the guinea pig, LPL activity 
increases approximately 11-fold during the latter gestation. Furthermore, as pregnancy 
proceeds, LPL activity declines in adipose and skeletal tissue and increases in 
placental and mammary tissues (Martin-Hidalgo et al 1994). These changes in LPL 
activities in various tissues would appear to facilitate targeting of lipoproteins to 
placental and mammary tissues.
The majority, if not all, of the LPL activity appears to be in placental macrophages and 
it has been demonstrated that VLDL-triglyceride fatty acids (and possibly also 
chylomicrons) predominate as a source of FA uptake for placental cells, while FFA 
predominate for the hepatocyte. If macrophages are the main source for the placenta, 
it is noteworthy that they are not in direct contact with the maternal blood. However, 
there is the possibility of transfer of LPL from macrophages to trophoblasts, cells that 
are in direct contact with the blood. Accordingly, placental macrophages may play a 
role in the uptake of triglyceride-rich lipoprotein FA for placental storage and transfer 
to the fetus.
7.2 Fatty Acid Binding Protein (FABP).
Upon release by LPL hydrolyses, how are fatty acids taken up the placenta? Recent 
work suggests that a specific Fatty Acid Binding Protein (FABP) may be involved 
(Dutta-Roy et al 1995) (Figure 3). This FABP, which is -40 kDa in size, behaves like 
other physiological receptors, and significantly appears to have a strong preference for 
long chain polyunsaturated fatty acids. As such, this placental protein may be vital to 
the development and growth of the human fetus.
7.3 VLDL receptors
Until recently, very little was known about VLDL-receptor localisation and regulation. 
VLDL-receptor is expressed in the human placenta predominantly in trophoblast cells, 
and in a pattern consistent with a role in placental lipid transport (Wittmack et al, 
1995). VLDL-receptor expression is high at term relative to that in the first trimester, 
and thus is likely to be involved in transfer of lipid to the placenta for the growing 
fetus. Interestingly, the trophoblast VLDL-receptor is subject to up-regulation by 
insulin (and fasting insulin levels more than double in pregnancy) and fibrate class 
hypolipidemic drugs.
7.4 LDL receptors
LDL receptor activity is present in human placenta cells and the cholesterol delivered to 
these cells can be used for progesterone synthesis (Winkel et al 1980). Recently, 
scavenger receptor activity, greatly exceeding that of the LDL receptor, has been 
identified in human placental trophoblasts and macrophages (Bonet et al 1995). 
However, cholesterol assimilated via the scavenger receptor activity appears to be
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disconnected from endocrine steroid genesis in trophoblasts and may function to 
degrade modified lipoproteins and prevent toxic effects on placental cellular function 
and fetal growth and development. Indeed, given the changes in plasma triglyceride 
concentration during pregnancy, it is likely that the LDL subfraction profile tends 
towards smaller, denser species (see Chapter IV). These particles are more 
susceptible to oxidative damage and oxidative stress is increased in pregnancy, in 
particular in pre-eclampsia (Uotila et al, 1993). As such an increase in the levels of 
modified lipoproteins during pregnancy may be a direct consequence of the increase in 
plasma triglyceride levels that facilitate placental lipid uptake. Accordingly scavenger 
receptors may function as an essential buffer against the inevitable rise in modified 
lipids.
7.5 High Density Lipoprotein cholesterol uptake
Uptake of free and esterified cholesterol from HDL by the placental trophoblast cells 
takes place through a receptor independent mechanism (Lascuncion et al, 1991). The 
HDL2 subfraction is primarily involved. As such, HDL may provide a reserve or
alternative supply to LDL of cholesterol for progesterone synthesis and for transport to 
the fetus to support growth and development.
8. PRE-ECLAM PSIA
8.1 Clinical Signs and pathogenesis
Pre-eclampsia and eclampsia are the most important causes of maternal death in the 
USA, Scandinavia, Iceland, Finland and the United Kingdom (Roberts & Redman 
1993). They occupy the same prime position as they did nearly 40 years ago. Despite 
intensive research the pathogenesis remains unclear and there is no specific diagnostic 
test; the disorder is recognised by the concurrence of pregnancy-induced changes that 
regress after delivery, of which hypertension and proteinuria are the easiest to 
recognise and the signs by which the maternal syndrome is defined.
From recent reviews the emerging consensus is that poor placental perfusion which is 
the result of immunologically mediated abnormal implantation, microvascular disease, 
or excessive placental size, is the unique feature of pregnancies predisposed to pre­
eclampsia. But how can abnormal placental perfusion lead to multiorgan systemic 
disease? It is proposed that the poorly perfused placenta is the origin of blood-borne 
materials that affect maternal systemic function by activating vascular endothelial cells 
(Rodgers et al 1988).
8.2 Endothelial dysfunction in pre-eclam psia
There is increasing evidence that endothelial cell injury and altered endothelial cell 
function play an important role in pathogenesis of pre-eclampsia (Roberts & Redman 
1993). Increased levels of Factor VUI-related antigen, increased levels of fibronectin
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(cFN) of fibronectin ED1+, a disturbance of plasminogen-activator inhibitor, and 
crucially a disturbance of the Prostacyclin (PGI2)/ Thromboxane A2 (TXA2) balance,
all support the hypothesis that endothelial damage is intimately involved in the 
pathogenesis of pre-eclampsia. Recent studies have shown that cFN serves as an 
early indicator of pre-eclamptic endothelial damage. Serum from pre-eclamptic 
women injures endothelial cells in vitro. Abnormalities of the haemostatic system in 
pre-eclampsia are compatible with a local low-grade or compensated intravascular 
coagulation, secondary to platelet adherence at sites of vascular endothelial damage. 
The critical question therefore is what is the nature of the blood-borne materials 
causing altered endothelial function.
8.3 Lipid changes in Pre-eclampsia: possible role in pathogenesis
In the course of normal pregnancy women have altered lipoprotein metabolism as 
reflected in a hyperlipidaemia that grows more marked as pregnancy proceeds. 
Among those in whom pre-eclampsia develops, changes in lipid metabolism have been 
shown to be more pronounced in that the plasma triglyceride levels are further 
increased (by 50% on average) compared with those women with normal pregnancies 
(Potter & Nestel 1979). The rise in plasma triglyceride also precedes clinical signs of 
pre-eclampsia (Lorentzen et al 1995). From the area of cardiovascular research there 
is increasing evidence that hyperlipidaemia can cause endothelial dysfunction (see 
section 5.2) The question arises, therefore, whether endothelial dysfunction of pre­
eclampsia is causatively related to alterations in metabolism of lipids and lipoproteins
Evidence from recent studies suggests several potential mechanisms of interaction 
between altered lipoprotein metabolism and endothelial dysfunction in women with 
pre-eclampsia. Firstly, significant elevations of lipid peroxide levels occur in pre­
eclampsia as compared with normal pregnancy (Maseki et al 1981, Uotila et al 1993). 
The source of lipid peroxide production is postulated to be placental (Wang et al
1992). The finding of elevated lipid peroxides is interesting because lipid peroxides 
interfere with endothelial physiology: lipid peroxides impair endothelial prostacyclin 
synthetase (Higgs & Vane 1983), inactive endothelium-derived relaxing factor 
(EDRF) (Gryglewski et al 1986), and stimulate endothelin production and release 
(Dekker et al 1991). Therefore, in the absence of adequate production of prostacyclin 
and probably the antiaggregatory auticoid EDRF, surface-mediated platelet activation 
may be expected to occur. Direct activation of platelets by lipid peroxides is also 
likely. Thus, lipid peroxides could be the blood-borne materials responsible for 
endothelial dysfunction in pre-eclampsia.
Secondly, a number of recent studies have demonstrated that hypertriglyceridaemic 
serum and triglyceride-rich lipoproteins are cytotoxic to cultured human endothelial 
cells (Spiedel et al 1990, Gianturco et al 1980). Therefore, the exaggerated
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hypertriglyceridaemia might itself be contributory to endothelial dysfunction. In 
addition, if this 'excess' triglyceride is largely in the form of VLDLi * the large, 
buoyant VLDL, then this will favour increased production of LDL-III, the small, 
dense, atherogenic LDL subfraction. This LDL, as described previously, is more 
susceptible to oxidation and therefore raised LDL-III, secondary to raised triglyceride, 
might also contribute to the lipid peroxide load by providing a more abundant and 
better substrate for peroxidation as lipoproteins circulate through the placenta. With 
this in mind, it is interesting to note that one of the histopathological changes seen in 
the placenta of pre-eclamptic women is the occlusion of vessels by fibrinoid material 
with adjacent foam cell invasion (Roberts & Redman 1993). These features are 
suggestive of the presence of oxidised LDL.
Thirdly, pre-eclamptic women have altered fatty acid metabolism, as demonstrated by 
recent elegant work by Henriksen's group. They have shown that sera from women 
with pre-eclampsia induce accumulation of triglyceride in cultured endothelial cells 
with resultant reduced prostacyclin synthesis (Lorentzen et al 1991). This enhanced 
intracellular triglyceride accumulation appears largely to be the result of raised serum 
free fatty acids. The authors suggest that lipolytic activity of serum is stimulated and 
this is the major cause for the increase in free fatty acid/albumin ratio (Endresen et al
1993).
Finally, raised triglyceride-rich lipoproteins drive enhanced neutral lipid exchange 
thereby explaining the lower HDL-cholesterol concentrations seen in pre-eclampsia 
(Potter & Nestel 1979). ApoA-I levels also are lower. There is evidence that HDL2
stimulates PGI2 secretion from endothelial surfaces (Kaaja et al 1995). HDL particles
also have antioxidative properties and, as a result, lower HDL concentrations favour 
an increased lipid peroxide load and endothelial dysfunction. Interestingly, in non­
pregnant individuals plasma HDL-cholesterol concentrations relate positively and 
significantly to endothelium-dependent relaxation of coronary vessels in patients with 
coronary heart disease (Kuhn et al 1991, Chowienczyk et al 1994). In addition, in a 
study in patients with type 2 diabetes mellitus, decreased HDL-cholesterol was the 
best predictor of impaired vasodilatation to acetylcholine even after adjustment for all 
lipid and lipoprotein concentrations (O’Brien et al 1997).
9. INTRAUTERINE GROWTH RESTRICTION
9.1 Background
Normal fetal growth occurs by a sequential process of cellular hyperplasia, 
hyperplasia plus hypertrophy and, lastly, by hypertrophy alone. Growth deficiency is 
the end result of numerous pathologies which reduce fetal cell size and, when early 
and severe enough, cell number. The loss of cell number is not generally corrected
2 0
after delivery and these children remain small. Broadly categorised, causes of growth 
deficiency include fetal, maternal, uterine and placental disorders. Risk factors for 
growth deficiency common to any obstetric practice include smoking and maternal 
vascular disease.
9.2 Lipids and Birthweight
The effect on fetal growth of hyperlipidaemia in pregnancy is not well understood at 
present. From available evidence, it appears that plasma triglyceride demonstrates a 
curvilinear relationship to birth weight in normal pregnancies. Further, apo A-I (the 
apoprotein principally associated with the HDL2 subfraction) has been shown to 
correlate positively and apo A-II (principally associated with the smaller HDL3 
subfraction) correlate negatively with birth weight (Knopp et al, 1985).
9.3 IUGR and Lipids
Given the importance of maternal hyperlipidaemia in supplying both cholesterol and 
triglyceride to the rapidly developing fetus, it is conceivable that pregnancies 
complicated by IUGR exhibit abnormal lipoprotein metabolism. However, it would 
appear from the literature that such studies are sparse.
9.4 Fetal origins of coronary heart disease
The fetal origins hypothesis states that fetal under-nutrition in middle to late gestation, 
which leads to disproportionate fetal growth, programmes later coronary heart disease. 
Animal studies have shown that undernutrition before birth programmes persisting 
changes in a range of metabolic, physiological and structural parameters. Studies in 
humans have shown that men and women whose birth weights were at the lower end 
of the normal range, who were thin at birth, or who were small in relation to placental 
size have increased rates of coronary heart disease. The mechanisms underlying these 
associations remain unclear. The programming of blood pressure, insulin resistance, 
lipoprotein metabolism, blood coagulation, and hormonal settings are all active areas 
of research (Barker 1995).
9.5 Maternal lipoprotein metabolism and fetal birthweight
It is possible that maternal lipoprotein metabolism during pregnancy (or governing 
factors, such as degree of insulin resistance) may also influence fetal 
programming/birth weight and predict future risk of CHD. Previous literature as 
detailed above suggest that maternal apo Al concentrations near term correlate directly 
with birthweight, whereas apo A ll concentrations correlate negatively with birth 
weight and length (Knopp et al, 1985). Total apo A or HDL-cholesterol 
concentrations have also been shown to be lower in mothers with pregnancies 
complicated by IUGR or pre-eclampsia (Potter & Nestel 1979). In addition, although 
babies born to mothers with gestational diabetes tend to be macrosomic, they also have 
an increased future risk of CHD, and at term their mothers also exhibit significantly
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lower HDL-cholesterol concentrations (Montelongo et al 1992). Interestingly, HDL2 
subfractions stimulate placental progesterone synthesis and might affect fetal growth 
by controlling the provision of cholesterol via the placenta (Lascuncion et al 1991). 
Alternatively, the magnitude of insulin resistance may be a unifying hypothesis as it 
not only relates inversely to HDL (and thus Apo Al) metabolism, but also is greater in 
women with gestational diabetes and pre-eclampsia. Further support for this 
possibility comes from a study which demonstrated that in mothers with BMI less than 
25 kg.m-2, plasma insulin and insulin response to an oral glucose tolerance test were 
inversely related to birth weight (p<0 .0 2 ), after simultaneously adjusting for 
physiological factors and glucose concentrations (Breschi et al 1993).
Thus, it is tempting to speculate that the mother’s metabolic characteristics, particularly 
insulin resistance (and thus CHD risk), is transmitted to the offspring through direct 
effects on fetal growth rather than by genetic factors. Accordingly, maternal metabolic 
factors may also aid in predicting future CHD risk of their children. These findings 
clearly deserve more detailed investigation.
10. AIMS
10.1 Lipoprotein subfraction changes in normal pregnancy
As described above, one of the mechanisms by which triglyceride influences coronary 
risk is through its effect on LDL subfractions, with higher triglyceride concentrations 
promoting increased synthesis of small, dense LDL-III particles. However, this 
relationship is not linear, rather recent cross-sectional studies imply a threshold effect: 
synthesis of LDL-III proceeding only once triglyceride concentrations go beyond a 
‘threshold’ value. To the best of our knowledge no longitudinal studies have been 
designed to examine this phenomenon in individual subjects. The physiological 
changes in plasma triglyceride which accompany pregnancy provide such an 
opportunity. Thus, we have measured LDL subclasses throughout gestation using 
density gradient ultracentrifugation. This technique, allowed us to examine 
quantitatively the relationship between plasma triglyceride and perturbations in the 
LDL subfractions during pregnancy. This study is detailed in Chapter III
10.2 A longitudinal study of the relationships between haemostatic, 
lipid, and hormonal changes during normal human pregnancy.
Increased activation of both blood coagulation and fibrinolysis occurs during normal 
pregnancy. The responsible mechanisms are unclear, but from studies in non­
pregnant individuals, may include increases in blood lipids. The associations between 
fasting plasma cholesterol and triglyceride, serum oestradiol, and Factor VII activity, 
PAI activity, t-PA antigen, fibrin D-dimer, and vWF antigen during normal pregnancy 
were studied and the results of this study are detailed in Chapter IV.
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10.3 Lipoprotein subfraction concentrations in pre-eclampsia
In women with pre-eclampsia, plasma triglyceride concentrations climb substantially 
above those observed in normal pregnancy and do so well in advance of the 
appearance of clinical manifestations of the disorder. As described above, however, 
lipoprotein classes are not homogeneous entities but include subclasses of differing 
function and metabolic potential. Information in the literature of the concentrations of 
very low density (VLDL) and LDL subfractions in pre-eclampsia was lacking. This 
was particularly important to investigate as small, dense LDL are more atherogenic 
than larger LDL species. With this background we explored the hypothesis that in this 
disorder large triglyceride-rich lipoproteins (VLDLi), and small, dense LDL (LDL- 
III), were significantly increased over and above the concentrations seen in normal 
pregnancy. The results of this investigation are detailed in chapter V.
10.4 A relationship between m yom etrial resistance artery behaviour 
and circulating lipid composition in pre-eclampsia
Substantial evidence suggests that alterations in endothelial behaviour underlie the 
maternal pathophysiology of pre-eclampsia, a disease with a high maternal and fetal 
morbidity and mortality. Researchers from Nottingham have demonstrated an 
alteration in endothelium dependent myometrial resistance artery function in women 
with this syndrome, and have induced a similar functional change in myometrial 
resistance vessels from normal pregnant women after incubation with plasma from 
women with pre-eclampsia. These findings are consistent with the hypothesis that 
some circulating humoral factor(s) affects maternal systemic function directly or 
indirectly, by activating endothelial cells with resultant vascular injury. In 
collaboration with this group the relationship between plasma lipid concentrations and 
endothelial behaviour of myometrial resistance vessels bathed in plasma from normal 
pregnancies and those complicated by pre-eclampsia, was examined. We measured 
plasma cholesterol, triglyceride, Apo A l and Apo B concentrations from normal 
pregnancy samples and samples from women with pre-eclampsia and related these 
data to observed changes in myometrial resistance artery behaviour. The results are 
presented in chapter VI.
10.5 Potential pathogenic roles of aberrant lipoprotein and fatty acid  
metabolism in pre-eclampsia
Based upon results of some of the above work, and allied with existing data from 
other studies in the literature, a mechanistic scheme for the generation of the 
hyperlipidaemia in pre-eclampsia was devised. In addition, the potential role of the 
hyperlipidaemia in the pathophysiology of the syndrome is detailed. These 
hypotheses are described in Chapter VII.
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10.6 L ipoprotein  concen trations in pregnancies com plicated by 
Intrauterine Growth Restriction
Finally, since data on lipid changes in IUGR pregnancies are sparse, the aim of the 
final study in this thesis (Chapter VIII) was to compare lipid and lipoprotein 
concentrations in the third trimester from normal pregnancies and those complicated by 
IUGR.
1 0 .7  Potential effects o f progesterone on lipid and haem ostatic  
changes in pregnancy
It should be noted that whilst we have examined a potential role for oestradiol in 
promoting the lipid and haemostatic changes during pregnancy, we have not excluded 
a potential impact of the significant rise in progesterone concentrations on such 
changes. Current literature would suggest, however, that natural progesterones, in 
contrast to androgenic progestogens, have minimal, if any, effect on lipid metabolism 
(Knopp et al 1994).
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CHAPTER II
METHODS
1. Materials
Names and addresses of manufacturers and suppliers of reagents, hardware and 
software used for this thesis are given in Appendix 1.
2. Subject selection  
2. 1 Pregnant subjects
All pregnant subjects including those with preeclampsia and IUGR were recruited 
from Glasgow Royal Maternity Hospital. For the purposes of studies carried out in 
Chapters III, IV and V, women who had no identifiable risk factors for the current 
pregnancy as determined by detailed obstetric history were recruited by N. Sattar at 
their booking visit. These women represented the normal pregnancy cohort. Each 
woman was followed up at home and fasting blood samples for lipid, lipoprotein and 
subfraction measurements were taken at 5 week intervals up to and including 35 
weeks of gestation.
Women with preeclampsia were identified by Senior House Officers (Dr Astrid 
Bendormir and Dr Colin Berry) at Glasgow Royal Infirmary Hospital. The inclusion 
and exclusion criteria are described in detail in Chapter V and in Appendix 3. All 
patients were instructed to fast and blood samples were withdrawn around 7.30 am in 
the morning usually by N.Sattar although on occasions Dr's Bendormir and Berry 
helped out in this respect.
Women with IUGR were identified by Dr Alan Mathers (Consultant Obstetrician with 
an interest in Fetal Medicine, and Clinical Director of GRMH) and Dr Theresa Kelly 
(Senior Registrar). The inclusion and exclusion criteria for these patients are 
described in detail in Chapter VIII. All patients were instructed to fast and blood 
samples were withdrawn in the morning by Dr Theresa Kelly.
2. 2 Non-pregnant female controls
Non-pregnant female controls were recruited from laboratory staff, friends and 
colleagues. None were taking medication known to affect lipid or lipoprotein subclass 
concentrations. Once again, all blood samples were taken following an overnight fast.
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3. Sample handling
In all cases, blood samples were placed on ice and spun within two hours of 
venesection at 3000rpm for 10 mins. Separated serum or plasma was then either
frozen immediately at -70°C or stored temporarily at 4°C.
4. Ethical approval
All studies were approved by the Ethical Committee of Glasgow Royal Infirmary.
5. Laboratory techniques
The myography techniques used are described in detail in Chapter VI.
5. 1 p Quantification
Plasma total cholesterol, triglyceride, HDL cholesterol, VLDL cholesterol and LDL 
cholesterol measurements were performed by a modification of the standard Lipid 
Research Clinics protocol (1975). Five ml of plasma was placed in a Beckman ultra- 
clear tube (13 x 64 mm) and over layered with 2 ml of d 1.006 g/ml solution. Tubes 
were capped and centrifuged overnight at 35, 000 rpm (4°C) in a Beckman 50.4 rotor. 
The supernatant was collected from the top 25 mm into a 3 ml flask, this being the 
VLDL. The contents of the bottom fraction were transferred to a 5.0 ml volumetric 
flask. The tube was washed with saline and the wash added to the flask and the final 
volume adjusted to 5.0 ml with 0.15 M NaCl. A 1.0 ml aliquot of this bottom fraction 
was then placed in a Beckman centrifuge tube and 50 pi of precipitating agent (9.56 g
Mn CL2 .4 H2O + 1.05 g (approximately 5 x 105 units) heparin sodium salt in 25 ml
0.15M NaCl) were added and mixed. This mixture was kept at 4°C for 15 minutes 
and then centrifuged at 10, 000 rpm for 30 minutes. This would precipitate the LDL 
fraction leaving the supernatant as the HDL fractions. The cholesterol content of 
whole plasma, top fraction (VLDL), bottom  fractions (LDL + HDL) and 
heparin/Mn2+ precipitated supernatant (HDL) were then determined by enzymatic 
colorimetric assays as described in the next section. The total plasma cholesterol, 
triglyceride, LDL cholesterol and HDL cholesterol were measured by kind courtesy of 
the routine staff of the Lipid section of the Department of Pathological Biochemistry, 
at the Glasgow Royal Infirmary.
Calculations
Bottom fraction cholesterol - HDL cholesterol = calculated LDL 
Total cholesterol - Bottom fraction cholesterol = calculated VLDL 
Measured VLDL should agree with calculated VLDL by ±0.35 mmol/1.
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5. 2 Compositional Analyses
Total cholesterol and triglyceride were determined in whole plasma and in the 
lipoprotein fractions by enzymatic colorimetric assays on an Hitachi 717 auto analyser.
The principal of the cholesterol assay is shown diagrammatically below:
Cholesterol esterase
Cholesterol esters + H20 ---------------------------------- > Cholesterol + RCOOH
Cholesterol oxidase
Cholesterol + C> 2 ----------------------------------> A4-cholestenone + H2O2
POD
2 H2C>2 + 4-aminophenazone + phenol-------------- > 4-(p-benzoquinone-mono-
imono)- phenazone + 4H20
The principle of the triglyceride assay is as follows:
Lipase
Triglyceride + 3H20  >. glycerol + 3 RCOOH
GK
Glycerol + A TP---------------------- >. glycerol-3-phosphate + ADP
GPO
Glycerol-3-phosphate + 0 2 -------------- > dihydroxyacetone phosphate + H2O2
Peroxidase
H2O2 + 4-aminophenazone + 4-chlorophenol-------------- >
4-(p-benzoquinone-mono-imino)-phenazone + 2H20  + HC1.
The assay kits used for the cholesterol and triglyceride were Boehringer Kit No 
704121 and 704113 respectively and resultant colour changes were measured at 505 
nm.
Free cholesterol and phospholipid were estimated with Boehringer Kit No 310328 and 
691844 respectively using enzymatic colorimetric assays on a Centrifichem Encore 
centrifugal analyser (Baker Instruments).
Phospholipids were measured by an enzymatic colorimetric test kit (Boehringer 
Mannheim Cat. No. 691844), measured at 500nm, using a Centrifichem Encore 
analyser (Baker Instruments).
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Quality controls Precinorm (Boehringer Mannheim Cat. No 781827)
Precipath (Boehringer Mannheim Cat. No. 1285874).
Free Cholesterol was measured using an enzymatic colorimetric test kit (Boehringer 
Mannheim Cat. No. 310328) by the CHOP-PAP method of a total cholesterol but 
omitting the enzyme cholesterol esterase. It was analysed using a Centrifichem Encore 
analyser (Baker Instruments) and read at wavelength 500nm.
Esterified Cholesterol was calculated from the total and free cholesterol as follows:-
1.68 x (total chol. -free chol.)
The correction factor of 1.68 is to account for the molecular weight of the different 
cholesterol esters.
Conversion Factors - The factors used to convert from mmol/1 to mg/dl are as follows 
cholesterol in mg/dl = 38.7 x value in mmol/1 
triglyceride in mg/dl = 88.7 x value in mmol/1
5. 3 Modified Lowry Protein Assay
Protein measurements were performed according to a modified Lowry Protein Assay. 
Reagents
1 . Stock Reagents:
Solution A - 2% Na2C 0 3 in 0 .1M NaOH (w/v)
Solution B - 2% NaK Tartrate (w/v)
Solution C - 1% Q 1SO4 (w/v)
Folin Ciocalteu Reagent - BDH
2 . Working Reagents:
Biuret Reagent - 100 ml Solution A, 1 ml Solution B, 1 ml Solution C.
If sample to be analysed is turbid, add 1 mg/ml sodium docecyl (Lauryl) 
sulphate .
Dilute stock Folin Ciocalteu 1:1 with deionised water.
Standards
A stock solution of human albumin (Fraction V) Sigma A-8763, Lot 127F-9037 1
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mg/ml is stored at 20°C.
Working standards in the range 0-50 |ig (0, 15, 25, 50 pg) were prepared by taking 
appropriate volumes of stock standard 0-50 pi) and adjusting the final volume to 400 
pi with deionised water.
Quality Control
Bovine serum albumin (Fraction V) Sigma A4503, Lot 17F-0150.
Two stock solutions of bovine serum albumin at 0.15 mg/ml and 0.30 mg/ml were 
stored at 20°C. One hundred pi will be equivalent to 15 pg and 30 pg respectively. 
The final volume in the assay was adjusted to 400 pi with deionised water.
Sample Preparation
Samples requiring dilution were adjusted to a final volume of 400 pi with deionised 
water. For VLDLi and VLDL2 fractions, 100 pi samples as used whilst 50 pi sample 
was used for IDL fractions. In LDL fractions, 50 pi sample was diluted to 500 pi 
with distilled water and 100  pi of this dilutes ample was used for the assay.
Method
1. Two ml of Biuret reagent were added to 400 pi standard, control and samples.
2. These were vortexed and then allowed to stand for 10 minutes.
3. Two hundred pi (200 pi) working Folin Ciocalteu reagent was added with 
immediate mixing.
4. Allowed to stand for 30 minutes.
5. Read optical density at 750 nm within 2 hours.
5. 4 Measurement of Apo A l and ApoB.
These were measured using liquid-phase immunoprecipitation test kits (Orion 
Diagnostica Cat No. 67249 & 67265), read at 340 nm, in a Centrifichem Encore 
analyser (Baker Instruments).
5. 5 Method for LDL Subfraction Analysis (see Griffin et al, 1990)
Density Solutions
Density solutions d = 1.006 g/ml and d = 1.182 g/ml were prepared as described in 
the preceding section. The respective density solutions were then prepared as follows.
29
S o lu tio n s Volume d = 1.006 g/ml Volum e d
g/m l
1.019 100  ml + 8.5 ml
1.024 100  ml + 13.6 ml
1/034 100  ml + 18.6 ml
1.045 100  ml + 27.8 ml
1.056 100  ml + 42.9 ml
1.060 100  ml + 49.3 ml
All densities were checked with a digital densitometer.
Methods
Three ml (3 ml) of fresh plasma was adjusted to a density of 1.09 g/ml by adding 0.25 
g KBr and 0.3 ml of d = 1.182 g/ml solution. The sample and 6 -step salt gradient 
were introduced sequentially into polyvinyl alcohol coated polyallomer SW-40 tubes 
by peristaltic pump. The gradient was prepared and centrifugation carried out at 23 °C 
in a Beckman L8-60. The rotor was accelerated to 170 rpm and then centrifuged at 
40, 000 rpm for 24 hours. On completion of the run the rotor was stopped with the 
brake off. After centrifugation, the LDL subfractions were eluted by upward 
displacement using dense hydrophobic material (Maxidens, 1.6 g/ml, Nyegaard Ltd) 
by a constant infusion pump (Sage Instruments, Orion Research Incorp, USA) at a 
flow rate of 0.69 ml/minute. The eluate was passed through a UV detector 
(MSE/Fisons, UK) and detected by continuous monitoring of absorbance at 280 nm. 
In most instances, it was possible to resolve three distinct subfractions, ie LDL-I, 
LDL-II and LDL-III. The individual subfraction areas beneath the LDL profile were 
quantified using Beckman 'Data Graphics' software (Beckman, UK). The detection 
system measured LDL concentration as absorbance at 280 nm and this was corrected 
to lipoprotein mass equivalence by applying previously calculated extinction 
coefficient. LDL-I 1 optical density (OD) = 2.63 mg lipoprotein/ml, LDL-II 1 OD = 
2.94 mg lipoprotein/ml and LDL-III 1 OD = 1.92 mg lipoprotein ml.
The integrated areas were corrected for differences in extinction coefficient and 
expressed as percentage of total LDL concentrations in mg of lipoprotein/dl plasma. 
The total value for total LDL (d 1.019-1.063) lipoprotein mass (free cholesterol + 
cholesteryl ester + triglyceride + phospholipid + protein) was then used to generate 
individual subfraction concentration. Cholesteryl ester was calculated from (total 
cholesterol minus free cholesterol) times 1.69.
5. 6 Sequential Isolation of V L D L i, VLDL2, IDL and LDL
VLDLj, VLDL2 , IDL and LDL were prepared from plasma by a modification of the
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cumulative gradient centrifugation technique described by Lindgren et al (1972). 
Density Solutions
The density solutions for the gradient was prepared from d = 1.006 g/ml and d =
1.182 g/ml solutions.
Density (g/ml) Volume d = 1.006 g/ml Volume d = 1.182 g/ml
1.0988 25 ml + 27.89 ml
1.0860 25 ml + 20.83 ml
1.0790 25 ml + 17.72 ml
1.0722 25 ml + 50.05 ml
1.0641 25 ml + 12.31 ml
1.0588 25 ml + 10.73 ml
Methods
Two ml of plasma was adjusted to a density of 1.118 g/ml with 0.341 g NaCl. This 
was mixed well and allowed to stand for a short time before sampling. 0.5 ml of d =
1.182 g/ml solution was pipetted into the bottom of the tube and then plasma and 
density solutions over layered in the order and volumes shown below using an AAII
pump.
Density in g/ml Vol
1.182 0.5
Plasma 2
1.0988 1
1.0860 1
1.0970 2
1.0722 2
1.0641 2
1.0588 2
When the gradient was prepared, centrifugation was carried out in a Beckman SW40 
rotor at 39, 000 rmp at 23°C for 1 hour and 38 minutes. The top 1 ml (VLDLi) was
carefully removed using a long-form glass pipette at the end of the run. This was then 
replaced with 1 ml d = 1.0588 solution and centrifuged at 18, 5000 rpm for 15 hours 
and 41 minutes. At the end of this second run, the top 0.5 ml (VLDL2) is removed
with the long-form glass pipette. Further volumes are not replaced. IDL is removed 
in 0.5ml following centrifugation at 39, 000 for 2 hours and 35 minutes and LDL is 
removed in 1 ml following 30, 000 rpm for 21 hours and 10 minutes. The 
subfractions are stored at 4°C until analysis.
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5 .7  Hepatic lipase assay
The technique used was a modification (Watson et al, 1995) of the post-heparin lipase 
activity measurement. Therefore, first the post-heparin lipase assay technique is 
described followed by modifications necessary for measuring pre-heparin lipase 
activities.
5.7.1 Post-heparin lipase assay
Plasma was incubated with a i4C-labelled triglyceride/gum arabic emulsion; free fatty 
acids released by lipase activity were captured by albumin and extracted into a solvent. 
The ratio of radioactivity in the extracted fraction to the total present in blank 
incubations provided the basis of calculating the activity of the enzyme source. 
Selective measurement of lipoprotein lipase (LPL) is facilitated by preincubation of 
plasma with sodium dodecyl sulphate (SDS) to inactivate hepatic triglyceride lipase 
(HL) and the inclusion of serum as a source of LPL activator (apoC-II). HL activity is 
measured in 0.1 M sodium chloride to ensure inactivation of LPL.
Reagents
Glycerol Tri (1-14C) oleate in toluene,
Triolene 
Gum Arabic
Bovine Serum Albumin Fraction V 
Trizma Base
Sodium Dodecyl Sulphate 
Potassium Sulfate 
Thrombin
Preparation of Stock Reagents 
Cold Triolein (20 mg/ml in toulene) - Dissolve 0.5g triolein in 25 ml toluene. 
Radioactive Triolein
To 50 pCi (0.5 ml) glycerol tri (1-14C) oleate add 24.5 ml toluene.
Divide into 7 x 3.5 ml aliquots in round bottomed glass flasks.
To each aliquot, add 3.5 ml cold triolein.
Dry under nitrogen.
Wash each flask three times with 3 ml heptane. Dry down under nitrogen between 
washes and keep the flask in a hot water bath.
Store the tubes dried down under nitrogen and sealed at -20°C.
5% Gum Arabic in 0.2 M Tris-HCl pH 8.4
250 pCi (Amersham CFA 258) 
(Sigma T-7140) 
(Sigma G-9752) 
(Sigma A-4503) 
(Sigma T-3253) 
(BDH 44244) 
(Sigma P-4020) 
(Sigma T-4265)
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Five g gum arabic in 100 ml volumetric flask, made up to volume with 0.2 M Tris- 
HC1 (T-1503) pH to 8.4.
Filter through cotton gauze.
Divide into 18 x 5.5 ml aliquots and freeze at -20°C.
10% BSA in 0.2 M Tris-HCl pH 8.4
Weigh out 10 g BSA
Make up 20 ml of 1 M Tris-HCl (2.422 g of 20 ml).
To 20 ml of 1 M Tris-HCl, add approximately 40 ml of water, add 10 g BSA.
When the BSA has dissolved, adjust pH to 8.4.
Dilute to 100 ml with distilled water and divide into 18 x 5.5 ml aliquots and freeze at
20°C.
Extraction Solution
Methanol : 1.4 parts (141 ml)
Chloroform : 1.25 parts (125 ml)
Heptane : 1.00 parts (100 ml)
Extraction Buffer
0.14 M potassium carbonate, 0.14 boric acid, pH 10.5
Dissolve 3.8699 g K2CO3 and 1.7312 g H3BO3 in 200 ml distilled water.
Adjust pH to 10.5 with 2 M KOH.
Serum
Collect 100 ml of fasted blood into EDTA from a number of individuals.
Add 0.1% w/v CaC12 bovine thrombin 1 U/ml.
Incubate at 39°C for 30 minutes.
Remove the clot.
Dialyse against 0.15 M NaCl distilled water, pH 7.0, using 6,000-8,000 MWCO 
membrane.
Heat at 56°C for 30 minutes.
Dialyse against PBS.
Store as 1 ml aliquots at -20°C.
SDS Reagent
02. M Tris-HCl, 25 mm SDS (50 mm SDS for horses)
0.360 g SDS 1.21 g Tris-Base in 40 ml distilled water
Correct pH to 8.2, then make up volume to 50 ml in a volumetric flask.
Low Salt Buffer: 0.1M Tris, 0.216 M NaCl, pH 8.4
33
12/11 gTris Base 6.31 g NaCl in 500 ml distilled water. This gives a final NaCl 
concentration of 0.1 M in the reaction solution.
High Salt Buffer: 0.2M Tris, 2.16 M NaCl, pH 8.4
12/11 g Tris Base, 63.11 g NaCl in 500 ml distilled water. This gives a final NaCl
concentration of 1M in the reaction solution.
Assay Design
Low Salt Assay (four tubes)
Tubes 1, 2 Tubes 3, 4
-SDS +SDS
30 |il 0.15 M NaCl 20 pi 0.15 M NaCl
10 pi PHP 20 |il preincubation mixture
NB: Each samples in duplicate
All tubes, samples substrate and serum kept on ice prior to incubation.
Include two tubes with 40 pi 0.15 M NaCl (no PHP) in each assay half to 
measure blank (B) and total counts (TC).
Assay Procedure
Preincubation with SDS reagent
Place 0.5 ml post heparin plasma in TMU tube and add 0.5 ml SDS reagent and 
vortex. Incubate in the water bath at 26°C for 60 minutes and remove 20 pi for the 
low salt assay. Twenty pi is removed for the assay.
Preparation o f Substrate Mixture (30 minutes before required)
Radioactive triolein was placed in a glass flask and 5.5 ml gum arabic solution was
added. This was sonicated on ice at 18 microns for four minutes so that no fat
droplets are visible. (Sonicator tip 1/2 cm from bottom of flask). Add 5.5 ml of 10% 
BSA solution, mixed and vortex and keep on ice.
Reaction Mixtures
Tubes 1, 2, 3 4 : To each add 200 pi substrate
To each add 250 pi low salt buffer (0.2 M Tris/0.1 M NaCl)
To each add 50 pi serum
Tubes 5, 6 : To each add 200 pi substrate
To each add 250 pi high salt buffer (0.2M Tris/1.0 M NaCl)
To each add 50 pi 0.15 NaCl
High Salt Assay (tw o  
tubes)
Tubes 5, 6
30 pi 0.14 M NaCl 
10 pi PHP
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Incubation
Cap all tubes and incubate in water bath at 28°C for 60 minutes and return to ice 
immediately. Add 3.25 ml extraction solution to each tube. Add 0.75 ml extraction 
buffer to each tube, mix on vortex. Then centrifuge at 4°C, 3 K for 30 minutes. Take 
1 ml of upper phase for counting in scintillation vial. Add 10 ml Ultima Gold 
(Packard) scintillation fluid and 200 j l l I  acetic acid. For blank, take 1 ml upper phase 
and for total counts, take 1 ml of lower phase.
Calculations o f Results
Lipase activity in jimol FFA released/ml/hour=(CPM samples - CPM blank") x 755.1
CPM total - background
5.7.2. Pre-heparin lipase assay
Modification of the lipase assay for the measurement of lipoprotein lipase (LPL) and 
hepatic lipase (HL) in preheparin plasma.
1. Samples were collected into lithium heparin tubes and kept on ice. Plasma 
should be separated at 4°C and frozen at -70°C within one hour of collection.
2. Sample are assayed in triplicate for LPL, HL and blanks.
3. For the measurement of LPL, plasma was preincubated with 35 mm SDS
(instead of 25 mm) in 0.2 M tris base, pH 8.2 which was made up fresh on the 
day of assay. Incubation was for 60 minutes at 26°C as per the standard 
assay.
4. Forty pi ( 40 pi) of the plasma-SDS mixture (instead of 20 pi) was taken for 
the LPL incubation: the LPL substrates contains 0.2 M NaCl as per the 
standard assay.
5. The HL incubation contains 20 pi of plasma (instead of 10 pi) with substrate 
containing 2.0 M NaCl as per the standard assay.
6 . Both the LPL and HL incubations were for 1.5 hours (instead of one hour).
7. Following solvent extraction, 2 ml of the upper layer (instead of 1 ml) was
taken for liquid scintillation counting (added to 10 ml Ultima Gold, 200 pi of 
acetic acid). Use 1 ml of blank lower phase for total counts.
Calculations o f Results
Lipase activity = (CPM samples - CPM blankl x 755.1 x 1/1.5 x 1000 x 0.5
(CPM total - background) x 2
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5.8 Surface Modification of Beckman Ultraclear Centrifuge Tube
This was a procedure for coating the interior surface of Beckman ultraclear 
centrifuge tubes (in particular those used in swing-out rotors) with polyvinyl alcohol. 
Once Coated, salt solutions are then able to run smoothly down the sides of the tubes.
6. HAEMOSTATIC MARKERS 
6.1 Plasminogen Activator Inhibitor (PAI) Activity
Plasma plasminogen activator inhibitor activity levels were determined by a 
commercially available chromogenic substrate assay (Coatest PAI; Chromogenix, 
Epsom, U.K.). The assay involves the addition of a fixed amount of single-chain 
tissue plasminogen activator (tPA) in excess to undiluted plasma, where most of it 
rapidly forms an inactive complex with the fast inhibitor PAI-1. (Single-chain tPA is 
used in this assay since PAI-2, another inhibitor of tPA found in plasma, inhibits this 
single-chain form very poorly). The residual tPA then activates plasminogen to 
plasmin in the presence of a stimulator. The amount of plasmin formed is directly 
proportional to the PAI activity in the plasma sample (which under most circumstances 
is mostly PAI-1). Plasmin levels formed are determined by measuring the amidolytic 
activity of plasmin on a chromogenic substrate (S-2403), which releases p- 
nitroaniline, levels of which are determined using an automatic microplate reader 
(MR700 from Dynatech, West Sussex, UK), at 405nm. The absorbance of the sample 
is then compared with the standard curve generated for each test run, and a value for 
the level of PAI activity obtained. This is expressed in arbitrary units (AU), one AU 
being defined as the amount which inhibits one IU of tPA/ml under the test conditions 
(Chmeilewska et al 1986, Gram et al 1993). The inter assay CV performed on a 
normal pool on 10 occasions was found to be 8.1%. The intra assay CV calculated on 
5 single assays of a normal pool was 7.9%.
6.2 Tissue Plasminogen Activator (tPA) Antigen
Plasma levels of tPA were measured with a commercially available enzyme linked 
immunosorbent assay (ELISA) from Biopool AB, Umea, Sweden (Tintelize 
#101120). The assay quantifies human single chain and two chain tPA antigen. No 
cross reaction with urokinase is observed. Maximal sensitivity of the assay is reported 
by the manufacturer as 1.5 ng/ml.
In this assay some interference may occur from plasma levels of other antibodies such 
as anti-goat antibodies and rheumatoid factor. To exclude false positives, each sample 
is applied to two wells, one containing normal goat IgG, and the other containing goat 
anti-human tPA IgG. The difference in assay response between these two wells is 
highly tPA specific. After initial binding to the pre-coated well, the second antibody 
which is conjugated to horseradish peroxidase is added to the wells. This will bind to
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free antigenic determinants on the tPA molecules present. Unbound conjugate is 
washed away after a further incubation period, and the remaining peroxidase is then 
measured by the addition of its substrate orthophenylenediamine dihydrochloride. The 
colour development is proportional to the amount of tPA bound to the well. The 
absorbancies were read at 492 nm on an MR 700 plate reader (Dynatech, West 
Sussex,UK). Because of the blank reading for each test and standard, the curve had to 
be plotted manually and the results from each test read from the curve. Inter assay CV 
was 9.8%. Intra assay CV was 9.0%.
6.3 Von Willebrand Factor (VWF) Antigen
Plasma von Willebrand factor (VWF) antigen levels were measured using an in-house 
enzyme linked immunosorbent assay (ELISA), employing rabbit anti-human 
polyclonal antibodies obtained from DAKO pic, High Wycombe, UK (Short et al 
1982). The standard curve was constructed using a normal pooled plasma from 20 
volunteers, and the 5th British Standard (obtained from National Institute for 
Biological Standards and Control, South Mimms, UK) was used for pool calibration. 
This meant that the results could be reported as international units/decilitre (iu/dl), 
instead of as a percentage of the pool.
The capture antibody is coated onto the wells of a 96 well microtitre plate 
(Dynatech, West Sussex, UK). Diluted plasma samples and standards are then added 
and incubated for 30 minutes. After washing with buffer, the antibody, which is 
conjugated to horseradish peroxidase, is added. After this has incubated for a further 
30 minutes, another washing procedure takes place. The peroxidase substrate, 
orthophenylenediamine which has been activated by addition of hydrogen peroxide is 
added and after a rapid colour development, the reaction is stopped by the addition of
1.5 M sulphuric acid. The absorbance in the wells is read using the microplate reader 
(MR700 from Dynatech, West Sussex, UK) at 492 nm and the results of the test 
samples are read against the standard curve plotted for the assay. Using the 5th 
British Standard in 10 assays, the CV for the inter-assay variability was 7.7%. The 
intra-assay variability was 6.0%, being the CV of 5 aliquots of the standard in a single 
assay.
6. 4 Fibrin D-dimer antigen
The measurement of plasma fibrin D-dimer, which is present in several cross-linked 
fibrin degradation products, was carried out using the 'Dimertest' enzyme linked 
immunosorbent assay (ELISA) kit from Agen Biomedical Limited ( Parsippany, New 
Jersey, U.S.A.). The cleavage of both fibrinogen and fibrin by the fibrinolytic enzyme 
plasmin yields fibrin(ogen) degradation products (FDPs). However, only those 
products from the degradation of cross-linked fibrin contain D-dimer. Elevated levels 
of cross-linked FDPs detected by this method indicate increased formation and lysis of
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cross linked fibrin, and imply an increase in the turnover of cross-linked fibrin.
The principle of the test involves the use of the monoclonal antibody DD-3B6, which 
recognises D-dimer and FDPs containing it. The DD-3B6 is bound to microtitre plates 
to which either plasma or standard dilutions of D-dimer are added. After an incubation 
period to allow binding of the D-dimer to the capture antibody, the plate is washed 
with buffer and a second monoclonal antibody (DD-4D2) is added. This is conjugated 
to horseradish peroxidase and binds to the cross-linked FDPs that have been 
immobilised by the DD-3B6 antibody bound to the wells. After further washing, a 
substrate, 3-ethyl benzthiazoline sulphonic acid (ABTS) is added, which is hydrolysed 
by the horseradish peroxidase resulting in a coloured product which is proportional to 
the amount of D-dimer present in the well. The absorbance is then read 
spectrophotometrically on an MR700 plate reader (Dynatech, West Sussex, UK) at 
405nm, and compared with the standard curve.
The CVs for this assay were higher than for other assays, with an inter assay variation 
of 15.8% calculated by measuring the D-dimer level of the pool in 10 different assays. 
The intra assay CV calculated from 5 aliquots of pool run on the same assay was 
14.2%.
6. 5 Factor VIIc
FVIIc was determined by a one stage clotting assay in an ACL-300 Research 
coagulameter (IL, Warrington, UK). The principle of this assay involves adding to 
diluted patient plasma, plasma deficient in factor VII. Correction of the prolonged 
clotting time of deficient plasma is proportional to the concentration (activity %) of 
factor VII in the patients plasma. The exact activity is interpolated from a standard 
curve automatically measured on the instrument.
7. MYOMETRIAL RESISTANCE ARTERY BEHAVIOUR
The myography work was performed by Dr Richard Hayman, Clinical Research 
Fellow in Obstetrics and Gynaecology, School of Human Development, City Hospital 
Nottingham. The subject selection criteria, vessel collection methodology and 
myography techniques employed to examine the relationship between circulating lipid 
concentrations and endothelial function in normal pregnancy and pre-eclampsia are 
described in detail in Chapter VI.
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CHAPTER III
A LONGITUDINAL STUDY OF LIPOPROTEIN SUBFRACTION  
CHANGES IN NORMAL PREGNANCY
1. INTRODUCTION
During the course of normal pregnancy, plasma triglyceride and cholesterol 
concentrations rise by 200-400 % and 25-50 %, respectively. Although the rudiments 
of this process have been the subject of many studies (Warth et al 1975, Knopp et al 
1982, Ordovas et al 1984, Fahraeus et al 1985, Desoye et al 1987, Alvarez et al 
1996), few were undertaken throughout the gestational period, and fewer still 
incorporated measurements of lipoprotein subclasses. This information is important 
because it has become apparent that lipoprotein particles are not homogeneous but 
contain discrete subfractions differing in structure, physico-chemical properties, 
kinetic behaviour and origin. Low density lipoprotein (LDL), for example, 
incorporates a spectrum of lipoproteins of differing atherogenic potential. Small, 
dense LDL (LDL-III) in distinction to the larger more buoyant LDL-I and LDL-II 
particles, exhibit enhanced oxidation potential and reduced receptor binding (Steinberg 
et al 1989). Once oxidised, these particles are believed to be highly atherogenic 
promoting foam cell formation and initiating endothelial dysfunction (Steinberg et al 
1989).
The role of small, dense LDL as a risk factor for coronary heart disease (CHD) is 
becoming well established (Austin et al 1990, Coresh et al 1993, Tornvall et al 1993, 
Griffin et al 1994), and the above atherogenic mechanisms have been proposed. 
Furthermore, recently reported prospective studies have demonstrated that the 
presence of small, dense LDL particles precedes CHD (Krauss et al 1994, Gardner et 
al 1996) and predicts the development of non-insulin dependent diabetes mellitus 
(Austin et al 1995).
In man and non-pregnant women, plasma triglyceride is the major determinant of 
small dense LDL, accounting for 40-60% of the variability of this fraction in the 
plasma (Tornvall et al 1993, Griffin et al 1994, Tan et al 1995, Austin & Edwards 
1996). In addition, recent cross-sectional studies (Griffin et al 1994, Tan et al 1995) 
have prompted the suggestion that within the relationship between plasma triglyceride 
and the LDL subfraction profile, there is a threshold effect. However, to the best of 
our knowledge no longitudinal studies have been designed to examine this 
phenomenon in individual subjects. The physiological changes in plasma triglyceride 
which accompany pregnancy provides such an opportunity.
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In an earlier study of pregnant women, Silliman et al (1994) showed that the raised 
concentrations of plasma triglyceride which are prevalent one month prior to term are 
accompanied by a reduction in mean LDL size. Those women who experienced the 
greatest increase in plasma triglyceride exhibited the most significant shrinkage in their 
LDL particle diameter. By six weeks postpartum, reversal of this process was 
apparent, but the study design did not permit identification of the dynamics of the 
phenomenon or the timing of this particle size transition.
To address these issues, we have measured LDL subclasses throughout gestation 
using density gradient ultracentrifugation. This technique, allowed us to examine 
quantitatively the relationship between plasma triglyceride and perturbations in the 
LDL subfractions during pregnancy. Our primary hypothesis was that as pregnancy 
proceeded and plasma triglyceride increased, the LDL subfraction profile would be 
perturbed with the appearance of smaller, dense particles. A secondary hypothesis was 
there would exist a threshold above which LDL-III formation accelerated. We also 
wished to define whatever simultaneous changes in the spectral distribution of very 
low and intermediate density lipoprotein particles would accompany this process. To 
gain insight into potential mechanisms responsible for these changes we undertook 
serial measurements of serum oestradiol throughout pregnancy.
2. SU B JEC TS, SAM PLES AND M ETH O D S
Twelve pregnant women who registered for obstetric care at Glasgow Royal Maternity 
Hospital were recruited. Eight were multigravida with normal previous deliveries and 
four were primigravida. All women had no identifiable risk factors for the current 
pregnancy as determined by detailed obstetric history. During the course of pregnancy 
one woman emigrated and another woman had a positive test for Down's syndrome in 
the fetus and was excluded by mutual consent. The remaining ten women all had 
normal course and outcome of pregnancy, term delivery, ate a customary diet and did 
not receive any medication known to interfere with lipid metabolism or lipid 
determination. Additionally, none were phenotype apo E2/E2, an inherited trait which 
may generate disturbances in the plasma lipid profile even in normolipaemic subjects. 
The subject characteristics are given in Table 1.
For comparison, we also measured plasm a lipid and lipoprotein subfraction 
concentrations in 20 age, and BMI matched, healthy non-pregnant females. None 
were taking medication known to affect lipid or lipoprotein subclass concentrations.
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Table 1. Characteristics of study subjects
Parameters
Pregnant subjects 
Mean ±SD Range
Non-pregnant 
Subjects 
Mean ±SD
Prim/parous 
Age (yrs)
Height (m)
Weight (Kg)
BMI (Kg/m2)
Blood pressure (mmHg)
2/8
29.5±4.0
164±5
62±6
22.9±2.3
24-35
155-173
55-74
20-28
5/15
29.0±5.3
22.6+2.6
164+7
61±6
Systolic
Diastolic
104±6* 95-110
69+4* 58-70
39.6±1.3 38-41
3.5±0.2 3.1-3.8
115±9 
77±9
Length of gestation (wks) 
Birth Weight (Kg)
*Blood pressure at booking
The pregnant women were first seen at 10 weeks gestation (+/- 1 week) and thereafter 
at five week intervals until delivery. Each woman was seen six times. The gestational 
age was confirmed by ultrasound. All subjects were sampled after an overnight fast of 
12 hours. Twenty-five mL of blood was collected by venepuncture into K2EDTA 
(final concentration lmg/mL), lithium-heparin (5 mL), and plain tubes (5 mL). 
Plasma and serum were harvested at 4C by low speed centrifugation (3000 rpm) and 
aliquots of plasma for lipid and lipoprotein measurements and assessment of 
circulating hepatic lipase activity, and serum for oestradiol determination were used 
immediately.
The methods employed are described in their entirety in Chapter II. Plasma total 
cholesterol, triglyceride and HDL cholesterol were determined by a modification of the 
standard Lipid Research Clinics Protocol (1975). VLDLi (Sf 60-400), VLDL2 (Sf 20- 
60), IDL (Sf 12-20) and LDL (Sf 0-12) were prepared from plasma by a modification 
of the cumulative gradient ultracentrifugation technique described by Lindgren et al 
(1972). The cholesteryl-ester, triglyceride, free cholesterol, phospholipid and proteins 
of the lipoprotein were assayed as described (Chapter II) and concentrations calculated 
as the sum of the components (expressed as mg/dL plasma). Isolation of LDL 
subfractions from fasting plasma was achieved by density gradient ultracentrifugation 
using a discontinuous salt gradient (Griffin et al 1990). Circulating hepatic lipase (HL) 
activity was determined in fasting plasma using a method that has been developed in 
our laboratory to measure the low amounts of the enzyme normally present in the
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circulation, ie, without heparinisation which is normally used to release all hepatic 
lipase bound to endothelial sites (Watson et al 1995).
Statistical Analysis
The lipid and lipoprotein data were parametrically distributed as judged by the 
examination of normal probability plots. Nevertheless, as numbers were small, data 
are presented as medians and ranges. Comparisons of lipoprotein composition and 
between changes in circulating hepatic lipase activity between 10 and 35 weeks were 
performed by Students paired t-test. The level of significance required in comparisons 
of lipoprotein composition analysis was subject to Bonferroni correction.
Associations between initial triglyceride concentration, triglyceride/oestrogen ratio and 
final percentage abundance LDL-III were tested by calculating the Pearson correlation 
coefficient (R) and the coefficient of determination (R2) which was expressed as a 
percentage, (i.e. R2 gives the percentage of variation in the dependent variable which 
is explained by variation in the independent variable). The significance of association 
between pairs of variables was determined by linear regression.
3. RESULTS
3.1. Lipids and circulating hepatic lipase
Gestational age 10 15 20 25 30 35 Non-pregnant
subjects
Triglyceride (mmol/L) 0.78 1.20 1.40 1.53 1.73 2.55 0.80
0.6-1.5 0.6-1.8 0.8-2.3 0.9-2.4 1.2-2.7 1.6-3.6 0.5-1.3
Cholesterol (mmol/L) 4.40 5.45 6.23 6.53 6.73 7.20 4.53
3.2-6.8 4.0-7.5 4.7-7.6 5.0-8.5 5.4-8.7 5.6-8.4 3.0-6.2
HDL-Chol (mmol/L) 1.68 1.80 2.00 1.95 1.80 1.70 1.50
1.3-2.2 1.3-2.1 1.4-2.6 1.2-2.4 1.2-2.2 1.1-2.4 1.0-1.8
Oestradiol (nmol/L) 8.4 19.0 38.7 46.2 58.1 73.0 <1.0
3.6-22 8.8-39 17-60 34-76 40-73 47-105 <1.0-<1.0
Table 2. Median (range) of lipid and oestradiol concentrations at each gestational 
time point.
As pregnancy progressed from 10 to 35 weeks, median plasma triglyceride and 
cholesterol concentrations in our subjects rose from 0.78 to 2.55 mmol/L, and from 
4.40 to 7.20 mmol/L, respectively (Table 2). Mean (SE) circulating hepatic lipase 
activity fell by 40% (P=0.0007) from 24.9 (1.9) to 15.8 (2.3) pmol FFA/mL/min, 
between 10 and 35 weeks gestation. HDL-cholesterol concentration increased from a 
median of 1.68 mmol/L at 10 weeks to a maximum at 20 weeks gestation of 2.00
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mmol/L and thereafter fell to a concentration at 35 weeks of 1.70 mmol/L (Table 2).
3.2.VLDL subfractions and IDL com position and concentration during 
pregnancy
The rise in plasma triglyceride between 10 and 35 weeks encompassed the range of 
concentrations seen in a normal population of pre-menopausal women (Table 2) (Tan 
et al 1995). The concentration of the large triglyceride-rich VLDL (VLDLi), increased 
from a median of 19 mg/dL to 109 mg/dL at 35 weeks (Table 3).
Gestational age (wks) 10 15 20 25 30 35 Non-pregnant
subjects
VLDLi (mg/dL) 19 37 47 58 68 109 23
range 12-55 12-81 26-110 27-122 27-139 38-170 5-85
VLDL2 (mg/dL) 17 36 36 47 66 103 23
range 7-45 15-67 20-77 20-112 38-114 46-168 13-44
IDL (mg/dL) 26 48 58 72 91 124 35
range 13-54 14-69 24-100 44-121 55-140 79-157 18-62
LDL (mg/dL) 200 241 292 308 329 353 207
range 135-323 128-388 206-410 204-390 272-453 244-534 150-363
LDL-I (mg/dL) 33 37 49 53 62 67 50
range 16-52 22-54 37-70 37-82 33-104 27-96 22-130
(%) 17 19 18 18 18 20 25
range 7-20 10-20 14-21 15-21 12-23 11-22 11-49
LDL-II (mg/dL) 143 155 160 189 218 201 135
range 95-231 88-268 103-287 95-285 65-263 59-316 72-258
(%) 70 69 68 69 60 49 60
range 62-75 37-72 33-73 34-73 24-69 24-72 42-76
LDL-III (mg/dL) 28 28 32 44 79 123 31
range 15-56 15-134 24-165 23-142 36-174 43-192 5-68
(%) 14 15 14 13 21 32 15
range 9-24 8-53 9-53 6-51 11-64 10-65 3-23
Table 3. Median (range) of lipoprotein subclass concentrations at each gestational 
time point.
There was a parallel increase in the smaller cholesterol-rich VLDL subfraction, VLDL2 
(17 to 103 mg/dL), so that the ratio of VLDLi to VLDL2 remained constant.
43
Examination of VLDLi and VLDL2 compositions (Table 4), indicated that the make-up 
of the particles was not significantly different between 10 and 35 weeks despite the 
increase in plasma triglyceride. Further the composition of these fractions was similar 
to that seen in a recent cross-sectional survey of healthy adults (Tan et al 1995).
The plasma concentration of IDL (26 to 124 mg/dL) increased in a similar proportion 
to increments in VLDLi and VLDL2 (Table 3) and the particle became more 
triglyceride rich as pregnancy progressed (Table 4).
10 weeks
Subfraction Protein Free chol Chol esters Triglyceride Phospholipid
VLDLi
VLDL2
IDL
LDL
9.9 (0.8)
15.4 (0.6)
21.5 (0.9) 
23.3 (0.9)
2.8 (0.4) 
3.7 (0.5) 
5.0 (0.3) 
9.5 (0.8)
8.78 (0.9) 
2 0 .6  ( 1 .0 ) 
39.7 (0.9) 
43.1 (1.2)
64.9 (1.6) 
43.7 (1.4) 
15.1 (0.9) 
6.0 (0.7)
13.5 (1.0)
16.6 (0.9)
18.7 (0.8) 
18.1 (0.7)
35 weeks
Lipoproteins Protein Free chol Chol esters Triglyceride Phospholipid
VLDLi
VLDL2
IDL
LDL
7.9 (0.2) 
13.4 (0.3) 
18.6 (0 .2 ) 
24.2 (0.4)
2.5 (0.3)
5.4 (0.4)
6.5 (0.5) 
10.3 (1.2)
11 .6  ( 1 .0 ) 
2 2 .8  ( 1 .0 ) 
35.7 (1.1) 
35.7(1.1) *
63.9 (1.1) 
39.4 (1.3) 
18.9(0.8) * 
9.6 (0.8) t
14.2 (0.3)
19.1 (0.3)
20.3 (0.3)
20.2 (0.3)
Table 4. Chemical composition of apolipoprotein-B containing lipoproteins.
Values are mean (standard error) expressed as percent composition (g/lOOg) *P<0.01, 
t  P<0.002 refer to the significance of difference between 10 and 35 weeks as 
determined by Student’s paired t-test after correction for multiple comparisons by 
Bonferroni correction.
3.3 LDL subfraction mass, composition and profile
Total LDL mass increased during gestation in all subjects so that the median 
concentration increased by around 70% (200 to 353 mg/dL) between 10 and 35 
weeks. Compositional analysis revealed that the lipoprotein became enriched in 
triglyceride and depleted in cholesteryl ester over the period (Table 4).
On examining LDL subfractions it was seen that in 4 of the 10 subjects (ED, LC, KA, 
CH), no significant change in the LDL subfraction pattern occurred throughout
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gestation so that the relative proportions of LDL-I, LDL-II and LDL-III were relatively 
unaltered (see Figures 4, CH as a representative example, and Figures 5 and 6  ). In 
contrast, in the other six women (AM, AP, EG, EL, RM, AS), the LDL subfraction 
pattern was modified towards a smaller denser pattern in a manner suggestive of a 
threshold transition (see Figure 4, AM as a representative example, and Figures 5 and 
6 ), with the proportion of LDL-III increasing at the expense of LDL-II. Once again, 
the proportion of LDL-I remained unchanged (Table 3). Overall, therefore, median 
percent LDL-I remained relatively unaltered at between 17-20%, whereas LDL-II 
declined from 69% to 49% as the relative proportion of LDL-III doubled (14 to 32%) 
(Table 3).
In line with the observed perturbations in LDL subclasses and total LDL mass, LDL-I 
mass increased around two-fold, from 33 to 67 mg/dL; LDL-II mass increased least 
by around 40% from a median of 143 to 201 mg/dL, reaching a maximum of 218 
mg/dL at 30 weeks gestation; whereas in sharp contrast, LDL-III mass increased by 
greater than four-fold from 28 to 123 mg/dL (Table 3).
3 .4 . R e la tio n sh ip  betw een  serum  oestra d io l and lip o p ro te in  
perturbations.
From  10 weeks to 35 weeks of pregnancy mean serum oestradiol concentration 
increased steadily from a mean of 10 nmol/L to greater than 78 nmol/L. For each 
individual there was a strong relationship between the rise in oestradiol and the 
increment in plasma triglyceride (R2 0.71-0.98, mean R2 = 0.92; Figure 7) and 
plasma cholesterol (R2 0.79-0.97, mean R2= 0.87, data not shown). It was noted, 
however, that the slope of the association between increments in serum oestradiol and 
plasma triglyceride differed between subjects (see Table 5 and Figure 8 ). Additionally, 
the magnitude of rise in serum oestradiol during gestation correlated significantly 
(R2=41.7%, p=0.044) with the change in HDL-cholesterol between 10 and 35 weeks 
(Figure 8 )
3.5. Factors relating to LDL subclass modification
When the rate of change in plasma triglyceride for a given increment in oestrogen was 
calculated (see Table 5 and Figure 8 ) it appeared that the present cohort could be 
divided into two, those with a gradient of < 2  and those with a gradient > 2  
(mmol/nmol *10-2). Five of the six subjects who developed high LDL-III levels were 
all in the latter category, whereas three of the four women in whom LDL-III 
percentage remained relatively unchanged were in the former category. Similarly, the 
subjects could be divided on the basis of starting triglyceride (Table 5). In five of the 
six in whom the profile was altered towards a smaller denser LDL pattern, starting 
plasma triglyceride was 0.8 mmol/L or above, whereas it was below this level in the 
four subjects in whom no change in LDL subclass proportions was apparent. As a
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result, both the 10 week triglyceride and the the ratio of increment in triglyceride 
corrected for oestrogen correlated with 35 weeks concentration of small, dense LDL- 
III, and together these two parameters accounted for 67% (p=0.021) of its variability.
Subject
Booking
Trig
mmol/L
Trig/ 
E2
gradient
LDL
profile
shift
LDL-III 
mass at 35 
wks[mg/dL]
Plasma Trig 
@ LDL 
shift
VLDLi
@10/35wks
(mg/dL)
Gest age HL activity 
(wks)@ @10/35 wks 
LDL shift [umolFA/mL/Hr]
CH 0.60 1.32 - 45 1.70 20/80 26/19
LC 0.60 1.39 - 43 1.65- 15/38 20/6
AP 0.65 4.63 + 192 1.3-1.4 12/123 25-30 25/27
KA 0.75 2.31 - 57 2.10- 17/58 28/2
ED 0.75 1.98 - 46 1.95- 17/81 20/12
AM 0.80 1.62 + 132 1.8-2.4 18/102 30-35 30/16
RM 1.00 3.15 + 114 2.3-2.5 35/170 25-30 32/21
AS 1.10 3.98 + 159 1.1-1.6 55/131 10-15 32/17
EG 1.50 3.49 + 149 1.7-2.3 55/162 15-20 19/4
IL 1.55 2.17 + 189 1.9-2.3 50/116 20-25 15/12
LDL III mass = 16.9 + 36.7 * Trig/E2 gradient, R 2= 48.6%, p=0.025;
LDL III mass = 14.0 + 105 * [booking triglyceride], R2=36.7%, p=0.063 
LDL III mass = -38.7 +77.7 [booking triglyceride] + 30.2 * Trig/E2 gradient, 
R2=67.0%, p=0.021
Table 5. Patients characteristics in relation to LDL perturbation and LDL III mass at 
35 weeks
In addition, it was notable that the 35 week concentration of VLDLi was greater than 
100 mg/dL only in those individuals in whom alteration in the LDL profile was
apparent (%2, p<0 .0 0 1 ), whereas hepatic lipase activity was not significantly different
(p>0.05) between those group of individuals demonstrating no change in LDL 
subclass pattern compared to those exhibiting a significant increase in percentage LDL- 
III (Table 5).
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3.6. Characteristics of threshold triglyceride levels
The alteration in the LDL subclass profile if it occurred was observed at differing 
gestational times and plasma triglyceride concentrations in each women (Table 5 and 
Figures 5 and 6 ); that is the “threshold” triglyceride level, at which LDL-III 
concentration began to increase substantially, exhibited wide variation. In subject AS, 
for example, the LDL pattern altered early sometime between 10 and 15 weeks 
corresponding to a plasma triglyceride of 1.1-1.6 mmol/L. In contrast, in subject RM, 
alteration in the profile was not evident until 30 weeks and therefore must have 
commenced sometime between 25 to 30 weeks, and at a plasma triglyceride 
concentration of between 2.3-2.5 mmol/L.
W ith respect to gestational age, the alteration in profile was evident earliest in those 
women (AS, EG, IL) with the highest 10 week plasma triglyceride levels. In contrast, 
alteration in the profile was evident at the lowest triglyceride concentrations in those 
women (AS and AP) exhibiting the highest triglyceride to oestrogen gradients. 
Additionally, AS had by far the lowest HDL-cholesterol concentration throughout 
pregnancy (1.35 to 1.15 mmol/L), whereas AP had the highest, around ten-fold 
increment (12-123 mg/dL) in VLDLi concentration (Table 5).
4. DISCUSSIO N
This study set out to define the alterations in lipoprotein concentration and lipoprotein 
subfraction proportions and concentrations occurring throughout gestation in a group 
of healthy women. Serum oestradiol was measured and related to the increases in 
plasma triglyceride concentration. The increase in plasma triglyceride, cholesterol and 
HDL-cholesterol during gestation are in agreement with reports by numerous other 
investigators (Warth et al 1975, Knopp et al 1982, Ordovas et al 1984, Fahraeus et al 
1985, Desoye et al 1987, Alvarez et al 1996) and therefore our results may be applied 
more widely.
As pregnancy progressed and plasma triglyceride increased across the normal range, 
VLDLi and VLDL2 increased in parallel. The significant rise in VLDL2 concentration 
during gestation corroborates the results of one previous study (Silliman et al 1994). 
The results of that study allied to our data further highlight the uniqueness of the 
hyperlipidaemia of pregnancy. To elaborate, in the normal non-pregnant population, 
higher concentrations of plasma triglyceride are associated with a preferential higher 
VLDLi concentrations (Tan et al 1995). This particle is secreted by the liver to supply 
tissues with triglyceride fatty acids in the post-absorptive state. The concentration of 
VLDL2, the principal precursor in the circulation to IDL and LDL, does not change as 
dramatically. In the normal adult population, a high concentration of VLDLi is often 
associated with a failure of insulin action and increased risk of coronary heart disease. 
In contrast, as pregnancy progressed and high triglyceride levels developed, VLDLi
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and VLDL2 rose together so that their ratio, instead of increasing by two-fold, as 
would be predicted from population studies in the non-pregnant (VLDLi to VLDL2 
ratio at a plasma triglyceride of 0.5 mmol/L is 1.0 compared to 2.0 at plasma 
triglyceride of 2.5 mmol/L) (Tan et al 1995), remained constant.
In the absence of kinetic data, it remains unclear to what extent the increase in VLDL 
subclass concentrations represent increased synthesis or reduced catabolism. 
Oestrogen mediated increased synthesis is likely to be the predominant mechanism in 
early pregnancy. Micronised ethinyl oestradiol has been reported to increase large 
VLDL (VLDLi) production rates of healthy post-menopausal women 1.8 fold (Walsh 
et al 1991), whereas more potent oestrogens in oral contraceptives have been shown to 
promote increased plasma levels of both large (3-fold) and small VLDL (2.2 fold) 
subclasses, by increasing production rates of both particles, fractional catabolic rates 
remaining unchanged (Walsh et al 1993). It follows, therefore, that the significant 
elevations in oestradiol seen in gestation may favour balanced elaboration of both 
VLDL subclasses. However, relative insulin resistance is a feature of late gestation 
(Herrera et al 1988) and may also contribute to increased VLDLi levels.
Reduced catabolism of VLDL (specifically VLDLi), however, may be an additional 
factor for increased VLDL concentrations in late pregnancy as a significant reduction 
(around 50%) in post-heparin LPL activity and a significant negative correlation 
between LPL activity and VLDL levels during pregnancy have been reported 
previously (Alvarez et al 1996). From studies in rats (Herrera et al 1988), it is known 
that adipose tissue is the main site of the decreased LPL activity seen in late gestation 
and that this change is caused by insulin resistance.
The rise in IDL concentration during pregnancy has also been previously demonstrated 
(Silliman et al 1994, Warth et al 1975). It is notable, however, that the degree in 
elevation in IDL concentration was significantly greater (almost double) than 
previously reported (Tan et al 1995) in non-pregnant individuals for a similar 
increment in plasma cholesterol. This is in keeping with the markedly elevated VLDL2 
levels in pregnancy and subsequent delipidation to IDL in the circulation. In line with 
previous studies (Wart et al 1975, Montelongo et al 1992), as pregnancy progressed 
IDL and LDL particles became triglyceride enriched, reflecting in part oestrogen 
mediated inhibition of hepatic lipase activity with resultant reduced triglyceride 
hydrolysis of IDL and LDL particles, and second an increase in the interchange of 
neutral lipids between lipoproteins (Montelongo et al 1992, Iglesias et al 1994).
Recent work from our laboratory (Griffin et al 1994, Tan et al 1995) has suggested the 
presence of a critical triglyceride threshold at which significant changes in LDL 
subclasses may occur. The current longitudinal data from individual subjects, studied 
repeatedly during the appearance of the physiological hyperlipidaemia, provides 
additional strong support for this important concept. In all subjects with the exception
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of AS, percent LDL-III (and LDL-III mass) changed little in early gestation despite 
increasing triglyceride concentrations. However, as gestation progressed and plasma 
triglyceride levels increased further, in six of the 10 subjects the LDL profile changed 
dramatically with the proportion of LDL-III (and therefore LDL-III mass) increasing 
simultaneous with a decrease in LDL-II. Because we sampled at four week intervals, 
we were able to determine only an approximate gestational age or plasma triglyceride 
concentration at which LDL profile change first occurred. Nevertheless, there 
appeared to be considerable variation between individuals in the gestational age and 
plasma triglyceride intervals at which change in the LDL profile first manifested. In 
general, the alteration in profile towards small dense LDL-III, was earliest in those 
individuals with the highest initial 10 weeks triglyceride concentrations. However, it 
may be significant that LDL profile alteration occurred at the lowest triglyceride 
concentrations in the two individuals with the highest triglyceride to oestrogen 
increments, and that one of these two individuals had the lowest HDL-cholesterol 
level, whereas the other had the greatest proportional increase in VLDL]. Both low 
HDL-cholesterol and raised VLDLi concentrations are associated with insulin 
insensitivity, and although none of our subjects developed frank glucose intolerance, 
relative insulin insensitivity may be linked to earlier LDL profile shift during 
pregnancy.
In each of the six patients in whom LDL profile change took place, as plasma 
triglyceride increased further, the decrease in the proportion of LDL-II accompanying 
the dramatic LDL-III rise, caused LDL-II mass to plateau and then decline (data not 
shown). In the other four patients, LDL subclass pattern did not alter by 35 weeks of 
gestation. Significantly, these four subjects also had the lowest triglyceride increments 
in gestation and presumably did not reach their critical threshold triglyceride 
concentration. These observations therefore provide a basis for understanding the 
previous relationships between LDL subclasses and plasma triglyceride described in 
population studies.
The most widely accepted mechanism of LDL subclass formation and modulation is 
that of neutral lipid exchange (Griffin et al 1994, Tan et al 1995). This process 
involves the transfer of triglyceride from triglyceride-rich lipoprotein (VLDLi and 
chylomicron remnants) into the core of LDL in exchange for cholesteryl esters, a 
reaction mediated by cholesterol ester transfer protein (CETP). Although CETP 
activity has been shown to increase significantly by the second trimester of pregnancy 
before declining towards gestation (Iglesias et al 1994), in most normal situations the 
activity of this enzyme is not rate limiting (Bagdade et al 1991). In contrast, it is likely 
that VLDLj concentration determines the rate of of triglyceride transfer into LDL since
large triglyceride-rich VLDL is a preferred substrate for cholesteryl ester transfer 
protein action (Eisenberg 1985). It follows that during pregnancy, progressively 
increasing circulating concentrations of VLDLi promote triglyceride enrichment of
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LDL particles. The subsequent hydrolysis of this newly acquired triglyceride in LDL 
via the action of hepatic lipase, even when the activity of this enzyme is low as in 
pregnancy, results in the remodelling of LDL subclasses into smaller, denser species. 
Nevertheless, as we have now shown, remodelling of LDL particles towards smaller, 
denser particles does not proceed immediately but requires in each individual patient 
that a specific triglyceride threshold is attained.
Why should there be a threshold for the formation of small, dense LDL ? The recent 
model proposed by Tan et al (1995), is that a step-wise change in size from LDL-II to 
LDL-III occurs when HL acts upon a triglyceride-enriched LDL particle. It may be 
speculated that LDL-II has to have a certain minimum triglyceride enrichment so that in 
a single exposure to the lipase, sufficient surface and core lipid are removed to 
generate a conformational change in apolipoprotein B to a new thermodynamically 
stable state, characteristic of LDL-III. Indeed, there is recent evidence (McKeone et al 
1993, McNamara et al 1996) to support the idea that apolipoprotein B configuration 
differs between small and large LDL.
Finally, it is noteworthy that triglyceride increments were minimal in those subjects 
who entered pregnancy with low basal triglyceride concentrations, whereas those 
subjects who entered pregnancy with higher basal triglycerides showed greatest 
increases and were frankly hyperlipidaemic by 35 weeks. This was not due to 
differences in the increments in serum oestradiol but may reflect different responses to 
oestrogen stimulated hyperlipidaemia. That is, pregnancy may reveal a latent 
hyperlipidaemia due possibly to an inherited lipolytic problem. We are not the first to 
suggest this possibility. Montes et al (1984), have described case examples of subjects 
who have triglyceride levels that are above the ninety-fifth percentile values at 36 
weeks gestation and return to normal postpartum, but hyperlipidaemia is present 
among family members. Interestingly, these subjects also appeared to have lower 
HDL cholesterol concentrations when not pregnant. It would be of interest to confirm 
these findings in larger studies.
In conclusion, the present study makes several new and important observations: [1] 
As plasma triglyceride increases in pregnancy, there are parallel rise in median 
concentrations of VLDLi, VLDL2 and IDL, around 5-fold; [2] As a result of this 
progressive increase in plasma triglyceride, in particular in VLDLi, the LDL profile is
altered in some individuals towards smaller, dense particles; [3] In general, the higher 
the initial (booking) fasting plasma triglyceride concentration or the larger the rate of 
change in triglyceride for a given increment in oestradiol, the greater the probability of 
change in LDL profile towards smaller denser species; [4] Significantly, LDL subclass 
change towards smaller denser species occurs not in a gradual and progressive manner 
but exhibits “threshold” behaviour; and finally, [5] this “threshold” is achieved at 
differing gestational ages and triglyceride concentrations for different women.
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Subject AM
Subject CH
1 . 0 2 5 1 .034  1.044
D e n s i t y  ( g / m l )
1.060
F i g u r e  4. R ep re sen ta t iv e  ex am p le s  o f  L D L  su b frac t io n  d en s i ty  p ro f ile s  as 
p re g n an cy  p rogresses  in subjects A M  and CH, at 15 w eek s (  ), 25 w eeks (------- ),
and  35 w eek s  (------- )4 o f gestation. In A M , the p lasm a triglyceride concentra tion  at
the th ree  ges ta tional time points w ere 1.5, 1.6 and 2.4 m m ol/L , respectively . T he 
profile  w as  per tu rbed  towards smaller, denser pattern with the percen tage  abundance 
o f  L D L -III  increasing  at the expense o f LDL-II. In CH, the trig lyceride values at the 
th ree  ges ta t iona l  t im e points were 0.75, 0.95 and 1.70 m m olL , respectively , and in 
this case, a lthough total area under the curve increased reflecting increased L D L  mass, 
no  perturbation  in the pattern was observed.
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-  - Q10
0
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Plasma triglyceride (mmol/L)
F ig u re  5. This  graph dem onstra tes  the sequentia l re la tionship  between p lasm a 
triglyceride (m m ol/L) and percent LD L-III .  L ines connect the data for a g iven 
women. It was seen that percentage abundance LDL-III remained relatively constant
throughout gestation in four o f the 10 subjects (--------- ). In five o f  the remaining six
subjects (— ) (IL, EG, AM, AP, RM ), percent LDL-III remained relatively constant 
for varying lengths of time but at differing triglyceride threshold levels and gestational 
time points, increased in a step-wise fashion. In the final subject, AS, an immediate 
increment in percent LDL-III was evident. For all patients, percentage abundance o f 
LDL-II behaved in a reciprocal manner to LDL-III and percentage abundance o f LDL-I 
remained relatively constant across the plasma triglyceride range (see Table 3).
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F ig u r e  6. This graph demonstrates the sequential relationship between LDL-III m ass 
(m g/dL) and gestational age (weeks). Lines connect the data for a given women. It 
was seen that LDL-III mass increased only slightly during gestation in four of the 10
subjects (--------- ). In five of the rem aining six subjects (___ ) (EG, EL, AP, AM, R M ),
L D L -III  m ass remained re la tively  unchanged  for varying lengths o f  time but at 
d iffering gestational time points, increased dramatically. The timing o f this ab rup t 
increase in LDL-III mass corresponded to the timing o f the observed perturbations in 
LDL profile (see Figure 5). In the final su b je c t , AS, an immediate increment in L D L - 
III m ass was evident. In each o f  the latter six patients, the decrease in the proportion 
of L D L -II  accom panying the dram atic  LDL-III rise, caused LD L-II  mass to p la teau  
and then decline as plasma triglyceride increased further (data not shown).
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F ig u r e  7. T h is  graph dem onstrates the re lationship betw een  plasma trig lyceride 
(m m ol/L ) and serum oestradiol (nmol/L) in each o f  the 10 subjects as pregnancy
progressed . Lines, (-------- ) if no LDL perturbation, against (----- ) if per turbation
present, connect the data for a given women. A close correlation between increment 
in p lasm a triglyceride and serum oestradiol was observed for each individual, although 
the slope o f  the associations appeared to vary widely (see also Table 5). In general, 
the higher the slope of association, the greater the likelihood o f  L D L  perturbation. It is 
also noteworthy that while all the subjects had similar lipid concentrations at 10 weeks 
g es ta t ion ,  they end-up at d iffe ring  tr ig lycer ide  co ncen tra t ions .  By the en d  o f  
p reg n an cy  six showed frank hyper lip idaem ia  (i.e. [ trig lyceride] >2.3  m m o l/L ) ,  
whereas the other four remained normolipidaemic.
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Figure 8 . This figure demonstrates the significant positive (R2=41.7% , p=0.044) 
relationship between the magnitude o f rise in serum oestradiol during gestation w ith  
the change in HDL-cholesterol between 10 and 35 weeks.
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CHAPTER IV
A LONGITUDINAL STUDY OF THE RELATIONSHIP BETWEEN 
HAEMOSTATIC, LIPID AND HORMONAL CHANGES DURING
NORMAL PREGNANCY  
1.0 INTRODUCTION
Normal human pregnancy is associated with major increases in blood coagulation 
factors (fibrinogen, Factors VII, X and VIIIc and von Willebrand Factor [vWF]). 
Fibrinolytic factors (Plasminogen activator inhibitor-1 (PAI-1), plasminogen activator 
inhibitor-2 (PAI-2), and tissue plasminogen activator (t-PA) antigen), and turnover of 
cross-linked fibrin, as measured by plasma fibrin D-dimer, are also increased 
(Hellgren & Blomback 1981, Beller & Ebert 1982, Stirling et al 1984, Ballageer et al 
1987, Kruithof et al 1987, Greer 1994). The physiological mechanisms underlying 
these changes are unclear, but they may be important for the maintenance of the 
placento-uterine interface, or to meet the haemostatic challenge of delivery (Greer 
1994). The regulation of these changes is unclear. Possible mechanisms include (a) 
hormonal changes in pregnancy, particularly increased oestrogen which can induce 
changes in coagulation and fibrinolysis when administered exogenously in oral 
contraceptives (Kluft & Lansink 1997) or hormone replacement therapy (HRT) 
(Meade 1997); and as described in Chapter I (section 5.1) (b) blood lipid changes in 
pregnancy, especially triglyceride which induces changes in coagulation and
fibrinolysis following dietary intake (Mitropoulos 1994) (or oestradiol administration). 
The object of this study was to determine the associations between changes in fasting 
serum oestradiol, plasma triglyceride and cholesterol, and changes in Factor VII and 
PAI activities, and t-PA, D-dimer and vWF antigens; each of which has been related to 
risk of arterial and/or venous thrombosis in epidemiological studies. A detailed 
analysis of lipid and lipoprotein changes for the patients in this study are described in 
the preceding chapter (Chapter III).
2.0 SUBJECTS, SAMPLES AND METHODS
Patient recruitment, bleeding shedule, and characterisitics precisely as described in 
Chapter III. In addition to the serum and K2 EDTA samples collected for oestradiol
and lipid determinations as described previously, citrated plasma aliquots for the 
determination of haemostatic factors were collected, spun and stored immediately at - 
70°C until analysis.
Methods are given in Chapter II. Briefly, plasma total cholesterol, triglyceride and 
HDL-cholesterol were determined by a modification of the standard Lipid Research 
Clinics Protocol. Oestradiol was determined by a quantitative immunoassay on the
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Technichon Immuno-l system (‘Heterogeneous Magnetic Separation Assay’, Bayer 
Diagnostics, UK). FVIIc was determined by a one stage clotting assay in an ACL-300 
Research Coagulameter (IL, Warrington, UK). PAI activity was measured by a 
chromogenic assay (Chromogenix, Stockholm, Sweden), tPA (Biopool, Stockholm, 
Sweden), fibrin D-dimers (AGEN, Parsippany, NJ, USA), and vWF antigen (Dako, 
Copenhagen, Denmark) were all measured by ELISA techniques.
Statistical Analysis
The lipid, haemostatic and hormonal variables were parametrically distributed as 
judged by the examination of normal probability plots. Nevertheless, as numbers 
were small, data are presented as medians and ranges. Associations between changes 
in plasma lipid and haemostatic variables and oestradiol concentrations were tested by 
calculating the Pearson correlation coefficient (R) and the coefficient of determination 
(R 2) which was expressed as a percentage, (i.e. R2 gives the percentage of variation in 
the dependent variable which is explained by variation in the independent variable). 
The significance of association between pairs of variables was determined by linear
regression.
3.0 R ESU LTS
3.1 Lipids & O estradiol (Table 6 )
Gestational age (wks) 10 15 20 25 30 35
Triglyceride (mmol/1) 0.78 
0.6-1.5
1.20 
0.6-1.8
1.40 
0.8-2.3
1.53 
0.9-2.4
1.73 
1.2-2.7
2.55 
1.5-3.6
Cholesterol (mmol/1) 4.40 
3.2-6.8
5.45 
4.0-7.5
6.23 
4.7-7.6
6.53 
5.0-8.5
6.73 
5.4-8.7
7.20 
5.6-8.4
Oestradiol (nmol/1) 8.4
3.6-22
19.0
8.8-39
38.7
17-60
46.2
33-76
58.1
40-73
73.0
47-105
FVIIc (IU/dl) 95.0
81-138
121.0
99-137
125.5
106-149
132.0
107-179
151.0
116-179
168.0
137-193
PAI activity (% pool) 87.0
33-125
86.5
72-125
108.5
59-153
140
79-179
178.5
129-222
223.5
181-273
tPA-antigen (ng/ml) 4.80 
2.4-6.5
5.30 
3.4-7.5
6.90 
4.7-7.6
6.45 
5.4-8.3
7.40
5.0-10
9.05
6.8-10.8
D-dimer (ng/ml) 68.5
29-127
72.0
30-101
98.5
47-123
159.5
66-200
199.5
127-310
295.5
196-420
vWF (IU/dl) 136.0
93-253
189.0
78-249
194.0
81-252
183.0
134-325
205.0
89-296
231.0
109-293
T able 6. M edian (range) o f lip id , oestradiol and haem ostatic  
concentrations at each gestational time point.
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3.2 Haemostatic parameters
PAI activity increased by a factor of 2.56 from a median of 87 % normal pool to 226% 
at 35 weeks. Increments in median circulating concentrations of t-PA (4.80-9.05 
ng/ml), FVIIc (95.0-168.0 IU/dl), and vWF (136.0-231.0 IU/dl) were slightly less 
pronounced, whereas median D-dimer concentration increased by more than 4-fold 
(68.5 to 295.5 ng/ml) (Table 6 ). The patterns of increase in plasma triglyceride, PAI 
activity, t-PA and D-dimer were similar, in that the maximum rise in each of these 
parameters occurred after 25 weeks (Table 6 ). In contrast, increments in FVIIc and 
vWF were more uniform in nature.
3.3 Relationship between serum  oestradiol, plasm a triglyceride and  
cholesterol, and Factor VII
For each individual there were strong and significant relationships (Table 7) between 
the rise in factor VIIc and the increment in plasma triglyceride (Figure 9), and 
increment in serum oestradiol (Figure 10). Furthermore, the slopes of the association 
between increments in factor VIIc and plasma triglyceride or serum oestradiol were 
similar (3-fold vs 2.35-fold). The associations between rise in factor VIIc and
increment in plasma cholesterol were equally strong (Table 7).
Triglyceride_______Cholesterol________ Oestradiol
FVII 0.93 (0.83-0.99)* 0.93 (0.82-0.97)* 0.93 (0.85-0.99)*
P A M 0.93 (0.88-0.99)* 0.82 (0.64-0.96) 0.91 (0.81-0.98)*
tPA 0.94 (0.71-0.99)+ 0.79 (0.49-0.99) 0.92 (0.71-0.99)+
D-Dimer 0.92 (0.84-0.97)* 0.79 (0.71-0.96) 0.89 (0.79-0.95)+
vW F 0.63 (0.03-0.93) 0.72 (0.02-0.90) 0 .6 8 (0.03-0.94)
Table 7: Associations in individual patients between the change in 
plasma concentrations of haemostatic factors and alterations in plasma 
triglyceride and cholesterol and serum oestradiol concentrations.
Values presented are the median (range) of the correlation coefficients (R) for the 
associations between the change in plasma concentrations of haemostatic factors and 
alterations in plasma triglyceride and cholesterol, and serum oestradiol concentrations 
for the 10 subjects.
*P<0.05 in all 10 patients; +P<0.05 in 8 of the 10 patients.
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3.4 R elationships between serum  oestradiol, plasm a triglyceride and 
cholesterol, and PAI activity.
For each individual there were strong and significant relationships (Table 7) between 
the rise in PAI activity, and the increment in plasma triglyceride (Figure 11), and 
increment in serum oestradiol (Figure 12). The associations between changes in 
plasma cholesterol and PAI activity were somewhat weaker (Table 7). In contrast to 
the pattern seen with FVII activity, however, the range of the slopes of association 
between increments in PAI activity and plasma triglyceride was greater than that 
between changes in plasma PAI activity and serum oestradiol (4.9 fold vs 2.6 fold).
3.5 R elationship between serum  oestradiol, plasma triglyceride and 
cholesterol, and tPA antigen.
There were strong and significant relationships (Table 7) between the rise in tPA 
antigen, and the increment in plasma triglyceride (Figure 13), and increment in serum 
oestradiol (Figure 14) in 8 of the 10 individuals. Once again, the associations between 
changes in plasma cholesterol and tPA antigen were somewhat weaker (Table 7). 
Congruous to the association between the rise in PAI activity and the increment in 
plasma triglyceride, the relationship between the rise in tPA antigen and the increment 
in plasma triglyceride also exhibited considerable variability between individuals in the 
slopes of association (4.7 fold difference, Figure 13).
3.6 R elationship between serum  oestradiol, plasma triglyceride and 
cholesterol, and D-dimer
For each individual there was a strong and significant relationship (Table 7) between 
the rise in plasma D-dimer concentration and the increment in plasma triglyceride 
(Figure 15), whereas the association between alterations in plasma D-dimer and serum 
oestradiol concentrations were significant in 8 of the 10 subjects studied (Figure 16).
3.7 R elationship between serum  oestradiol, plasma triglyceride & 
cholesterol and vWF
The associations between changes in vWF with increases in serum oestradiol, plasma 
triglyceride or cholesterol, in each individual, were considerably weaker than the 
associations described above (Table 7).
4. DISCUSSIO N
The increases in coagulation and fibrinolytic variables during normal pregnancy which 
were observed in the present study were similar to those described in previous studies 
(Hellgren & Blomback 1981, Beller & Ebert 1982, Stirling et al 1984, Ballageer et al 
1987, Kruithof et al 1987, Greer 1994), as were the increases in serum oestradiol and
59
plasma lipids (Montelongo et al 1992, Silliman et al 1994) To our knowledge, the 
present study is the first to report strong and similar correlations in individual patients 
between the increments in Factor VII and PAI activities, t-PA and D-dimer antigens, 
and serum oestradiol and plasma triglyceride. These results are consistent with the 
hypothesis that oestradiol-induced hypertriglyceridaemia may be one mechanism 
through which increases in these coagulation and fibrinolytic variables occur during 
pregnancy.
There is much evidence that hypertriglyceridaemia in non-pregnant subjects is 
associated with increases in Factor VII and PAI activities: in part, this may reflect 
causal effects of triglyceride-rich lipoproteins on both activation of Factor VII, and 
synthesis and release of PAI-1 from endothelial cells (Juhan-Vague & Alesi 1993, 
Mitropoulos 194). Exogenous oral oestrogens increase Factor VII activity even in low 
doses (HRT) (Kluft & Lansink 1997, Meade 1997) and it has been suggested that this 
may be related to increased plasma triglyceride levels (Lowe 1996). While lower 
doses of exogenous oestrogens (HRT and contraceptives) decrease plasma levels of 
PAI-1 (Lowe 1996, Kluft & Lansink 1997, Meade 1997) pregnancy results in far 
higher levels of endogenous oestradiol. Thus a stimulatory effect on PAI-1 in 
pregnancy cannot be excluded, and further research is required to examine the effects 
of varying oestradiol doses on PAI-1 synthesis in vitro. It should be noted that the 
assay of PAI activity used in the present study is relatively specific for PAI-1, and 
relatively insensitive to PAI-2 which increases greatly during pregnancy (Kruithof et al 
1987). It should also be noted that the relationship between PAI-1 and triglyceride 
may be related to insulin resistance (Juhan-Vague & Alesi 1993).
The increase in plasma t-PA antigen during pregnancy was only slightly lower than the 
increase in PAI activity. This may reflect a primary increase in PAI which binds t-PA, 
and circulates as t-PA-PAl complexes. These complexes are detected by the t-PA 
assay used in the present study. Additionally and /or alternatively, it may reflect 
endothelial release of t-PA. While the increase in t-PA antigen during pregnancy was 
accompanied by a similar increase in vWF antigen, suggesting a related change in 
endothelial release, the correlation between the t-PA increment and the oestradiol and 
triglyceride increments was much stronger than the correlation between the vWF 
increment and the oestradiol and triglyceride increments. This finding suggests that 
either oestradiol-induced hypertriglyceridaemia is more important in endothelial release 
of t-PA than vWF in normal pregnancy, or that the increase in t-PA may be secondary 
to a primary increase in PAI-1 due to oestradiol-induced hypertriglyceridaemia.
The correlations between increases in plasma fibrin D-dimer, oestradiol and 
triglyceride during normal pregnancy suggest that the changes in Factor VII associated 
with oestradiol-induced hypertriglyceridaemia may result in increased fibrin turnover 
in vivo. There is evidence in non-pregnant subjects that increasing Factor VII activity
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is associated with increased thrombin activity in vitro, as measured by plasma levels of 
fibrinopeptides, fragments Fl+2, or thrombin-antithrombin complexes (Miller 1997, 
Lowe 1997). Further studies are required to examine the relationships between 
oestradiol, triglyceride, Factor VII and D-dimer.
These findings may be relevant not only to the possible mechanisms of change in 
coagulation and fibrinolysis during pregnancy, but also to the pathogenesis of 
atherosclerosis and thrombosis. Pregnancy is an interesting transient model of 
hyperlipidaemia and the development of an "atherogenic" lipoprotein profile is also 
related to changes in coagulation and fibrinolysis, which have been related to 
thrombotic risk in epidemiological studies (Lowe et al 1997). A notable finding in the 
present study was the inter-individual variability in increments in coagulation and 
fibrinolytic variables with elevations in oestradiol and triglycerides during pregnancy, 
suggesting the possibility of gene-environmental interactions (Green & Humphries 
1994). Clearly, further studies of individual changes in hormones, lipids and 
haemostatic variables during pregnancy may offer insights into the regulation of 
coagulation and fibrinolysis, and their relationships to atherothrombosis.
In conclusion, the results of this study show that in individual women undergoing 
normal pregnancy, there are significant correlations between oestradiol, triglyceride, 
Factor VII, PAI, t-PA and fibrin D-dimers, but not vWF, suggesting that oestradiol 
induced triglyceride changes may be responsible for the changes in coagulation.
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Lines connect the data for a g iven w om en . A  significant and strong l inear co r re la tion  
(Table 7) between increment in p lasm a triglyceride and FVIIc was observed  in each  o f  
the individuals studied.
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linear correlation (Table 7) be tw een  increments in the two parameters was observed  in 
each o f the individuals studied.
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m arkedly  (4.9 fold difference).
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F ig u re  12. T h is  g raph  d e m o n s t r a te s  the  seq u en tia l  re la tionsh ip  b e tw e e n  s e ru m  
oestradiol (mmol/1) and PA I-1  ac tiv i ty  in  each  o f  the 10 subjects  as p re g n an cy  
progressed. L ines  connec t  the d a ta  fo r  a g iven  w om en . A sign ifican t and  s trong  
linear correlation (Table 7) b e tw e en  increm en ts  in the two parameters was observed  in 
each of the individuals studied.
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and t-PA.Ag levels in each o f  the 10 sub jec ts  as pregnancy progressed. Lines connect  
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between increm ents in the tw o p a ram e te rs  w as observed  in each o f  the ind iv idua ls  
studied, although the slope o f  the assoc ia tions  appeared to vary widely.
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F ig u re  14. This graph d em o n s tra te s  the re la tionship  between serum oestrad io l and  
t-PA.Ag levels in each o f  the 10 subjects  as pregnancy  progressed. Lines co n n ec t  the 
data for a given w om en. A significant and strong linear correlation (Table 7) b e tw een  
increments in the two param eters  w as observed  in each o f the individuals studied.
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Lines connect the data for a g iven w o m en .  A  significant and strong corre la tion  (Table 
7) between increments in the tw o p a ram ete rs  was observed  in 8 o f the 10 ind iv iduals  
studied.
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CHAPTER V
LIPOPROTEIN SUBFRACTION CONCENTRATIONS IN
PRE-ECLAMPSIA
1.0 INTRODUCTION
As discussed in detail in Chapter I, current concepts on the pathophysiology of pre­
eclampsia suggest endothelial cell injury and altered endothelial cell function play a 
pivotal role. It is proposed that the poorly perfused placenta is the origin of a humoral 
factor that affects maternal systemic function, directly or indirectly, by activating 
endothelial cells with resultant vascular injury. The characteristic pathologic lesion 
seen in the utero-placental bed of patients with pre-eclampsia is a necrotising 
arteriopathy consisting of fibrinoid necrosis, accumulation of foam cells or lipid laden 
macrophages in the decidua, fibroblast proliferation, and a perivascular infiltrate. This 
lesion has been termed ‘acute atherosis.’ (Roberts & Redman 1993).
Work in the field of cardiovascular research has shown that serum lipids have a direct 
effect on endothelial function and that abnormal serum lipid profiles are associated 
with endothelial dysfunction (Chapter I, section 5.2). As such, the potential role of 
abnormal lipid metabolism in the genesis or expression of pre-eclampsia is the subject 
of increasing interest. Lipid and lipoprotein levels undergo dramatic changes in 
pregnancy presumably to supply lipid nutrients to the growing fetus. Plasma 
concentrations of triglyceride and cholesterol increase around 300% and 50%, 
respectively (Chapter III). In some situations the mechanisms regulating this 
physiologic hyperlipidaemia may malfunction. In women with pre-eclampsia, plasma 
free fatty acids and triglyceride concentrations climb substantially above those 
observed in normal pregnancy and do so well in advance of the appearance of clinical 
manifestations of the disorder (Lorentzen et al 1995). Branch and co-workers (1994) 
have shown that antibodies to an epitope of oxidized low density lipoprotein (LDL) are 
increased in pre-eclamptic patients, and as a result suggested that oxidized LDL may 
contribute to the foam cell formation in the decidua by mechanisms analogous to those 
involved in atherosclerosis. It should be noted, however, that other groups (Kurki et 
al 1996) have found that antibodies to oxidized LDL fail to predict the risk of pre­
eclampsia. More recently, first trimester serum cholesterol concentrations have been 
shown to be significantly associated with the risk of pre-eclampsia (van den Elzen 
1996).
Lipoprotein classes are not homogeneous entities but include subclasses of differing 
function and metabolic potential. At present there is no information on the 
concentrations of very low density (VLDL) and LDL subfractions in pre-eclampsia.
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This is particularly important to investigate as small, dense LDL are more atherogenic 
than larger LDL species. Poor recognition by the LDL receptor-mediated clearance 
mechanisms allows them to stay in the plasma compartment for longer, thereby 
increasing their likelihood of penetrating the arterial intima more readily. Further, 
small, dense LDL are also more readily oxidized and may contain less antioxidant; 
interestingly, decreased levels of vitamin E, an endogenous antioxidant in LDL, have 
been reported in severe pre-eclampsia (Wang et al 1991). As a result, small dense 
LDL are more readily taken up by macrophages to create foam cells. There is also 
considerable evidence to suggest that oxidized small, dense LDL may be the prime 
candidate associated with endothelial dysfunction (Chin et al 1992).
In addition, Arbogast et al (1994) have hypothesised that VLDL toxicity may help to 
explain endothelial dysfunction in pre-eclampsia. Previous data (Gianturco et al 1980) 
suggest that large triglyceride-rich VLDL subfraction (VLDLi) exhibits greater 
cytotoxicity than the smaller, cholesterol-rich VLDL (VLDL2) fraction. With this
background this study explored the hypothesis that in this disorder large triglyceride- 
rich lipoproteins (VLDLj), and small, dense LDL (LDL-III), were significantly 
increased over and above the concentrations seen in normal pregnancy.
2. SUBJECTS, SAMPLES AND METHODS
Eight women with pre-eclampsia and eight women with uncomplicated pregnancies 
were studied. The patient details are shown in Table 8 .
Cases
n=8
Controls
n=8
P-Value
Age 32 (25-37) 32 (26-35) NS
Parity (Prim/parous) 8/0 7/1 NS
Gestational age (wk) 32 (26-36) 32 (27-34) NS
Weight (kg) 73 (57-99) 72 (63-94) NS
SBP (mmHg) 155 (130-210) 130(110-140) 0 .0 1
DBP(mmHg) 105 (90-115) 75 (70-90) 0.0016
Platelets (x 10 /^1) 238 (111-377)
Urate (umol/L) 392 (243-482)
Fetal Weight (Kg) 2.7 (1.0-3.2) 3.4 (2.7-3.9) 0.013
NS = not significant. Values are given as medians (ranges).
Table 8 Characteristics of Normotensive Pregnant Women and Pre­
eclam ptic Women
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Cases, all primigravida, were recruited with confirmed pre-eclampsia (proteinuric 
pregnancy-induced hypertension) as defined by the International Society for the Study 
of Hypertension in Pregnancy (ie, diastolic blood pressure was greater than 110 mm 
Hg on one reading or exceeded 90 mm Hg on repeated readings; proteinuria was 
defined as 0.3 g/24 hours or greater, or 2+ or greater on dipstick testing, in the 
absence of infection or renal disease). Consecutive patients eligible for this study, 
where obtaining a fasting sample was possible, were recruited and all those 
approached agreed to participate. All patients were healthy before onset of pre­
eclampsia and were not receiving any medication known to interfere with lipid 
metabolism or lipid determination.
Eight normal pregnant women matched as a group for pre-pregnancy weight, age, and 
gestational age served as controls. All had normal course and outcome of pregnancy, 
term delivery, and customary diet, and did not receive any medication known to 
interfere with lipid metabolism or lipid determination. Additionally, none of the 
patients or controls were phenotype apo E2/E2, an inherited trait known to generate 
disturbances in the plasma lipid profile even in normolipaemic subjects. Further, none 
of the patients or controls were in labour at the time of sampling.
All subjects were sampled after an overnight fast of at least 10 hours. Twenty mL of 
blood was collected by venepuncture into K2EDTA (final concentration lmg/mL) and
lithium heparin tubes. Plasma was harvested at 4C by low speed centrifugation and 
aliquots of plasma for lipid and lipoprotein measurements were used immediately. 
Plasma for pre-heparin hepatic lipase was stored at -70C until analyses. The assay 
methods are described in their entirety in Chapter II. Briefly, plasma total cholesterol, 
triglyceride, and HDL-cholesterol measurements were performed by a modification of 
the standard Lipid Research Clinics Protocol. VLDLi, VLDL2, IDL, and LDL were
prepared and quantified as described earlier by cumulative flotation gradient 
ultracentrifugation. The cholesterol, triglyceride, free cholesterol, phospholipid, and 
proteins of the lipoprotein fractions were assayed and concentrations calculated as the 
sum of the components (expressed as mg/dL plasma). Isolation of LDL subfractions 
from fasting plasma was achieved by density gradient ultracentrifugation using a 
discontinuous salt gradient. Pre-heparin hepatic lipase activity was determined in 
fasting plasma as described in Chapter II.
Statistics
As the principal parameters of interest, ie, VLDLi and LDL-III, exhibited a lack of
normality, data are presented as median and range. Where appropriate, data were 
tested for statistical significance using Mann-Whitney U-test (Minitab, CA, USA). 
Comparisons between lipoprotein compositions were assessed by Student unpaired t- 
test and because of the multiple comparisons made, statistical significance was taken 
as the 0.01 (99 percent) level. The association between plasma concentrations of
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plasma triglyceride and mass LDL-III was performed using Spearman Rank 
correlation.
3. RESULTS
3.1 Lipid and lipoprotein concentrations
Cases
n=8
Controls
n=8
P-value
Triglyceride (mmol/1) 3.68 (2.35-5.00) 1.93 (1.25-2.90) 0.004
Cholesterol (mmol/1) 6 .8 8  (3.95-8.15) 7.35 (5.45-8.80) NS
HDL-Cholesterol (mmol/1) 1.43 (1.05-1.65) 1.70 (1.45-2.15) 0 .0 2 1
VLDLi (mg/dl) 184(111-385) 68  (27-135) 0.0016
VLDL2 (mg/dl) 146 (63-240) 76 (38-93) 0.014
IDL (mg/dl) 93 (60-160) 123 (70-184) NS
Total LDL (mg/dl) 279(172-410) 34 5  (174-453) NS
LDLrl (mg/dl) 22(12-33) 62 (23-86) 0.004
LDL-II (mg/dl) 55 (32-190) 211 (64-276) 0 .0 1 0
LDL-III (mg/dl) 170(16-356) 55 (11-126) 0.024
Hepatic lipase activity 
(umol FA/ml/Hr)
28.5 (18-50) 18 (10-25) 0.041
Values are given as medians (ranges). NS = not significant
Table 9 Lipid and Lipoprotein Concentrations, and Pre-heparin Hepatic 
Lipase Activity of Cases and Controls
The groups were comparable with respect to age, parity (although one control was 
parous), weight, and gestational age (Table 8 ). Median plasma triglyceride in patients 
with pre-eclampsia was almost double that in the control group. This was reflected in 
an almost three-fold increase in VLDLi and a two-fold increase in VLDL2, whereas
total plasma cholesterol, IDL and total LDL concentrations were the same in patients 
and controls (Table 9). Women with pre-eclampsia demonstrated significantly lower 
concentrations of LDL-I and LDL-II, the larger species, and markedly elevated plasma 
concentrations of small, dense LDL-III. The concentration of LDL-III correlated 
positively with plasma triglyceride concentration (r2 = 0.504, p=0.002, Figure 1). In 
line with the observed LDL profile, LDL particles were protein enriched (25.6 % [1.6] 
versus 23.3% [1.2], mean [SD] of g protein/100 g total lipoprotein mass for pre- 
eclamptics vs controls respectively, p=0.006, see below, Table 10). High density 
lipoprotein-cholesterol concentration was also statistically significant lower in the pre­
eclamptic group (p= 0.021). Pre-heparin hepatic lipase activity was significantly 
elevated in the pre-eclamptic group (p= 0.041, Table 9)
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3.2 L ipoprotein compositions
C ases
Lipoprotein Protein Free chol Chol esters Triglyceride Phospholipid
VLDLi 6.7(0.9)+ 3.4(1.6 ) 11.0(3.5) 62.6(3.0) 16.3(1.7)
v l d l 2 13.4(1.3) 7.0(2.6 ) 17.9(2.5)t 40.9(3.5) 2 0 .8 ( 1 .0 )
IDL 19.9(1.9) 5.7(2.2) 32.3(2.5) 20.2(3.4)* 2 1 .8 ( 1 .6 )
LDL 25.6(1.6)* 6 .2 ( 1 .9) 38.3(2.2) 9.4(2.6) 20.5(1.6)
C ontrols
Lipoprotein Protein Free chol Chol esters Triglyceride Phospholipid
VLDLi 9.2(1.3) 3.0(0.67) 10.4(2.9) 62.2(4.1) 15.2(3.0)
v l d l 2 15.7(2.0) 4.3(1.8 ) 27.7(4.7) 32.7(7.6) 19.7(1.8)
IDL 2 0 .0 (2 .2 ) 7.7(2.2) 36.6(4.2) 14.6(2.6) 21.1(1.7)
LDL 23.3(1.2) 9.9(4.1) 37.3(1.7) 9.0(1.9) 20.5(1.2)
Data are presented as mean (standard deviation) expressed as percent composition 
(g/lOOg); Choi esters = cholesteryl esters; Free chol = free cholesterol.
*P<0.01, +P<0.001 refer to the significance of difference between cases and controls 
as determined by Student unpaired t-test.
T able 10. C hem ical C om position of A polipoprotein-B  C ontaining  
Lipoproteins
When the composition of these particles was determined (Table 10) the following was 
found: the cholesteryl-ester to triglyceride ratio (the lipid composition of the 
hydrophobic core of the particle) was reduced in VLDL2 (0.44 [0 .10] versus 0.93
[0.44], mean [SD], for pre-eclamptics and controls respectively, p=0.019) and IDL 
(1.66 [0.37] versus 2.60 [0.66], p= 0.005) but not in VLDLi (0.17 [0.07] vs 0.18 
[0.05], p =0.77) and LDL (4.36 [1.30] versus 4.30 [1.00], p=0.91). Put another 
way, both VLDL2 and IDL were triglyceride enriched suggesting that both VLDL2 and
IDL were increasingly products of VLDLi catabolism in pre-eclampsia.
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4. D ISC U SSIO N
T h e  find ing  o f  s ign ifican tly  e levated p lasm a concen tra tions  o f  triglyceride and low er 
H D L -ch o les te ro l  concen tra tions  in w o m en  with p re -ec lam psia  is in good  ag reem en t 
w ith  p rev ious la rger studies (L orentzen et al 1995, K aaja  et al 1995). T he resu lts  o f  
th is  s tudy  have  d em o n s tra te d ,  for the first t im e, that ra ised  p lasm a tr ig ly ce r id e  
co n c en tra t io n s  in p re -ec lam p sia  are asso c ia ted  w ith  substan tia l ly  e leva ted  p la sm a  
concen tra t ions  o f  V L D L i and im portantly  o f  small, dense LDL-III. These l ipoprotein
su b fra c t io n  c h a n g e s  (and ra ised  hepa tic  lipase  ac tiv ity ) are in k eep in g  w ith  the
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metabolic pattern associated with the insulin resistance syndrome of which 
hypertriglyceridaemia is a key component (See Chapter I, section 4.7).
The close correlation in our study between mass LDL-III and plasma triglyceride 
concentration is in good agreement with previous studies of non-pregnant individuals. 
Using multivariate analysis, we and others (Griffin et al 1994, Tan et al 1995, Austin 
& Edwards 1996) have shown that in the non-pregnant situation plasma triglyceride is 
the major determinant of the concentration of small LDL, accounting for anywhere 
between 40-60% of its variability. Thus, the higher plasma triglyceride concentrations 
seen in women with pre-eclampsia may account for the substantially increased (around 
three-fold) levels of small, dense LDL.
A model has been published (Tan et al 1995) in which the generation of LDL-III is 
linked to increased triglyceride exchange into LDL followed by hepatic lipase-induced 
lipolysis of the particle. In that study it was seen that in women, but not in men, 
hepatic lipase activity was an independent predictor of the plasma concentration of 
small, dense LDL. Therefore, the higher hepatic lipase activity we observed in our 
pre-eclamptic cases may also contribute to the smaller, denser LDL profile.
It is as yet unclear why plasma triglyceride concentrations are elevated in pre­
eclampsia. It may be hypothesized that higher free fatty acid levels in conjunction with 
reduced hepatic p-oxidation may be involved (See Chapter VII). Equally, enhanced 
peripheral or hepatic insulin resistance may play a role (Kaaja et al 1995) as could 
reduced catabolism of triglycerides, ie, reduced lipoprotein lipase activity secondary to 
cytokine inhibition (See Chapter VII).
Whatever the mechanism, increased concentrations of triglyceride-rich lipoproteins in 
the circulation are potential contributors both directly, and through the generation of 
small, dense LDL, indirectly, to endothelial dysfunction and therefore the expression 
of pre-eclampsia.
Small, dense LDL are known from atherosclerosis studies to be more susceptible to 
oxidation than their larger counterparts and there is ample evidence of oxidative stress 
in pre-eclampsia (Wang et al 1991). Consistent with this finding, antibodies to an 
epitope of oxidized LDL have been shown to be significantly elevated in pre-eclamptic 
patients (Branch et al 1994). There is also evidence of enhanced type II phospholipase 
A2 (PLA2) concentrations in the plasma of women with severe pre-eclampsia (Lim et
al 1995). This may be associated with an increased intrinsic LDL-PLA2 activity, 
which is necessary for oxidation to occur (Witztum 1993). Therefore, the observation 
that small dense LDL is markedly elevated in pre-eclampsia may be the key link in 
explaining the recently reported relationship (Hubei et al 1996) between serum 
triglyceride levels and oxidation products in pre-eclamptic patients, and as such may 
play an important role in the genesis of endothelial dysfunction.
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Moreover, oxidized LDL inhibits endothelial prostacyclin synthesis, inactivates (and 
reduces synthesis and release of) endothelial derived relaxing factor (Chin et al 1992), 
and simultaneously increases endothelin production and release. These changes 
prom ote platelet activation with resultant enhanced thromboxane release. 
Lysophosphatidylcholine in oxidized LDL also stimulates expression of vascular 
endothelial-cell adhesion molecule-1 (Kume et al 1992) a monocyte adhesion molecule 
expressed by activated endothelial cells and previously demonstrated to be elevated in 
pre-eclampsia (Lyall et al 1994) and promotes rapid adhesion of neutrophils to 
endothelium by up-regulation of CD1 lb/CD 18 adhesion receptors on neutrophils 
(Lehr et al 1995). Large triglyceride-rich VLDL are also known to be cytotoxic and to 
promote synthesis and release of plasminogen activator inhibitor-1 (Hamsten & 
Eriksson 1994).
As many of these changes have also been documented and implicated in the 
pathogenesis of pre-eclampsia, the question arises whether endothelial dysfunction of 
pre-eclampsia is causally related to alterations in metabolism of fatty acids and 
triglyceride.
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CHAPTER VI
A RELATIONSHIP BETWEEN MYOMETRIAL RESISTANCE 
ARTERY BEHAVIOUR AND CIRCULATING LIPID COMPOSITION
1.0 INTRODUCTION
In the previous Chapter (V) it was shown that in pre-eclampsia, plasma triglyceride 
and small, dense LDL concentrations are substantially higher and HDL-cholesterol 
concentrations substantially lower than concentrations observed in normal pregnancy. 
In addition, Lorentzen et al (1995) have reported that FFA and triglyceride 
concentrations climb higher in pre-eclampsia well in advance of clinical manifestations 
of the disease.
In turn, Chapter I section 5.2 cites plentiful evidence from studies in non-pregnant 
individuals revealing the capacity of plasma lipids to promote endothelial changes. 
Briefly, hypercholesterolaemia has repeatedly been shown to be associated with 
endothelial dysfunction, whereas cholesterol-lowering therapy has been demonstrated 
to result in improved endothelial-dependent vasomotion (Anderson et al 1995, 
Treasure et al 1995). In contrast, plasma high density lipoprotein-cholesterol (HDL- 
cholesterol) concentrations are positively related to endothelium-dependent relaxation 
(Zeiher et al 1994, Kuhn et al 1991). Subsequently, it has been proposed that the 
higher HDL-cholesterol concentrations observed in pre-menopausal women may be 
responsible for their observed protection against the adverse effects of 
hypercholesterolaemia on endothelium-dependent vasodilatation (Chowienczyk et al 
1994). There is also plentiful evidence to suggest that triglyceride-rich particles, partly 
through oxidative pathways, and particularly in the post prandial state, may be 
damaging to the endothelium (Sattar et al, In press).
By collaborating with colleagues in Nottingham, an opportunity to examine the 
relationship between lipids and endothelial function in normal pregnancy and pre­
eclampsia, presented. The Nottingham group have demonstrated an alteration in 
endothelium dependent myometrial resistance artery function in women with pre­
eclampsia (Ashworth et al 1997a), and have induced a similar functional change in 
myometrial resistance vessels from normal pregnant women after incubation with 
plasma from women with pre-eclampsia (Ashworth et al 1997b). Their findings are 
consistent with the hypothesis that some circulating humoral factor(s) affects maternal 
systemic function directly or indirectly, by activating endothelial cells with resultant 
vascular injury. Furthermore, there is evidence from other in vitro work that a 
circulating factor in women with pre-eclampsia is capable of causing endothelial
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dysfunction (Roberts & Redman 1993, Baker et al 1995).
In this study, we examined the relationship between plasma cholesterol, triglyceride 
Apo Al (the apoprotein associated with HDL particles) and Apo B (the apoprotein 
associated with triglyceride-rich lipoproteins) concentrations and endothelial behaviour 
of myometrial resistance vessels bathed in plasma from normal pregnancies and those 
complicated by pre-eclampsia.
Our hypothesis was that, in line with the situation in non-pregnant individuals, plasma 
cholesterol and/or apo Al (HDL-cholesterol) concentrations would associate strongly 
with endothelial function in normal pregnancy and pre-eclampsia. For completeness, 
we also measured apo B and non-fasting triglyceride concentrations
2. SUBJECTS, SAMPLES, METHODS
Ethical approval was obtained from Nottingham City Hospital and University Hospital 
Nottingham Ethics Committees prior to commencement of the study. Written informed 
consent was obtained from all patients before enrolment into the trial. This applied to 
both those donating plasma and those donating vessels at the time of Caesarean 
section.
Study Group
The normal pregnant women from whom all the vessels were obtained (n= 20) had 
singleton pregnancies and were undergoing elective lower segment Caesarean section 
at term. Indications for operative delivery were malpresentation, previous Caesarean 
section and/or maternal request. Neither these pregnancies, nor any proceeding 
pregnancy were complicated by pre-eclampsia, intrauterine growth restriction or any 
other medical complications (e.g. diabetes, epilepsy etc.).
Plasma was collected from 10 nulliparous patients with pre-eclampsia and 10 
gestational-age matched nulliparous normal pregnant women. Pre-eclampsia was 
defined as a clinical syndrome developing in a previously normotensive woman after 
2 0  completed weeks gestation (with no pre-existing renal disease), characterised by 
the presence of significant proteinuria (greater than 300mg/litre in a 24 hour urine 
collection and in the absence of a urinary tract infection) in the presence of 
hypertension (a blood pressure of greater than 140/90 mm Hg on two separate 
occasions at least 4 hours apart), both of which resolve by the 6 th post partum week 
(Davey & MacGillivary 1988). Blood was obtained from these patients at 8 am, into 
EDTA tubes onto ice, and was usually, but not invariably, collected from fasting 
subjects. These were centrifuged at 1500 x g at 4°C for 15 minutes to precipitate the 
cellular components of the blood. Plasma was then aliquoted into sterile eppendorf 
tubes, labelled and stored at - 80 °C until required.
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Vessel collection
At Caesarean section, following delivery of the baby and placenta, a full thickness 
biopsy of myometrium was taken from the upper margin of the lower segment uterine 
incision. Uterine biopsies were placed into physiological salt solution (PSS) at 40C, 
through which a mixture of 95% oxygen and 5% carbon dioxide had been bubbled 
prior to sample collection. Microscopic dissection was performed in 4°C PSS within 2 
hours of the Caesarean section, resistance arteries of 200 - 550 mm diameter, 
corresponding to uterine radial arteries in the myometrium, being removed. The 
dissected vessels were then separated into two groups and incubated with 2 % plasma 
(in PSS with heparin (1 IU/ml)) from either the pre-eclampsia or normal pregnant 
groups. Once carbonated in 5% CO2 / 95% O2 these vessels were then stored for up to
20 hours at 0-4 °C  prior to experimentation. It has been previously shown that storage 
of the vessels for up to 48 hours had no measurable deleterious effect on vessel 
response to a variety of vasoconstrictors and vasodilators in the experimental protocol 
used, provided that dissection had occurred within 2  hours of the biopsy specimens 
being taken (Ashworth et al 1996).
Myography
Following incubation, the paired vessels were mounted on two parallel 50 mm wires 
on a Mulvany wire myograph, the experiments being performed in PSS, with the 
operator blind as to which sample the vessels had been incubated in.
After an hour's equilibration to 370C, the vessels were normalised to allow calculation 
of that diameter at which the transmural pressure was equal to 100 mm Hg (Lioo)> and 
set at a diameter of 0.9 Lioo- This was an identical protocol to other studies performed 
previously at our unit. Vessels were contracted with vasopressin to a concentration of 
10“8M at which point a steady state contraction was achieved. Those vessels 
exhibiting significant vasomotion (>2 0 % of the contraction) or those failing to achieve 
a contraction of greater than 50 mm Hg were excluded from the study. In accordance 
with other studies, work performed in the Nottingham unit (Ashworth et al 1996) has 
demonstrated that other vasoconstrictors (such as norepinephrine, prostaglandin F2a, 
angiotensin II, or 5-hydoxytryptamine, which are found in vivo in the vascular beds 
under investigation), were not capable in vitro, of providing a consistent, repeatable, 
sustained contraction in human myometrial resistance vessels. These contracted 
vessels were then exposed to incremental doses of the endothelium dependent agent
bradykinin from lxlO ' 10 M to 3.3xl0"6 M, relaxation being expressed as a percentage 
of the size of the original contraction.
Solutions and chemicals
The physiological salt solution is a modified Krebs solution, its constituents being
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(mmol/L): NaCl (119), KC1 (5.9), CaCl2 (2.5), MgS04 (1.17), N aH C 03 (25), 
KH2PO4 (0.2), and EDTA (0.026). The glucose concentration was 5 mmol/L and the 
pH of the solution buffered to 7.4. All chemicals used were Analar reagents supplied 
by Merck Ltd, Poole UK, except calcium chloride and EDTA which were obtained 
from Sigma Chemicals, St Louis, USA. Sigma Chemicals also supplied vasopressin, 
bradykinin, and norepinephrine.
Lipid analysis
The plasma samples were assayed for cholesterol, triglyceride, Apo Al and Apo B as 
described in detail in Chapter II. It is important to note that although the non-fasting 
nature on some of the samples causes variability in triglyceride concentrations, 
cholesterol, apo Al and apo B concentrations are negligibly affected and thus their 
non-fasting measurements provide an accurate reflection of fasting concentrations.
Statistical analysis
Values are given as mean with standard error (SE), or as median (range) for non- 
parametrically distributed data. In all cases two arteries from each patient were studied, 
and mean data used for analysis. Maternal age, birth weight and individualised birth 
ratio (birth weight corrected for gestational age, parity, maternal body mass index, and 
maternal ethnic origin, Sanderson et al 1994), blood pressure at booking and delivery, 
and gestational age at delivery were analysed by the unpaired students t-test, or the 
Mann-Whitney unpaired two-tailed U test where appropriate.
Concentration response curves were analysed by comparison of the percentage 
relaxation for each woman at each dose of bradykinin, using repeated measures 
analysis of variance to compare the results obtained from different groups.
Statistical significance was accepted when p<0.05.
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3. RESULTS
3.1 Demographic details
Normal pregnant Pre-eclampsia P-Value
median (range) median (range) Mann-
Whitney U
Age 23 (22-26) 28 (25-30) 0.23
BMI 22 (21-25) 24 (22-25) 0.78
MAP (booking) mm Hg 88  (84-90) 84 (76-92) 0.73
MAP (delivery) mm Hg 92 (84-94) 112(76-92) 0 .0 0 0 1
Proteinuria g/dl 0  (0 -0 ) 1.2 (0.64-1.54) 0 .0 0 0 1
IBR 46 (27-82) 11 (2-36) 0.03
mean (standard dev) mean (standard dev) Students
ttest
Gestation
at venepuncture (days)
261 (2 0 ) 243 (25) 0.09
Gestation 
at delivery (days)
274(13) 243 (27) 0.03
Table 11 Demographic details of the patients from whom the plasma 
was obtained. BMI : body mass index; MAP: mean arterial pressure; IBR: 
individualised birth weight ratio.
There was a statistically significant difference between the normal pregnant plasma and 
pre-eclamptic plasma groups in the mean arterial pressure at delivery (p= 0.0001 Mann 
Whitney U); proteinuria (p= 0.0001 Mann Whitney U); and individualised birth 
weight ratio (p=0.03).
3.2 Percent residual contraction o f m yom etrial vessels with plasm a  
from normal and pre-eclamptic pregnancies.
Vessels from each patient (n=20) were divided into two groups prior to incubation 
with 2 % plasma from patients with pre-eclampsia or 2 % plasma from normal pregnant 
women. Incubation of vessels with 2% plasma from women with pre-eclampsia 
resulted in a significant loss of endothelium dependent relaxation when compared with 
vessels incubated in 2% plasma from normal pregnant women (p<0 .0 0 0 1  repeated 
measures ANOVA, Figure 18).
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3.3 Lipid concentrations of normal pregnant plasma and plasma from  
women with pre-eclampsia.
There was no significant difference in the lipid profiles measure between the normal 
pregnant women and the women with pre-eclampsia (p>0.15 in all parameters 
measured, Mann Whitney U).
Table 12 Lipid concentrations of normal pregnant plasma and plasma 
from  women with pre-eclam psia. Apo AI: apolipoprotein AI; Apo B: 
apolipoprotein B; Apo AI/B: ratio between apo AI/B.
3.4 Relationship o f percent residual contraction of vessels with plasma 
apo AI. (Figures 19 and 20).
We found a significant association between the concentration of circulating Apo AI 
(indicative of HDL cholesterol) and the endothelium-dependent behaviour of the 
vessels (Spearman rank correlation. p=0.025). On subgroup analysis of those vessels 
incubated with plasma from women with pre-eclampsia this correlation persisted 
(Spearman rank correlation. p=0.036). This was not the case in vessels incubated in 
plasma from normal pregnant women (Spearman rank correlation p=0.25). No other 
significant associations between lipid parameters and endothelium dependent vessel 
behaviour were found.
Normal pregnant Pre-eclampsia P-Value
median (range) median (range) Mann-
______________________________________ Whitney U
Cholesterol (mmol/1) 
Triglyceride (mmol/1) 
Apo AI (g/1)
Apo B (g/1)
Apo AI/B
6.4 (5.6 -6 .9) 6.7 {5.1-1.1)) >0.5
2.25 (1.71-3.55) 3.13 (2.33-4.43) 0.24
1.9 (1.6-1.9) 1.6 (1.4-1.9) >0.5
1.1 (0.9-1.3) 1.2 (1.0-1.4) >0.5
1.7 (1.3-2.1) 1.3 (1.2-1.7) >0.5
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4. DISCUSSION
It has been demonstrated, in an in vitro setting, that the plasma from women with pre­
eclampsia is capable of inducing a functional change in the behaviour of myometrial 
resistance arteries of normal pregnant women, such that these vessels mimic the 
behaviour of similar sized resistance arteries from women with pre-eclampsia.
In this study, we examined whether plasma lipid (triglyceride, cholesterol, Apo AI or 
Apo B) concentrations in normal pregnancy and pre-eclampsia contributed to the 
observed endothelial behaviour. In contrast with data from several previous studies 
(Potter & Nestel 1979, Lorentzen et al 1995, Kaaja et al 1995), and the results 
presented in Chapter V, we did not observe a significant difference between the 
plasma triglyceride, Apo AI and Apo B concentrations between the pre-eclamptic and 
normal pregnant groups. A notable difference in this study, and one that may help to 
explain this lack of statistical difference in triglyceride concentrations is that not all the 
samples were collected in the fasting state. As a result, variability in triglyceride 
measurements was greater. Furthermore, although we had attempted to match the 
groups for gestational age at sampling, there was a tendency for samples to be 
collected from the pre-eclamptic group at an earlier gestation (261 vs, 243 days 0.1< 
p>0.05). This may have been relevant since triglyceride levels increase most 
dramatically in late pregnancy, and also at this stage of pregnancy HDL-cholesterol 
(and Apo AI) concentrations, which reach a maximum at around 25-30 weeks, are 
declining towards first trimester levels (See Chapter III).
Despite the lack of a statistical difference in the lipid concentration between the groups, 
a significant correlation between endothelium dependent relaxation and the plasma 
concentration of Apo AI (p=0.025), was observed. Furthermore, and perhaps more
importantly, a significant correlation (R2=0.59, p=0.036) between the endothelium 
dependent relaxation in vessels incubated with plasma from women with pre­
eclampsia and the plasma content Apo AI was seen (Figures 19 and 20). In contrast, 
plasma triglyceride, cholesterol, and Apo B concentrations did not relate significantly 
to endothelial behaviour.
Interestingly, these results in pregnant patients are broadly consistent with data from 
non-pregnant individuals. Plasma HDL-cholesterol concentrations have been 
demonstrated to relate positively and significantly to endothelium-dependent relaxation 
of coronary vessels in patients with coronary heart disease (Zeiher et al 1994, Kuhn et 
al 1991). In addition, in a study in patients with type 2 diabetes mellitus, decreased 
HDL cholesterol was the best predictor of impaired vasodilatation to acetylcholine 
even after adjustment for all lipid and lipoprotein concentrations (O’Brien et al 1997). 
Thus, in non-pregnant individuals there is good evidence for a role of HDL in 
favourably modifying endothelial function.
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Endothelial protection by HDL may relate to its antioxidant properties as HDL has 
been found to protect against LDL oxidation (Hessler et al 1992). HDL antioxidant 
actions may be related to its protein components (which bind transition metals) 
(Kunitake et al 1992), and to two intrinsic anti-oxidative enzyme systems: platelet 
activating factor acetylhydrolase (Stafforini et al 1993) and paraoxonase (Mackness et 
al 1991). HDL may also play a role in reverse transport of potentially reactive 
hydroperoxide species for hepatic detoxification as described by Tribble (1995). 
Impaired removal of these hydroperoxides (when HDL-cholesterol concentrations are 
low) could be particularly deleterious under conditions favouring a prolonged 
residence time and accumulation of susceptible sub-populations of particles, for 
example, small dense LDL (Tribble 1995). Indeed, both oxidative stress (as shown by 
increased lipid peroxide concentrations) (Uotila et al 1993), and high concentrations of 
small, dense LDL (Chapter V) are characteristics of pre-eclampsia. There evidence 
also that HDL particles stimulate prostacyclin secretion from endothelial surfaces 
(Kaaja et al 1995). Thus, there are also abundant possible mechanisms by which HDL 
particles may favour endothelial dilatation.
An alternative possibility for the findings in this study is that rather than a direct 
influence of Apo AI on endothelial behaviour, some other factor(s) dictating Apo AI 
metabolism and thus Apo AI concentrations may relate to endothelial behaviour. In the 
non-pregnant situation, Apo AI and HDL-cholesterol concentrations are largely 
governed by the efficiency of triglyceride catabolism. Interestingly, in non-pregnant 
subjects it has recently been demonstrated that post-prandial hypertriglyceridaemia (a 
test of the efficiency of triglyceride catabolism) transiently impairs endothelium 
dependent flow-mediated vasodilatation (Vogel et al 1997). Furthermore, in this study 
mean change in post-prandial flow-mediated vasoreactivity correlated with change in 
2-hour serum triglyceride concentration. Therefore, it would be interesting to examine 
the relationship in future studies between triglyceride metabolism and endothelial 
behaviour in women with pre-eclampsia.
W hatever the mechanism our data demonstrate that plasma Apo AI (and therefore 
HDL) concentrations are associated with altered endothelial behaviour of the 
endothelium in pre-eclampsia. Clearly, future studies are needed to examine in greater 
detail the relationship between endothelial behaviour and lipid concentrations in pre­
eclampsia.
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CHAPTER VII
HYPOTHESIS: MECHANISM FOR GENERATION OF 
HYPERLIPIDAEMIA IN PRE-ECLAMPSIA, AND A DISCUSSION OF 
ITS POTENTIAL PATHOGENIC ROLE.
1. INTRODUCTION
In the preceding 2 chapters (V and VI) lipoprotein subfraction concentrations were 
exam ined in pre-eclampsia, and lipid concentrations, specifically apo AI 
concentrations, were related to endothelial function in pre-eclampsia as measured in 
myometrial resistance vessels. In this current chapter, a hypothesis which brings 
together indirect evidence for the participation of cytokines and lipid peroxides in the 
development of the exaggerated hyperlipidaemia of pre-eclampsia is presented. This 
hypothesis incorporates a growing body of evidence based on clinical studies on pre­
eclampsia, but also on possible animal models, that focus attention on the liver and its 
handling of fatty acids as a key link in the pathogenic chain.
2. Liver dysfunction in pre-eclampsia
Liver dysfunction occurs frequently in pre-eclampsia. The severity of hepatic 
disturbance is variable ranging from mild elevations in the plasma concentrations of 
liver enzymes to more serious forms associated with clinical jaundice and gross 
hepatic impairment such as HELLP syndrome (haemolysis, elevated liver enzymes 
and low platelet count). Similarities with acute fatty liver of pregnancy (AFLP) 
suggest that these disorders form a spectrum of disease with common clinical and 
laboratory abnormalities (Minakami et al 1988).
3. Equine hyperlipaemia and Reyes syndrome
In a series of studies in our laboratory we sought to explain the pathogenesis of a 
condition common in certain breeds of horses, e.g. ponies, known as equine 
hyperlipaemia (Watson et al 1992). Normally, free fatty acids released from 
adipocytes by the action of hormone sensitive lipase (HSL) are taken up by liver and 
subject to two alternative routes of metabolism; one is their reassimilation into 
triglyceride molecules, while the other is oxidation by mitochondrial (3-oxidative 
pathways which results in the generation of energy and the synthesis of ketones 
(Figure 21). Horses as a species have a relative inability to undertake (3-oxidation and 
so the liver if presented with fatty acids generates triglyceride for storage and for 
secretion as very low density lipoprotein (VLDL). The delivery of substrate for 
triglyceride synthesis in the form of free fatty acids is known from cell culture work to 
be the major determinant of VLDL secretion (Dixon et al 1993).
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Figure 21. N orm ally  F F A s en tering  the liver have tw o routes  o f  m etabo lism ; they 
are e ither subjected to [3-oxidation resulting in CCL (and a small am ount o f  ketones) or
they are esterified and secreted as triglyceride in VLDL.
In cond it ions  o f  stress, e.g when horses are transported  over  long distances, there is a 
m ass iv e  re lease  o f  fatty  acids from  ad ipocy tes  and  w hen  these reach the liver they 
stim ulate  triglyceride synthesis with consequent hypersecretion o f V L D L  and a m arked 
hypertr ig lyceridaem ia  ensues. How ever, this pathway o f  triglyceride elim ination from 
the  l iver even tua lly  b eco m es  saturated and as a result trig lyceride accum ulates  in the 
h e p a to c y te s  g iv in g  the  c h a rac te r is t ic  h is to lo g ica l  p ic tu re  o f  hepa tic  s tea tos is .  
P a r t ic u la r ly  p e r t in e n t  to the p re sen t  d is cu ss io n  is the o b se rv a t io n  that eq u in e  
h y per lipaem ia  is m ore  prevalent in pregnancy , particularly in animals with abdom inal 
obesity  (W atson et al 1992).
S im ilarly , the hepatic steatosis observed in R ey e’s syndrom e is thought to be the result 
o f  a com bination  o f  increased flux o f  FFA s (C haves-C arbello  et al 1979) and im paired 
hepa tocy te  [3-oxidation o f  fatty acids due to post-infec tious (H eubi et al 1987), and in 
s o m e  cases  sa licy lic  acid m edia ted ,  m itochondria l  d y sfu n c tio n  (D esch am p s  et al 
1991). In deed , im p a ired  m ito c h o n d ria l  o x id a t io n  is im p lica ted  in m an y  o th er  
exam ples  o f  m icro vesicular steatosis (G rim bert et al 1993).
B OXIDATION
TG SYNTHESI
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4. 1 FFA flux and (3-oxidation in normal pregnancy
In the late second trim ester o f  hum an  pregnancy there is an increased flux o f  free fatty 
ac ids  p rom oted  by a com bination  o f  s tim ulation  o f  H S L  by hum an  placental lactogen 
(H P L )  (M art in -H id a lg o  et al 1994), and re la tive  res is tance  to the effects  o f  insu lin
(S i l l im an  et al 1994) (w hich  n o rm a lly  acts to suppress  F F A  re lease  from  ad ipose  
tissue). Studies in the m ouse suggest that late pregnancy is also associated with a m ild  
im p a irm en t  in (3-oxidative function (G rim ert  et al 1993). H ow ever ,  as total hepatic  
lip ids rem ained  unchanged , it appears that in norm al m urine pregnancy this decreased 
ox ida tion  o f  fat in the liver is com pensa ted  for by  the increased secretion o f V L D L , in 
agreem ent with studies in other anim al m odels (W einste in  et al 1979, W asfi et al 1980) 
(F igure  22). Recently , in a single hu m an  case study oestrogen  has been  dem onstra ted  
to in h ib i t  h ep a tic  l ip id  o x id a t io n  w ith  re su ltan t  inc rease  in se ru m  tr ig ly ce r id e  
concentra tion  (O 'Sullivan et al 1995).
B OXIDATION
FFA
TG SYNTHESI
VLDL
Normal Pregnancy
Figure 22. L ate  p re g n a n c y  is a s so c ia te d  w ith  an in c re ased  flux  o f  F F A s an d  
im p a ired  fatty ac id  ox ida tion .  T h e  net e f fec t is in c reased  de livery  o f  FFA s in to  
t r ig ly ce r id e  syn thes is .  H ow ever ,  in norm al p re g n an cy  this inc reased  tr ig lycer ide  
syn thes is  is co m p en sa ted  for by increased  secretion  o f  V L D L . Consequently , hepatic  
triglyceride content rem ains unchanged.
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4.2 FFA flux and [3-oxidation in pre-eclampsia
In women with pre-eclampsia there is evidence to suggest that an increased flux of 
FFAs occurs over and above that seen in normal pregnancy and, significantly, this 
phenomenon is observed long before the onset of clinical disease (Lorentzen et al
1994). It has also been shown that the FFA/albumin ratio in women with pre­
eclampsia is twice that observed in normal pregnancy (Endersen et al 1992) and 
serum from affected women causes triglyceride accumulation in cultured endothelial 
cells with resultant impaired release of prostacyclin (Lorentzen et al 1991). Although 
the higher FF A/albumin ratio in pre-eclampsia may be partly explained by lower 
plasma albumin concentrations, enhanced adipocyte lipolysis with resultant higher 
circulating concentrations of FFAs is likely to be the major cause, as intravascular 
lipolytic activity did not account for the changes observed in plasma FFA 
concentrations pre-eclamptic women prior to clinical manifestations of their disease 
(Lorentzen et al 1994).
In pre-eclampsia, it is tempting to postulate that, as in the equine model, increased 
FFA flux overlaid on the impaired p-oxidation in late pregnancy promotes the 
excessive synthesis of hepatic triglyceride and thus VLDL hypersecretion. Plasma 
triglyceride concentrations are significantly raised in women with pre-eclampsia 
compared to unaffected controls matched for gestational age (Potter & Nestel 1979), 
and it has been further demonstrated that raised plasma triglyceride concentrations 
preceded the onset of clinical disease (Lorentzen et al 1994). This chain of events fits 
with earlier work and with findings from our laboratory of a specific accumulation of 
large, triglyceride-rich VLDL in the circulation of pre-eclamptic women (Chapter V). 
There is also the possibility that p-oxidation is further impaired in subjects with pre­
eclampsia since ketonaemia is not a feature despite fatty acid levels being increased. 
Also in AFLP there is more direct evidence for inhibition of fatty acid oxidation 
(Treem et al 1994, Wilcken et al 1993).
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Figure 23. In pre-ec lam psia , FFA  flux is further enhanced  and  [3-oxidation m ay be 
fu r ther im paired. T h e  liver responds by fur ther increasing  secre tion  o f  V L D L , but 
eventually  this m echanism  becom es saturated resulting in the deposition o f  triglyceride 
within the parenchyma.
W h en  the liver’s ability to produce V L D L  is satura ted it is likely that this is fo llow ed 
by  ac c u m u la t io n  o f  t r ig ly ce r id e  in h e p a to c y te  s tores .  S ig n i f ic an t  am o u n ts  o f  
m icro v es icu la r  fat drople ts  have been d em o n s tra ted  in cases  o f  pre -ec lam psia ,  w ith 
and  w ith o u t  l iver d y sfu n c tio n ,  in c reas in g  in den s i ty  in H E L L P  sy n d ro m e  and  
m ax im al in cases o f  A F L P  (M inakam i et al 1988) (Figure 23). Furtherm ore ,  in the 
last s tudy , the density  o f  hepa toce llu la r  fat co rre la ted  pos it ive ly  w ith  p lasm a ura te  
concen tra tion  and negative ly  with the platelet count, e s tab lished  m arkers  o f  severity  
and progression o f  pre-eclampsia.
D a ta  on  p la sm a  t r ig ly ce r id e  an d  h ig h  d en s i ty  l ip o p ro te in  (H D L )-c h o le s te ro l  
concen tra tions  in H E L L P  syndrom e and  A F L P  are curren tly  lacking. H ow ever ,  in a 
study o f  plasma lipoprotein concentrations in R e y e ’s syndrom e (Chaves-C arbello  et al 
1979), increased  p la sm a  tr ig lyceride  co n cen tra t io n s  and red u ced  H D L -ch o les te ro l  
co n c en tra t io n s  w ere  ob se rv ed  to be m o s t  m a rk e d  in fatal cases .  T h u s ,  p la sm a  
lipopro te in  concentra tions  m ay be useful indices o f  severity  in R e y e ’s syndrom e and  
by  ex t ra p o la t io n  m ay  be w orth  in v es t ig a t in g  as p ro g n o s t ic  in d ica to rs  fo r  p re -
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eclampsia.
Although we have emphasised the synthetic aspects of the control of plasma VLDL 
concentrations drawing on animal work and limited clinical data, it is possible that 
impaired adipose tissue lipoprotein lipase activity also contributes to the exaggerated 
hypertriglyceridaemia observed in pre-eclampsia.
5. Cytokines and lipid peroxides
Increased plasma cytokine concentrations, particularly TNF-a (Visser et al 1994, 
Vince et al 1995), IL-1 (Greer et al 1995) and IL-6  (Greer et al 1995), have been 
implicated in the pathophysiology of pre-eclampsia. It is of interest that these same 
cytokines can induce adipocyte lipolysis (TNF-a, IL-1) (Chajek-Schaul et al 1989, 
Feingold et al 1991), promote de novo hepatic fatty acid synthesis (TNF-a, IL-1, IL- 
6 ) (Chajek-Schaul et al 1989, Feingold et al 1991, Greenberg et al 1988), and impair 
hepatic fatty acid oxidation and ketogenesis (IL-1, TNF-a) (Memon et al 1992). The 
result is increased hepatic triglyceride synthesis (Figure 24). Furthermore, the 
significantly higher TNF-a (Visser et al 1994) and TNF-R levels (Vince et al 1995) 
reported in patients with the HELLP syndrome, support a role for TNF-a in liver 
dysfunction. TNF-a and IL-6  also reduce lipoprotein lipase activity (Greenberg et al 
1988, Saxena et al 1990), thereby impairing removal of triglyceride-rich lipoproteins 
from the circulation.
Lipid peroxides have been shown to be increased (and antioxidant defences depleted) 
in pre-eclampsia (Maseki et al 1981, Uotila et al 1993) and these could induce hepatic 
dysfunction. It has been demonstrated that free radicals, at biologically attainable 
levels, induce hepatic mitochondrial dysfunction promoting microvesicular fatty 
damage (Saibara et al 1994). Further evidence to support a role for lipid peroxide 
mediated hepatocyte fat accumulation and dysfunction comes from the common 
finding of burr cells (as produced in vitro under peroxidising conditions) in pre­
eclamptic women with liver damage (Stark et al 1993).
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Figure 24. This d iag ram  sum m arises  the potential role o f  a d is tu rbance  in fatty acid 
and  l ipopro te in  m e tab o lism  in the pa thogenes is  o f  pre -ec lam psia .  Increased  p lasm a
cy to k in e  (IL-1, T N F -a )  concen tra t ions  resu lt ing  from  ac tiva tion  o f  m acro p h ag es  /
n eu tro p h i ls  e i the r  d irec t ly  or ind irec tly  th ro u g h  en d o th e l ia l  ac tiva tion ,  or by the 
p lacen ta  itself, m ay enhance peripheral lipolysis which is a lready stimulated in norm al 
p regnancy  by HPL. This  results in an increased  flux o f  free fatty acids to the liver. As 
sh o w n  in F igure 23 these are ch an n e lled  p red o m in an tly  into  hepa tic  tr ig lyceride  
s y n th e s is  and  so the re  is in c reased  s ec re t io n  (o v e r  an d  ab o v e  th a t  o f  n o rm a l  
p re g n an cy )  o f  large, trig lyceride-rich  V L D L  partic les,  w h ich  are also rem oved  less 
e ff ic ien tly  than norm al. A ccum ula tion  o f  trig lyceride occurs  in the hepatocyte w hen  
this p a th w ay  is sa tu ra ted ,  and this re sp o n se  is a poss ib le  ex p lan a t io n  o f  the fatty  
c h a n g e s  in liver seen  in p re -ec la m p s ia  and  A F L P . In c rea se d  co n c en t ra t io n s  o f  
t r ig ly ce r id e -r ich  l ipopro te ins  in the c ircu la t io n  m ay co n tr ib u te  bo th  d irec tly  and, 
th rough  the generation  o f  small, dense L D L , indirectly to endothelial dysfunction  and  
th e re fo re  ex p ress ion  o f  p re -ec lam p sia  in the m other.  It is im p o rtan t  to note that 
m u lt ip le  in ter-re la tionsh ips  exist b e tw een  these  system s, e.g. h y p e r lip id aem ia  m ay  
result in platelet activation and oxidised L D L  m ay induce IL -16 release, but these have
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not been shown for clarity.
6. O besity/ Insulin resistance
It has been observed that there is a higher risk of pre-eclampsia with increasing obesity 
(Eskenazi et al 1991, Sibai et al 1995 ) and that insulin levels are higher in 
hypertensive pregnancies (Kaaja et al 1995). These findings are understandable if 
abnormalities in fatty acid metabolism are important in these disorders. Obesity, in 
particular abdominal, rather than gluteal-femoral, is associated with insulin resistance 
and hypertriglyceridaemia (Kissebah et al 1989). Insulin resistance in adipocytes 
causes lipolysis to proceed in a relatively unregulated fashion so that the flux of FFA 
to the liver is enhanced. Also, the accumulation of fat in the abdomen is associated 
with hypertrophy of the adipocytes, which renders them more responsive to lipolytic 
stimuli (Mauriege et al 1991). The release of fatty acids from omental fat cells directly 
into the portal circulation exposes the liver to higher FFA concentrations than would 
be the case if the same amount of fat were distributed at peripheral sites and this has 
consequences for triglyceride synthesis and VLDL secretion (Despres 1991). 
Furthermore, the increased hepatic uptake of FFA may itself reduce portal insulin 
extraction by the liver resulting in higher peripheral insulin levels (Bjorntorp 1994, 
Jensen et al 1989).
7. Latent genetic defect in (3-oxidation
A latent genetic defect in fatty acid oxidation in AFLP (and perhaps also the HELLP 
syndrome) unmasked by the increased flux of FFAs in pregnancy has been proposed 
(Treem et al 1994, Wilcken et al 1993). This is based upon several cases of AFLP 
reported in women heterozygous for a partial defect in hepatic fatty acid oxidation due 
to long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency, and the 
similarities of the clinical and pathological pictures of patients with AFLP to those with 
inherited disorders of fatty acid oxidation.
8. Consequences o f hypertriglyceridaemia in pre-eclampsia
There is increasing evidence in cardiovascular research that hyperlipidaemia, can cause 
endothelial dysfunction (See Chapter I section 5.2). Recent studies have demonstrated 
that hypertriglyceridaemic serum and triglyceride-rich lipoproteins are cytotoxic to 
cultured human endothelial cells (Spiedel et al 1990). Along with the raised plasma 
triglyceride concentration due to the increased secretion of large triglyceride-rich 
VLDL evident in women with pre-eclampsia as explained above, there is an associated 
increase in the plasma concentration of small, dense LDL. This is a predictable 
consequence of the elevation in plasma triglyceride (McNamara et al 1992). Data from 
our laboratory (Chapter V) support the finding of raised plasma concentrations of 
small, dense LDL in pre-eclampsia. Such LDL are known to be more susceptible to 
oxidation than their larger counterparts (deGraaf et al 1991) and both lipoprotein 
species i.e. large VLDL and small, dense LDL (particularly when oxidised), have the
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capacity to cause endothelial dysfunction, (Figure 24); for example, oxidised LDL and 
VLDL, stimulate expression of VECAM-1 (Kume et al 1992), a monocyte adhesion 
molecule expressed by activated endothelial cells and found to be increased in pre­
eclampsia (Lyall et al 1994). Oxidised LDL has also been shown to promote rapid 
adhesion of neutrophils to endothelium by upregulation of neutrophil adhesion 
receptors (CD1 lb/CD18) (Lehr et al 1995), while multiple oxidation products in LDL 
induce IL -ip release from human blood mononuclear cells (Thomas et al 1994). 
Large triglyceride rich VLDL is known to promote synthesis and release of PAI-1, 
while oxidised LDL inhibits endothelial prostacyclin synthesis. Additionally, oxidised 
LDL simultaneously increases endothelin production and release, and inactivates 
EDRF (Stewart & Monge 1993). As a result of these changes, oxidised LDL and 
large VLDL promote activation of platelets with resultant enhanced thromboxane
release (Stewart & Monge 1993), (Figure 24).
The observed lower plasma HDL-cholesterol levels in pre-eclampsia may also 
contribute to the reduced prostacyclin levels seen in this condition, as there is evidence 
that HDL particles stimulate PGI2 secretion from endothelial surfaces (Kaaja et al
1995). In addition, in the same study it was demonstrated that in pre-eclampsia, 
serum HDL (especially the larger HDL2 subfraction) cholesterol concentrations
correlated directly with 2,3-dinor-6-keto PG Fia  excretion, the urinary metabolite of
PGI2 , while serum triglyceride concentrations correlated positively with 2,3-dinor-
thromboxane B2 excretion (Kaaja et al 1995). Lower plasma HDL concentrations may
reduce antioxidative protection for other lipoproteins (Mackness & Durrington 1995).
As many of these changes in endothelial cell and blood mononuclear cell function and 
prostaglandin synthesis have been documented and implicated in the pathogenesis of 
pre-eclampsia (Greer 1994), the question arises as to whether endothelial dysfunction 
of pre-eclampsia is causally related to, and exacerbated by, alterations in the 
metabolism of fatty acids and triglyceride (Figure 24). The findings in the preceding 
chapter (VI) of a significant relationship between plasma apo AI concentrations and 
endothelial behaviour in pre-eclampsia support this concept.
9. Lipids, 'acute atherosis' and 'glom erular capillary endotheliosis'.
It is noteworthy that the characteristic pathological lesion seen in the utero-placental 
bed of patients with pre-eclampsia is a necrotising arteriopathy consisting of fibrinoid 
necrosis, accumulation of foam cells or lipid laden macrophages, fibroblast 
proliferation and a perivascular infiltrate. This lesion has been termed ‘acute atherosis’
(Roberts & Redman 1993) and shares many features with coronary atherosclerosis. It 
is also significant that lipoproteins have been implicated in the generation of renal 
disease (Walli et al 1993). Observations in experimental animals and in patients with 
genetically determined and acquired hyperlipidaemias suggest that lipids can damage
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the kidney and lead to glomerulosclerosis. In vitro studies of human glomerular cells 
have been useful in providing information on lipid-induced glomerular damage. Thus, 
there are strong indications that lipoproteins may play a role in the development of 
mesangial cell damage and progressive renal disease (Walli et al 1993). Indeed in pre­
eclampsia, renal morphology reveals hypertrophy of the cytoplasmic organelles in 
endothelial and occasionally mesangial cells, particularly the lysosomes, which 
undergo marked enlargement and vacuolisation (due to accumulation of free neutral 
lipids). These reactive changes have been termed 'glomerular capillary endotheliosis' 
(Garber et al 1994), and these histopathological changes are clearly in keeping with a 
disorder of lipoprotein metabolism.
10 . Hypertriglyceridaemia and fetal nutrition?
The exaggerated hypertriglyceridaemia in pre-eclampsia may benefit fetal nutrition 
since it is increasingly recognised that triacylglycerol fatty acids, and not albumin 
bound FFAs, are the predominant source of fatty acids for the placenta where they are 
released for trans-placental transport by lipoprotein-lipase mediated hydrolysis 
(Herrera et al 1988, Bonet et al 1992). Direct receptor mechanisms such as the newly 
described VLDL receptor may also play a role (Gafvels et al 1994). This permits fatty 
acids to be targeted more efficiently towards the placenta. In women with pre­
eclampsia and mothers of intra-uterine growth retarded fetuses, it has been shown that 
placental lipoprotein lipase activity is significantly greater than in normal pregnancy 
(Biale 1985). Conversely, peripheral adipose tissue lipoprotein lipase activity may be 
impaired further in pre-eclampsia due to the actions of the cytokines (Greenberg et al 
1988, Saxena et al 1990). Thus, the feto-placental unit may initiate chemical signals 
promoting the generation of an exaggerated hypertriglyceridaemia for the reward of 
receiving an increased supply of fatty acids in the form of triglyceride-rich 
lipoproteins. This suggestion, however, must remain tentative as we await further 
definitive data.
11. Conclusion
This review brings together indirect evidence for the participation of cytokines and 
lipid peroxides in the development of the hypertriglyceridaemia in, and the hepatic 
manifestations of pre-eclampsia (see Figure 24). Increased plasma cytokine (IL-1,
TN F-a) concentrations resulting from activation of macrophages/neutrophils either
directly or indirectly through endothelial activation, or the placenta itself, may enhance 
the peripheral lipolysis already activated in normal pregnancy by HPL. This, in 
association with cytokine mediated de novo hepatic fatty acid synthesis, results in an 
increased flux of free fatty acids to the liver. These are channelled predominantly into 
hepatic triglyceride synthesis and leads to an increased secretion (over and above that 
of normal pregnancy) of large, triglyceride-rich VLDL particles, which are also 
removed less efficiently than normal. Accumulation of free triglyceride occurs in the 
hepatocyte when there is saturation of this pathway. This triglyceride accumulation is
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sufficient to explain the fatty changes in the liver seen in pre-eclampsia and AFLP. 
Futhermore, we have demonstrated that increased concentrations of triglyceride-rich 
lipoproteins in the circulation may contribute both directly and, through the generation 
of small, dense LDL, indirectly to endothelial dysfunction and therefore expression of 
pre-eclampsia in the mother, despite potentially benefiting fetal nutrition.
Several aspects of this proposed scheme for the pathogenesis of pre-eclampsia are 
readily testable and experiments are currently underway in both our laboratory and 
others. Furthermore, if confirmed, this mechanism immediately suggests novel 
therapeutic strategies for the management of this life-threatening condition. 
Manipulation of fatty acid metabolism perhaps through the administration of drugs that 
inhibit free fatty acid fluxes may have potential clinical use.
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CHAPTER VIII
LIPID AND LIPOPROTEIN SUBFRACTION CONCENTRATIONS IN 
PREGNANCIES COMPLICATED BY IUGR
1. INTRODUCTION
Previous studies have shown that in pre-eclampsia, plasma lipids climb substantially 
above levels seen in normal pregnancies (Chapter V). It has been proposed that such 
lipid changes may play a role in the endothelial damage characteristic of pre-eclampsia 
(Chapters VI and VII). Pregnancies complicated by intrauterine growth restriction 
(IUGR) without pre-eclampsia have similar placental pathology to pre-eclampsia 
despite the absence of the maternal systemic manifestations of hypertension and 
proteinuria. In both conditions there is failure of trophoblast invasion of the maternal 
spiral arteries, vascular damage and placental infarction.
Given the physiological role of gestational hyperlipidaemia in supplying both 
cholesterol and triglyceride to the rapidly developing fetus, it is conceivable that 
pregnancies complicated by IUGR exhibit abnormal lipoprotein metabolism in an 
attempt to compensate for the placental insufficiency. Alternatively, abnormal 
lipoprotein metabolism may be a factor underlying poor fetal growth. However, it 
would appear from the literature that such studies are sparse.
The aim of the final study in this thesis, therefore, was to perform a cross-sectional 
study of lipid and lipoprotein concentrations in the third trimester from normal 
pregnancies and those complicated by IUGR without pre-eclampsia.
2. SUBJECTS, SAMPLES AND METHODS
Eight women with IUGR and 10 women with uncomplicated pregnancies were 
studied. The patient details are shown in Table 13. The study was approved by the 
Ethical Committee of Glasgow Royal Infirmary, and all women written gave informed 
consent.
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IUGR Pregnant P-Value
pregnancies Controls 
n= 8  n= 1 0
Age 26.3 (6.4) 29.5 (4.0) 0.46
Parity (Prim/parous) 4/4 2/8 0.16
Body Mass Index (Kg/m2) 
@ booking
24.4 (5.3) 2 2 .6  (2 .6 ) 0.46
Gestational age (wks) 
@ sampling
33.4 (3.4) 34.7 (1.2) 0.33
Gestational age (wks) 
@ delivery
34.5 (3.2) 39.6 (1.3) 0.003
Birth weight (grams) 1765 (657) 3482 (279) <0 .0 0 1
Table 13 Characteristics of normotensive pregnant women and women 
with pregnancies complicated by IUGR without pre-eclampsia.
Values are given as mean (SD).
Mothers with IUGR as assessed by ultrasound and without clinical signs of pre­
eclampsia were recruited (i.e. all had normal blood pressure and absence of 
proteinuria). IUGR was defined as estimated fetal weight <5th percentile for gestation 
and associated decreased liquor volume (oligohydrammnios). In addition, three of the 
eight patients had abnormal vascular blood flow on Doppler ultrasound. Patients with 
suspected genetic/anatomical anomalies likely to be contributory to reduced fetal 
growth were excluded. Consecutive patients eligible for this study, where obtaining a 
fasting blood sample was possible, were recruited and all those approached agreed to 
participate. All patients were healthy before pregnancy and had customary diet and 
were not receiving any medication known to interfere with lipid metabolism or lipid 
determination. Ten normal pregnant women matched as a group for pre-pregnancy 
weight, age, and gestational age served as controls. All had normal course and 
outcome of pregnancy, term delivery, and customary diet, and did not receive any 
medication known to interfere with lipid metabolism or lipid determination. 
Additionally, none of the patients or controls were phenotype apo E2/E2, an inherited 
trait known to generate disturbances in the plasma lipid profile even in normolipaemic 
subjects. Further, none of the patients or controls were in labour at the time of 
sampling.
All subjects were sampled after an overnight fast of at least 10 hours. Twenty mL of 
blood was collected by venepuncture into K2EDTA (final concentration lmg/mL) and 
lithium heparin tubes. Plasma was harvested at 4C by low speed centrifugation and
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aliquots of plasma for lipid and lipoprotein measurements were used immediately. 
The assay methods are described in their entirety in Chapter II. Briefly, plasma total 
cholesterol, triglyceride, and HDL-cholesterol measurements were performed by a 
modification of the standard Lipid Research Clinics Protocol. VLDLi, VLDL2, IDL,
and LDL were prepared and quantified as described earlier by cumulative flotation 
gradient ultracentrifugation. The cholesterol, triglyceride, free cholesterol, 
phospholipid, and proteins of the lipoprotein fractions were assayed and 
concentrations calculated as the sum of the components (expressed as mg/dL plasma).
Statistics
Data are presented as mean and standard deviation. Where appropriate differences 
were tested for statistical significance using Student unpaired t-test or the Chi square 
test (Minitab, CA, USA).
3. RESULTS
3.1 Lipid and lipoprotein concentrations
IUGR
n=8
Controls
n= 1 0
P-value
Cholesterol (mmol/1) 5.00 (1.23) 7.14 (1.01) 0.0016
Triglyceride (mmol/1) 2.19 (0.31) 2.59 (0.69) 0.13
HDL-Chol (mmol/1) 1.71 (0.40) 1.76 (0.36) 0.80
LDL-Chol (mmol/1) 2.28 (1.07) 4.20 (0.85) 0 .0 0 1 2
VLDLi (mg/dl) 94.9 (35.8) 105.8 (42.7) 0.57
VLDL2 (mg/dl) 60.9 (18.1) 102.9 (36.2) 0.007
IDL (mg/dl) 58.8 (27.3) 116.5 (27.0) <0 .0 0 1
Total LDL (mg/dl) 183.<4 (56.2) 368.1 (87.2) <0 .0 0 1
Table 14 Lipid and lipoprotein concentrations in women with IUGR  
and normal pregnancy controls.
Values are given as mean (SD).
Women with pregnancies complicated by IUGR had significantly lower median 
cholesterol, VLDL2, IDL and LDL concentrations compared with control patients
(Table 14 and Figure 25). There were no significant differences in concentrations of 
triglyceride, HDL and VLDLi. The relative percent increments compared to non­
pregnant values (as reported in Chapter III) in each of the parameters that exhibited 
differences were as follows: Cholesterol (10% vs 58%, IUGR patients vs pregnant 
controls, respectively, VLDL2 (165% vs 347%), IDL (6 8 % vs 252%), LDL (-1 1% vs
78%).
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3.2 Lipoprotein com positions
When the composition of these particles was determined (Table 15) the following was 
found: the cholesteryl-ester to triglyceride ratio (the lipid composition of the 
hydrophobic core of the particle) was reduced in VLDL2 in IUGR. In addition, LDL 
particles were enriched in cholesteryl-ester and depleted in free cholesterol.
IU G R
Subfraction Protein Free chol Chol esters Triglyceride Phospholipid
VLDLi 7.2 (0.5) 3.6 (0.3) 8.64 (0.6)* 65.2 (1.0) 15.5 (0.4)
VLDL2 12.4 (0.8) 4.7 (0.3) 19.1 (1.0)* 43.0 (1.2) 20.7 (0.6)
IDL 18.9 (1.1) 5.3 (0.5) 35.1 (1.4) 18.7 (1.0) 22.0 (0.7)
LDL 23.5 (0.7) 6.5 (0.7)* 40.8 (1.2)t 8 .0  (0 .8 ) 2 1 .1  (0 .6 )
C ontrols
Lipoproteins Protein Free chol Chol esters Triglyceride Phospholipid
VLDLi 7.9 (0.2) 2.5 (0.3) 11 .6  ( 1.0 ) 63.9 (1.1) 14.2 (0.3)
VLDL2 13.4 (0.3) 5.4 (0.4) 2 2 .8  ( 1.0 ) 39.4 (1.3) 19.1 (0.3)
IDL 18.6 (0 .2 ) 6.5 (0.5) 35.7 (1.1) 18.9 (0.8) 20.3 (0.3)
LDL 24.2 (0.4) 10.3 (1.2) 35.7 (1.1) 9.6 (0.8) 20.2 (0.3)
Data are presented as mean (standard deviation) expressed as percent composition 
(g/lOOg); Choi esters = cholesteryl esters; Free chol = free cholesterol.
*P<0.01, tP<0.001 refer to the significance of difference between cases and controls 
as determined by Student unpaired t-test.
Table 15 C hem ical C om position o f A polipoprotein-B  C ontaining  
Lipoproteins
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4 .  D IS C U S S IO N
In this study, we set out to establish the pattern of lipid and lipoprotein concentrations 
in the third trimester in women with pregnancies complicated by IUGR. The most 
prominent finding in this study was of a significantly lower (p=0.0016) cholesterol 
concentrations in IUGR cases, principally the result of substantially lower (p=0.0012) 
LDL-cholesterol concentrations. In addition, VLDL2 and IDL concentrations were 
also significantly lower in women with IUGR. In contrast, triglyceride, VLDLi 
concentrations, and HDL concentrations were similar to control population.
What are the potential mechanisms for this observation? Information on booking first 
term lipid levels was not available so it is possible that women destined to develop 
IUGR have lower starting cholesterol values. However, preliminary data from our 
laboratory which compared first trimester cholesterol levels in a group of women 
destined to have pregnancies complicated by IUGR [n=7; mean cholesterol 5.42 
(1.42) mmol/1, birthweight 2232 (423) grams; mean (SD)] with those having normal 
pregnancies [n=794; mean cholesterol 5.5 (0.97) mmol/1; birthweight 3394 (552) 
grams] would suggest that this is not the case. Therefore, it would appear that in 
pregnancies complicated by IUGR there is a failure of an appropriate rise in LDL 
concentrations. This failure for LDL to rise could be the result of increased LDL 
catabolism and / or a reduction in synthesis. The observed significantly lower VLDL2
and IDL concentrations, the synthetic precursors to LDL in the circulation, would 
imply a failure of appropriate LDL synthesis. We may speculate that in order to 
maintain energy supply (most efficiently delivered via triglycerides) to the growing 
fetus, triglyceride synthesis (in the form of VLDLi) is maintained at the expense of
cholesterol in the form of VLDL2, IDL and in particular LDL. As LDL is required to
supply cholesterol to the placenta for hormonal synthesis, lower LDL levels could 
contribute to the lower oestrogen levels seen in pregnancies complicated by IUGR.
Whatever the mechanism, the results of this study demonstrate that LDL levels which 
normally increase by around 70% in uncomplicated pregnancies (Chapter III), fail to 
rise appropriately in pregnancies complicated by IUGR, and as a result may play a role 
in the pathogenesis of growth retardation. Finally, if our results are confirmed in 
larger studies and longitudinal investigations, then serial LDL-cholesterol 
measurements (when LDL-cholesterol fails to rise appropriately) may be of use in 
identifying mothers with IUGR pregnancies.
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CHAPTER IX
CO NCLUSIO NS
1. INTRODUCTION
At the time the thesis was initiated, it was a novel thought that unique changes in 
lipoprotein metabolism might be central to the pathophysiology of pre-eclampsia rather 
than an epiphenomonen. We drew on our knowledge of other situations, particularly 
the hyperlipidaemic changes that lead to accelerated atherosclerosis, to postulate that 
similar mechanisms may be in operation in pre-eclampsia. Therefore, the primary 
objectives of the thesis were:
i) to establish mechanisms underlying the physiological hyperlipidaemia of normal 
pregnancies and the pathological hyperlipidaemia of pre-eclampsia.
ii) to determine the consequences of the altered lipoprotein metabolism in pre­
eclampsia for the promotion of the characteristic endothelial dysfunction present in this 
disorder.
iii) to establish the relationship between lipid changes and haemostatic factors during 
normal gestation.
iv) to determine lipid and lipoprotein concentrations in pregnancies complicated by 
IUGR, a condition in which the placental appearance is similar to that seen in pre­
eclampsia but where the maternal systemic problems of hypertension and proteinuria 
are absent.
The first part of this project entailed a detailed longitudinal examination of plasma 
lipoprotein subfraction concentrations and compositions in normal pregnancy. Plasma 
lipids and lipoprotein subfractions were quantified in 10 normal pregnant women at 5 
weekly intervals from 10 to 35 weeks of gestation, together with circulating hepatic 
lipase and serum oestradiol concentrations. Concentrations of VLDLi, VLDL2 and 
IDL increased in parallel as plasma triglyceride increased with advancing gestation, 
and LDL mass increased by 70%. Thus it appears that pregnancy promotes 
hypersecretion of VLDLi and VLDL2 particles to provide for both maternal and feto­
placental triglyceride and cholesterol needs.
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Figure 26 Pregnancy , partly  via increased lipolysis and oestrogen  induced  changes ,  
p rom otes  hypersecretion o f  V LD Li and V L D L 2 particles to provide for both  m aternal
an d  fe to-p lacenta l trig lyceride  and cholesterol needs and as a result, p lasm a V L D L ]
an d  V L D L 2 , ID L  and  L D L  rise together. T he  p lacen ta  exp resses  several d if fe ren t
receptors  and enzym es which act in concert to facilitate uptake o f  circulating lipids.
In addition, in six o f  the 10 w om en studied, the L D L  subfraction pattern was m odif ied  
tow ards a smaller denser pattern in a m anner indicative o f  a “ threshold” transition. T h e  
c o n c e p t  o f  a th re sh o ld  was o f  c r it ica l  im p o rtan ce  to o u r  u n d e rs ta n d in g  o f  th is  
im portan t aspect o f  lipoprotein physiology. This “ threshold” transition, if  it occurred , 
d id  so at varying gestational ages and triglyceride concentra tions for different w o m en  
[C hap ter  III].
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Second, as part of our longitudinal assessment of lipid changes during normal 
pregnancy, we took the opportunity to measure also the circulating concentrations of 
coagulation and fibrinolytic markers and relate these to changes in plasma lipids and 
oestradiol [Chapter IV]. The data suggest that gestation associated increments in PAI 
activity, FVIIc, t-PA antigen and D-dimers, factors associated with vascular disease 
in the non-pregnant, may be linked to changes in the circulating concentration of 
triglyceride and oestradiol. However, a notable finding in that study was the inter­
individual variability in increments in coagulation and fibrinolytic variables with 
elevations in oestradiol and triglycerides during pregnancy, suggesting the possibility 
of gene-environmental interactions. Clearly, further studies of individual changes in 
hormones, lipids and haemostatic variables during pregnancy may offer insights into 
the regulation of coagulation and fibrinolysis, and their relationships to 
atherothrombosis.
Next, plasma concentrations of VLDL, and LDL subfractions and pre-heparin hepatic 
lipase activity were compared in women with pre-eclampsia and healthy, age, 
gestational age and weight-matched controls [Chapter V]. Women with pre-eclampsia 
exhibited higher median plasma triglyceride,VLDL] and VLDL2 concentrations,
whereas total plasma cholesterol, IDL and total LDL concentrations were the same in 
cases and controls. Furthermore, women with pre-eclampsia demonstrated markedly 
elevated median plasma concentrations of small, dense LDL, LDL-III. Consistent 
with studies in non-pregnant populations, the concentration of small, dense LDL 
correlated positively with plasma triglyceride concentration. Since, both VLDL] and
small, dense LDL-III are damaging to the endothelium, we postulated that elevated 
concentrations of these lipoprotein species may contribute to the expression of pre­
eclampsia.
Fourth, we have related lipid, specifically apoAI levels, to endothelial behaviour in 
myometrial vessels bathed in plasma from normal and pre-eclamptic pregnancies 
[Chapter VI]. These results are consistent with data from studies in non-pregnant 
individuals where HDL cholesterol has been positively and strongly related to 
endothelial function. This relationship may reflect a direct effect of HDL particles since 
they are antioxidative and cardioprotective. Alternatively, rather than a direct influence 
of Apo AI on endothelial behaviour, some other factor(s) dictating Apo AI metabolism 
and thus Apo AI concentrations may relate to endothelial behaviour. In particular, the 
efficiency of triglyceride catabolism which in the non-pregnant situation, is a major 
determinant of Apo AI and HDL-cholesterol concentrations, may be involved.
In Chapter VII, a mechanistic scheme for the generation of the hyperlipidaemia in pre­
eclampsia was devised. It was suggested that increased plasma cytokine (IL-1, TNF-
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a )  concentrations resulting from activation of macrophages/neutrophils either directly 
or indirectly through endothelial activation, or the placenta itself, may enhance the 
peripheral lipolysis already activated in normal pregnancy by HPL. This, in 
association with cytokine mediated de novo hepatic fatty acid synthesis, would then 
result in an increased flux of free fatty acids to the liver. These are channelled 
predominantly into hepatic triglyceride synthesis and lead to an increased secretion 
(over and above that of normal pregnancy) of large, triglyceride-rich VLDL particles, 
which are also removed less efficiently than normal. Accumulation of free triglyceride 
occurs in the hepatocyte when there is saturation of this pathway. This triglyceride 
accumulation is sufficient to explain the fatty changes in the liver seen in pre-eclampsia 
and AFLP, which as previously discussed may be a variant of the pre-eclampsia 
process. Furthermore, it was suggested that increased concentrations of triglyceride- 
rich lipoproteins in the circulation may contribute both directly and, through the 
generation of small, dense LDL, indirectly to endothelial dysfunction and therefore 
expression of pre-eclampsia in the mother, despite potentially benefiting fetal nutrition.
Finally, we examined lipid changes in pregnancies complicated by IUGR [Chapter 
VIII]. The results of this study demonstrated that LDL levels which normally increase 
by around 70% in uncomplicated pregnancies (Chapter III), fail to rise appropriately in 
pregnancies complicated by IUGR. The mechanisms for this observation are unclear 
but clearly, given the importance of LDL particles in delivering cholesterol to the 
placenta for hormonal synthesis and for transport to the fetus, such low levels may 
contribute to poor fetal growth. In addition, these data suggest that LDL-cholesterol 
measurements may be useful in identifying mothers with IUGR pregnancies.
In conclusion, the results of our novel studies have given deeper insight into the 
unique features associated with the hyperlipidaemia of normal pregnancy, particularly 
with reference to lipoprotein subfraction concentrations. Some of this information is 
clearly relevant to our understanding of the factors which govern generation of small, 
dense LDL in the non-pregnant population, and atherosclerosis. Furthermore, data 
presented in this thesis suggest that in some situations (pre-eclampsia and IUGR) 
mechanisms regulating this physiologic hyperlipidaemia may malfunction, with 
potential ramifications for the clinical expression or diagnosis of these conditions.
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2. FUTURE WORK
Clearly, novel data have been generated from work performed in this thesis. 
However, the results have also suggested many more lines of investigation. In this 
final section, therefore, I will detail potential future studies which would help yield 
deeper insights into the conditions discussed.
2.1 Kinetic studies
In order to establish more precisely whether the gestational hyperlipidaemia is due 
predominantly to increased synthesis of lipoproteins or their reduced catabolism, 
kinetic (stable isotope) studies are necessary. The detailed methodology has already 
been established in the laboratory. Basically, the rates of VLDLi and VLDL2
synthesis and catabolism are measured by endogenous labelling of their primary 
protein component, apoB, with a non-radioactive amino acid tracer, trideuterated 
leucine (D3~leucine). This tracer is administered through an intravenous catheter as a
short constant infusion which is 'primed' by a small bolus. D3-leucine is incorporated
by the liver into apoB, which is assembled into VLDL and secreted into the 
circulation. Blood samples are obtained from the subject at frequently selected time 
points during and after the administration of the tracer. From these samples VLDLj
and VLDL2 is prepared and the amount of D3-leucine incorporated determined by GC-
MS. The change in isotopic-enrichment within the individual apoB-containing 
lipoprotein over time, provides a measure of the metabolism of that lipoprotein.
Kinetic studies could also be performed in women with pre-eclampsia and IUGR to 
confirm our belief that the former condition is characterised predominately by an 
increase in synthesis of VLDLj whereas the latter condition is characterised by a
breakdown of the VLDL2 to IDL to LDL synthetic chain.
2.2 Adipocyte lipolysis
From the mechanistic scheme presented in Chapter VI, it appears that enhanced 
adipocyte lipolysis may be pivotal in the chain of events leading to the metabolic 
perturbances and thus pathophysiology of pre-eclampsia. The factor(s) responsible 
for stimulating adipocyte lipolysis is unknown but could be of placenta origin. Using 
established laboratory techniques and in collaboration with Professor C.Redman’s 
group in Oxford (who have isolated syncytiotrophoblast villous membranes in the 
maternal plasma of women with pre-eclampsia) it would be interesting to examine the 
potential of these placental factors to stimulate adipocyte lipolysis.
2.3 Lipoprotein lipase assays
Another possible mechanism for the exaggerated hyperlipidaemia of pre eclampsia is 
reduced VLDL catabolism secondary to reduced adipose / skeletal tissue LPL
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activities. LPL activity may be reduced in these tissues to facilitate ‘targeting’ of lipids 
towards fetus. No such data in the literature are evident and assays for tissue LPL 
measurements are readily available.
2.4 L ong term  health o f wom en with h istory o f pregnancies  
complicated by pre-eclampsia / IUGR
Women who develop pre-eclampsia appear to have a predisposition towards central 
obesity and insulin resistance, these features being important to the development of the 
exaggerated hyperlipidaemia seen in that condition. As a result, such women may be 
at heightened risk of cardiovascular disease in later life. In contrast, women who 
develop IUGR tend to have low weights at pregnancy onset. Although, these women 
exhibit similar placental morphology to that seen in pre-eclampsia, their low weights 
(and by association low abdominal adipose tissue stores) may protect them from the 
systemic manifestations of hypertension and proteinuria. Data on the long term health 
of these women are sparse. Therefore, it would be interesting to characterise the 
metabolic profiles in groups of women with a history of pre-eclampsia or IUGR 
relative to those with a history of uncomplicated pregnancies.
2.5 IUGR and lipids
In Chapter VIII it was demonstrated that LDL levels which normally increase by 
around 70% in uncomplicated pregnancies (Chapter III), fail to rise appropriately in 
pregnancies complicated by IUGR, and this has potential implications for the 
pathogenesis of growth restriction. Larger studies are needed to confirm our 
preliminary observations. Furthermore, longitudinal studies would be useful.
2.6 Importance of future work
The importance of these disorders is not simply in relation to pregnancy as it is clear 
that disturbances in fetal growth and development have long term implications for 
adult health, particularly, with regard to metabolic and vascular disease. Thus, 
maternal programming of the fetus may occur with possible transmission of metabolic 
characteristics such as insulin-resistance. Furthermore there are implications for the 
mother, with the potential of increased metabolic conditions and vascular events in 
later life. Thus the purpose of the proposed programme of work is to elaborate the 
mechanism of increased lipids and lipoproteins in normal pregnancy and pre-eclampsia 
and how this influences the plasma lipoprotein concentrations in these situations and 
other disorders associated with metabolic dysfunction in pregnancy including 
gestational diabetes, insulin-dependent diabetes and IUGR. In addition, the 
consequences of the dyslipidaemia required to be studied to understand the 
relationship between these metabolic disturbances and abnormalities in endothelial 
function. Finally, it is important to determine the effects of the changes in lipids and 
lipoproteins associated with pregnancy and its complications on maternal health by 
way of long term follow-up studies.
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G LOSSARY
AFLP Acute fatty liver of pregnancy
ALP Atherogenic lipoprotein profile
Apo Apolipoprotein
BMI Body mass index
BP Blood pressure
CETP Cholesteryl ester transfer protein
CHD Coronary heart disease
EDRF Endothelial derived relaxing factor
FABP Fatty acid binding protein
FFAs Free fatty acids
FVII Factor VE
HDL High density lipoprotein
HELLP Haemolysis, Elevated Liver enzymes, Low Platelet count
HL Hepatic lipase
HPL Human placental lactogen
HSL Hormone sensitive lipase
IBR Individualised birth ratio
JDL Intermediate density lipoprotein
IUGR Intrauterine growth restriction
Lp (a) Lipoprotein (a)
LpL Lipoprotein lipase
LCAT Lecithin cholesterol acyl transferase
LDL Low density lipoprotein
MAP Mean arterial pressure
PAI Plasminogen activator inhibitor
TNF Tumor necrosis factor
tPA Tissue plasminogen activator
VLDL Very low density lipoprotein
vWF von Willebrand Factor
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Baker Instruments Ltd 
Rushman Park Whitehall Lane 
Egham, Surrey 
TW20 9NW, UK
Beckman Instruments (UK) Ltd Analytical Sales and Service Operation 
Progress Road, Sands Industrial Estate 
High Wyncombe, Bucks 
HP 12 4JL, UK
BDH Laboratory Supplies 
McQuilkin & Co 
21 Polmadie Avenue, Glasgow 
G5 OBB, UK
Bio-Rad Laboratories 
2000 Alfred Nobel Drive 
Hercules 
CA 94547, USA
Boehringer Mannheim UK (Diagnostics and Biochemicals) Ltd 
Bell Lane
Lewes, East Sussex 
BN71LG, UK
Chromacol Ltd 
3 Little Mundells, WGC 
Herts,
AL7 1EW, UK
Fisons Instruments 
Crewe Road
Wythemshaw, Manchester 
M23 9B, UK
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Genzyme Biochemicals 
50 Gibson Drive, Kings Hill 
West Mailing, Kent 
ME 19 6 HG, UK
VA Howe & Company Ltd 
Beaumont Close 
Banbury 
0X 16 7RG, UK
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San Diego
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B-2070 Zwijndrecht 
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3858 Benner Road, Miamisburg 
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Oslo, Norway
Orion Diagnostica 
Espoo, Finland
Packard Instrument Company 
Canberra Packard Ltd 
Brook House, 14 Station Road 
Pangbourne, Berks 
RG8 7DT, UK
Sigma Chemical Company 
Fancy Road 
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BH17 7TG, UK
Appendix 2
P R E G L IP  S T U D Y  
LONGITUDINAL SUBFRACTION CHANGES 
R E C O R D  F IL E  F O R
Patient's Name: _____________________________
Tick when completed:
Demographics 
Consent Form 
Screening Results 
Inclusion Criteria 
Exclusion Criteria 
Sampling Protocol 
Results
□
□
□
□
□
□
□
PREGLIP STUDY : DEMOGRAPHIC DETAILS
Date of Assessment:
Patient's Name:
Forename:
Surname: 
Date of Birth:
Address:
Post Code: __________________________________
Telephone No: __________________________________
General Practitioner: __________________________________________
Consultant: __________________________________________
Booking Weight:  kg Height (without shoes):
Estimated Date of Delivery:   LMP: __
Outcome:_____ _________________________________________________
Fetal Weight: _________________________________
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PREGLIP STUDY : CONSENT FORM
GREATER GLASGOW HEALTH BOARD 
GLASGOW ROYAL INFIRMARY UNIT - RESEARCH ETHICS COMMITTEE
FORM OF CONSENT FOR PATIENTS IN CLINICAL RESEARCH PROTECT
Brief Title of Pro ject:
Assessment of Lipoprotein Metabolism in Normal Pregnancy 
(lipoprotein subfraction changes)
Patient's Summary (Purpose of study, nature of procedure, discomfort and possible 
risks in terms which the patient can understand):
I understand that Professors Greer and Shepherd and their colleagues are investigating in 
detail changes in blood fat and cholesterol levels in normal pregnancy. My participation 
would involve the donation of a blood sample at 8 , 12, 16, 20, 24, 28, 32, 36 and possibly 
40 weeks of pregnancy. Giving a blood sample can be associated with minor discomfort.
The study may be of little or no benefit to me directly but the results may be of help to others 
in the future.
Participants can withdraw from the project at any time and this will not affect my regular 
care and treatment.
CONSENT
I, (Name) ____________________________________________________________________
of (Address) ____________________________________________________________________
agree to take part in the Research Project Study Programme described above.
Dr/Mr ____________________________________  has explained to me what I have to do,
how it might affect me and the purpose of the Research Project/Study Programme.
Signed: _________________________________________ Date:____________________
Witness: _________________________________________ Date:____________________
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PREGLIP STUDY: SCREENING RESULTS
BP
Urea and 
Electrolyte
Blood
Glucose
Full Blood 
Count
Lipids
Systolic
Diastolic
Na+
K+
ci-
HCO3
Urea
Cr
Liver
Function
GLU
Haematocrit
Haemoglobin
RBC
WBC
Platelets
Total Plasma Triglyceride
Total Plasma Cholesterol
Apo E Phenotype
Bil
ALB
AST
ALT
LDH
CPK
URATE
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PREGLIP STUDY : INCLUSION/EXCLUSION CRITERIA
INCLUSION CRITERIA
Gestational age between 8-12 weeks 
Aged between 18 and 35 years
Previous uncomplicated full-term pregnancy (ie, multigravida)
No significant risk factors for current pregnancy as determined 
by detailed obstetric assessment
Non-smoker
Singleton pregnancy
Fasting plasma triglyceride < 2 mmoL/1 and fasting plasma 
cholesterol between 3 and 6.5 at booking visit
Patients who have given their written informed consent to 
participate in the study
YES NO
□ □ 
□ □ 
□ □ 
□ □
□ □ 
□ □ 
□ □
□ □
All answers must be 'YES' for the patient to be eligible for study entry 
EXCLUSION CRITERIA
Patients with significant renal disease as evidenced by serum 
urea's and serum creatinine levels greater than twice the upper 
limits of normal
Patients with significant hepatic disease as evidenced by serum 
transaminases or serum bilirubin greater than twice the upper 
limit of normal
Patients with endocrine disease which may influence lipid 
metabolism, ie thyroid disease diabetes mellitus (defined as 
fasting blood glucose > 8 mmol/1)
Patients with hypertension (diastolic BP > 90 mmHg).
ApoE phenotype E2/E2
Previous gestational diabetes or pregnancy-induced hypertension
Patients taking any medication known to interfere with lipoprotein 
levels
YES NO 
□ □
□ □
□ □
□ □ 
□ □ 
□ □ 
□ □
All the answers must be 'NO' for the patient to be eligible for the study
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PREGLIP STUDY : SAMPLING PROTOCOL
FO R  EACH DATE:
Fasting sample (25 ml) should be taken into 2 x 10 ml K2 EDTA tubes (20 ml) and 1 x 5 ml 
Li/Hep (3 ml) and 1 x 5 ml plain tube (3 ml):
PR E G L IP STUDY - LSC 
Name of patien t and date
Note: The 5 ml Li/Hep sample must be placed on ice immediately.
The sample should be accompanied by a form marked:
PR EG L IP STUDY - LSC
FO R  TH E ATTENTION OF DR NAVEED SATTAR
DEPT O F BIOCHEM ISTRY, GLASGOW  ROYAL INFIRMARY
and sent to the Department of Biochemistry, GRI
G estational
Age
Tim e Window = 
EDD±1 Weeks
Date
Taken
Actual 
Gest. Age
Tick Name of Sender
10 Weeks
14 Weeks
18 Weeks
22 Weeks
26 Weeks
30 Weeks
38 Weeks
36 Weeks
■ - -■
EDD
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PREGLIP STUDY : RESULTS
10 WEEK GESTATION Time Window for Sample using EDD:______________
DATE OF SAMPLE: ___________________________ _______________________
Obstetric Progress:
NAME OF PATIENT: __________________________________________________
RESULTS HORMONES
TG
Choi
VLDL
LDL
HDL
Oestradiol
Progesterone
B-HCG
SHBG
Glucose
SUBFRACTIONS
VLDL-I
VLDL-II
IDL
LDL
LDL
LDL-I
LDL-II
LDL-III
h d l 2
HDL3
pmol FA Min*1 H r 1
Hepatic Lipase
Lipoprotein Lipase
Lp(a)
CETP
LCAT INSULIN
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Appendix 3
P R E G L IP  S T U D Y
PRE-ECLAMPSIA 
R E C O R D  F IL E  F O R
Patient's Name: ______________________________
Tick when completed:
Demographics 
Consent Form 
Screening Results 
Inclusion Criteria 
Exclusion Criteria 
Sampling Protocol 
Results
□
□
□
□
□
□
□
PREGLIP STUDY : DEMOGRAPHIC DETAILS
Date of Assessment:
Patient's Name:
Forename:
Surname: 
Date of Birth:
Address:
Post Code: __________________________________
Telephone No: __________________________________
General Practitioner: __________________________________________
Consultant: __________________________________________
Booking Weight:  kg Height (without shoes):
Estimated Date of Delivery: ___________________________________
Outcome:_____ _________________________________________________
Fetal Weight: _______________________________
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PREGLIP STUDY : CONSENT FORM
GREATER GLASGOW HEALTH BOARD 
GLASGOW ROYAL INFIRMARY UNIT - RESEARCH ETHICS COMMITTEE
FORM OF CONSENT FOR PATIENTS IN CLINICAL RESEARCH PROTECT
Brief Title of Project:
Assessment of Lipoprotein Metabolism in Normal Pregnancy and Pre-Eclampsia 
(Pre-eclampsia)
Patient's Summary (Purpose of study, nature of procedure, discomfort and possible risks 
in terms which the patient can understand):
I understand that Professors Greer and Shepherd and their colleagues are investigating in detail 
blood fat level changes that may be linked to the onset of high blood pressure in pregnancy. My 
participation would involve the donation of a blood sample. Giving a blood sample can be 
associated with minor discomfort.
The study may be of little or no benefit to me directly but the results may be of help to others in 
the future.
Participants can withdraw from the project at any time and this will not affect my regular care 
and treatment.
CONSENT
I, (Name) _____________________________________________________________________
of (Address) _____________________________________________________________________
agree to take part in the Research Project Study Programme described above.
Dr/Mr _____________________________________  has explained to me what I have to do,
how it might affect me and the purpose of the Research Project/Study Programme.
Signed:   Date:____________________
Witness: _________________________________________  Date:____________________
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PREGLIP STUDY: SCREENING RESULTS
BP
Date 1 Date2
Systolic
Diastolic
Urine
Protein
Dipstix
24 hour
Urea and 
Electrolyte Na+
K+
c i -
h c o 3
Urea
Cr
Liver
Function Bil
ALB
AST
ALT
LDH
CPK
Blood
Glucose
Full Blood 
Count
GLU
Haematocrit
Haemoglobin
RBC
WBC
Platelets
URATE
Lipids Total Plasma Triglyceride
Total Plasma Cholesterol
Apo E Phenotype
Drug
History Drug Prescribed Dose No. Taken
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PREGLIP STUDY : INCLUSION/EXCLUSION CRITERIA
INCLUSION
Age between 18-35 years
Diastolic BP > 110 mmHg on one reading or exceeding 90 mmHg 
on repeated readings
Proteinuria > 0.3 g/24 hours or > 2+ on dipstick testing in absence 
of infection or renal disease
Pre-pregnancy weight between 55-70 Kg
Non-smoker
Singleton pregnancy
Healthy before onset of pre-eclampsia 
(ie, normal obstetric and medical history)
Have given their written informed consent to participate in the study
All answers must be 'YES' for the patient to be eligible for study entry
YES NO
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
EXCLUSION CRITERIA
YES NO
Patients with significant renal disease as evidenced by serum □  □
ureas and serum creatinine levels greater than twice the upper 
limits of normal
Patients with significant hepatic disease as evidenced by serum □  □
transaminases or serum bilirubin greater than twice the upper 
limit of normal
Patients with endocrine disease which may influence lipid □  □
metabolism, ie thyroid disease diabetes mellitus (defined as 
fasting blood glucose > 8 mmol/1)
ApoE phenytope E2/E2  □  □
Patients taking any medication known to interfere with lipoprotein □  □
levels for longer than 48 hours
Evidence of gestational diabetes/impaired glucose tolerance □  □
(fasting glucose > 8.0 mmol/1)
All the answers must be ’NO' for the patient to be eligible for the study
PREGLIP STUDY : SAMPLING PROTOCOL
PRE-ECLAM PSIA
NAM E O F PATIENT: _________________________________________________________
Ideally following the day of admission, a 25 ml blood sample taken after an overnight fast into:-
2 x 10 ml K2 EDTA - 20 ml Note: The two 5 ml tubes must be
1 x 5  ml K2 EDTA - 2 ml placed on ice immediately
1 x 5  ml Li/Hep - 3 ml
and labelled:
PR EG LIP STUDY - PET 
NAME OF PATIENT AND DATE
The sample should be accompanied by a form marked:- 
PR EG LIP STUDY - PET
FO R TH E ATTENTION OF DR NAVEED SATTAR
DEPARTM ENT OF BIOCHEM ISTRY, GLASGOW  ROYAL INFIRMARY
and sent to the Department of Biochemistry, GRI, promptly
Note: All samples require separation and storage within two hours of collection
Sample
Date Taken Tick By Whom
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PREGLIP STUDY : RESULTS
PRE-ECLAM PSIA
DATE OF SAMPLE: 
NAME OF PATIENT:
TG
CHOL
VLDL
LDL
HDL
V LD Li
VLDL2
Concn Composition
Free
Cholesterol
Cholesterol
Ester Trigs Phos Protein
HL
LPL
LDL
Susceptibility to 
Copper Oxidation Inhibition Period
LDL-I FDR-IP
LDL-II FDR-PP
LDL-III
Plasm a Total LDL
Baseline MDA
P re Incubation Post Incubation
NEFA's
Lipid
Perox
(Dumfries)
LCAT INSULIN
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